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The work presented in this thesis investigates human immune responses to 
measles virus (MV). Identification of potential MV T cell epitopes for use as part of 
a new generation component vaccine could overcome problems associated with 
live vaccines in early life. HLA-A2*0201 -restricted epitopes, both predicted 
sequences and previously identified epitopes, were used to stimulate peripheral 
blood samples from immune adult donors. Responses were investigated using the 
IFNy ELISpot. This approach failed to identify dominant epitopes. Therefore 
methods of enhancing presentation were investigated. To screen for 
immunodominant epitopes, overlapping 15mer peptides from 3 major MV proteins 
F, H and NP were used, looking for responses to peptide pools and individual 
peptides. Although some responses were seen this did not identify any dominant 
epitopes.
In vivo boosting of the response was undertaken by vaccinating HLA-A2 individuals 
with MMR vaccine. PBMC and serum samples were stored from several time 
points’ pre and post vaccination. Cell phenotyping, serology and response to 
peptides, along with in vitro expansion of antigen specific cells, were used to 
assess response in vaccinees. In vitro expansion of cells responding to MV 
proteins was to be achieved using adenoviral vectors containing cDNA coding for 
individual MV proteins. This might allow expression of antigen in autologous 
dendritic cells (DC) via the natural route of infection without encountering the 
cytopathic effect of live MV on DCs. This work, although unsuccessful, led to the 
observation that adenovirus-infected DCs suppress T cell proliferation, leading to a 
novel body of work looking at the effects of adenoviral infection on human DCs.
In parallel with this work, similar methodology was used to investigate T cell 
responses to an OMV based meningococcus B vaccine in vaccinated donors. 
However it transpired that this vaccine did not stimulate an immune response in the 
majority of donors investigated.
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21Chapter 1 Introduction
1.1  The Immune System
Everyday, humans come into contact with a huge range of potentially infectious 
organisms. However illness only occurs relatively rarely. The human immune 
system has evolved side by side with these microorganisms and has developed a 
wide variety of both general and highly specific mechanisms to protect humans 
from infection. The first line of this defence are the obvious physical barriers 
preventing microorganism entry to the body, i.e. the epithelia. Internal epithelial 
surfaces such as those of the gastrointestinal and respiratory tracts also secrete 
mucus which contains glycoproteins known as mucins which can prevent 
microorganisms from binding to the epithelial surface and therefore prevent 
invasion or colonisation. These mucosal surfaces are further protected by the 
movement of epithelial cilia which expels any microorganism caught in the flow of 
mucus.
There are other chemical barriers such as lysozyme in tears and saliva and 
antimicrobial molecules such as defensins which reside in the respiratory tract and 
in the small intestine (Krisanaprakornkit et al., 2000). Another factor that protects 
humans from colonization with pathogenic microorganisms is the presence of the 
natural flora of non pathogenic bacteria which often have a survival advantage and 
are thought to compete with the pathogenic microorganisms for nutrients and 
attachment sites on epithelial cells. These commensals can also themselves 
secrete anti microbial molecules which prevent the colonization by other species. It 
is when this barrier is breached by either damage to the skin or exposure to a
22particularly successful human pathogen, that the immune system is required to 
clear the infection (Ouellette, 1999).
1.1.1  Innate Immunity
Once the outer defences have been breached the next line of defence against 
infection is the innate arm of the immune system. This is a comparatively non 
organism specific recognition of invading pathogens which allow activation of 
specific pathways which lead to the destruction of the pathogen or subsequent 
activation of other branches of the immune system. This arm of the immune 
system although effective, does not become more effective upon subsequent re 
infection with the same pathogen, meaning that there is no “memory” of each 
infection.
1.1.1.1 Cell mediated innate immunity
There are several major cell types and molecular pathways involved in the innate 
protection of the human body to infection. One of the most important cells involved 
in this process are the phagocytes which are cells that can recognize and ingest 
whole microorganisms. Macrophages are the predominant phagocytic cell in the 
tissues. These macrophages are constantly reconstituted from monocytes 
migrating from the peripheral blood. All phagocytic cells recognize cell surface 
markers that can distinguish host cells from pathogenic cells. They do this via the 
expression of the mannose receptor, scavenger receptors and CD14 which is one 
of the receptors for lipopolysaccharide (LPS), a major immunogenic constituent of 
bacterial cell membranes (see section 1.1.2.1). Once bound to the phagocyte the
active process of phagocytosis occurs where by the pathogen is enveloped in the
23phagocytic membrane and sealed within a phagosome. This becomes an acidic 
environment and is fused with lysosomes, granules within the cell that contain 
antimicrobial products, to make a phagolysosome where the destruction of the 
pathogen occurs. Phagocytes can also release several other toxic products such 
as hydrogen peroxide and nitric oxide which are toxic to the bacterium (Aderem 
and Underhill, 1999).
Neutrophils are the other major phagocytic cell type. These are not normally 
resident in resting tissue, although when macrophages and other pro-inflammatory 
pathways are activated, chemotactic agents are released which recruit neutrophils 
and other cells into the area. This process, known as inflammation, leads to blood 
vessels becoming more permeable allowing delivery of cells and effector 
molecules to the area of infection. Neutrophils are short lived since the toxic nature 
of the reagents they use to kill pathogens can also damage the cell (Segal, 2005). 
Macrophages are longer lived, and survive, which enables them to process and 
present antigens derived from the phagocytosed pathogen to other cells which 
have been recruited to the area such as T cells which form part of the adaptive 
immune system (which is discussed later in section 1.1.2).
The main difference between a pathogenic and non pathogenic organism is the 
ability of that organism to overcome innate immune defences. This may be through 
sheer numbers, or more commonly many microorganisms have developed wide 
ranging strategies to avoid being immediately identified by macrophages. These 
strategies include bacteria coating themselves with a polysaccharide capsule,
which is not recognized by receptors on phagocytes. Some intracellular bacteria
24such as mycobacteria have developed the ability to prevent fusion of the 
phagosome with the lysosome and therefore can survive within macrophages 
(Ferrari et al., 1999).
Other organisms, particularly viruses, have the ability to infect different cell types 
and in order to avoid detection alter the cell in which they are replicating to either 
suppress immune responses as with measles (MV) as will be discussed later, or to 
down regulate cell surface expression of the Major Histocompatibility Complex I 
(MHC I) which would normally display intracellular protein products to T cells. This 
is discussed in detail in section 1.1.2.3. There is another cellular component of the 
innate immune system which combats this specific phenomenon. Rather than 
relying on the recognition of non self in order to combat pathogens, Natural Killer 
(NK) cells rely on recognition of self MHC I molecules in order for them not to kill 
cells, this allows them to remove altered cells from the body. This not only aids in 
the fight against viruses and intracellular pathogens that alter cells, but can also 
play a role in the detection and removal of other abnormal cells such as cancerous 
cells (Moretta et al., 2002). Once activated, NK cells also play a role at 
inflammatory sites by releasing cytokines and other inflammatory mediators.
1.1.1.2  Complement
There is another major system in place that can recognize and destroy invading 
pathogens. This is the complement system, which is made up of a large number of 
plasma proteins that react with each other in a cascade mechanism, which both 
amplifies the response and can lead to the death of the organism.  The proteins
reside all over the body in a pro-enzyme form. Each enzyme in the pathway is the
25substrate of the enzyme before it in the cascade. When cleaved the enzyme 
becomes active and then cleaves and activates the next enzyme in the pathway. 
The smaller cleavage products in the cascade also act as pro inflammatory 
mediators and can recruit phagocytes to the site of infection.
There are three main pathways through which the complement system can be 
activated. These are the classical pathway, the mannose binding lectin (MBL) 
pathway and the alternative pathway. All of these pathways can result in the 
effector functions of the complement system which are: recruitment of phagocytes 
and mediating inflammation, formation of a membrane attack complex, which 
directly causes the lysis of certain pathogens or results in the opsonization of the 
pathogen by phagocytes (Tomlinson, 1993). A schematic diagram of the activation 
steps in the complement pathway and the different proteins involved is shown in 
figure 1.1.
At the centre of all of the pathways is the C3 protein. It is the cleavage of C3 that 
releases C3a, which is a peptide mediator of inflammation, but more importantly 
activates C3b, which can either bind directly to the target cell surface where it is 
the ligand for C3b receptors on some phagocytic cells marking the cell for 
phagocytosis. Either the pathogen is phagocytosed or C3b binds C3 convertase 
which forms C5 convertase which cleaves C5 to make C5a, the most important 
inflammatory mediator and C5b which initiates the late events in complement 
activation which leads to the formation of the membrane attack complex. The 
membrane attack complex which involves proteins C6, C7, C8 and C9, forms a
26pore in the target cell surface which can result in the death of that organism 
(Bhakdi and Tranum-Jensen, 1991;Tomlinson, 1993).
Lectin pathway Classical pathway
C3
Bb C3a
Bb
C3 (H20) C3 (H20)
Bacterium
Alternative pathway
Figure 1.1: A schematic diagram of the complement system and the three
pathways through which it is activated. Adapted from (Fujita, 2002).
Thus, activation of the complement pathway may occur through three major 
pathways. The alternative and MBL pathways are the two “innate” pathways. In the 
MBL pathway a collectin protein mannose binding lectin (MBL) binds mannose 
residues and certain other carbohydrates on the surface of pathogens which 
results in the recruitment of MBL-associated serine proteases MASP-1 and MASP- 
2, these then cleave C2 and C4 which result in the hydrolysis of C3 to C3a and 
C3b (Vasta et al., 1999).The alternative pathway is activated via spontaneous
hydrolysis of C3; this occurs spontaneously in plasma however C3b can not
27activate the alternative pathway unless it can combine with proteins B and D. This 
can only occur once C3b undergoes a conformational change caused by being 
bound to the surface of a pathogen (Platonov, 1999;Tomlinson, 1993).
The classical pathway requires the binding of antibodies specific for molecules on 
the target cell surface which are then bound by C1q, another collectin that is similar 
to MBL. This links the adaptive humoral immune response with the complement 
system, and this reaction forms the basis of the serum bactericidal assay (SBA), 
that is used to measure responses of individuals to vaccination against bacterial 
pathogens, which is discussed further in section 7.1.4. In some cases C1q can also 
bind directly to the target cell surface and can activate the classical pathway of 
complement directly, without the need for antibodies for certain pathogens. C1q is 
part of the C1  complex which also contains C1r and C1s. If more than one of the 
C1q globular lectin like heads binds the cell surface, a conformational change 
occurs which activates C1r which in turn activates C1s. C1s can then act on C2 
and C4 which results in the hydrolysis of C3 which activates the rest of the 
complement pathway (Cooper, 1985;Tomlinson, 1993).
These innate mechanisms used to combat infection rely on general recognition of 
pathogen structures as “non self in order to facilitate killing. Successful pathogenic 
microorganisms have evolved mechanisms to evade recognition by the innate 
immune system and establish an infection. In order to successfully deal with such 
infection the immune system requires a more specific arm. This is known as 
adaptive immunity.
281.1.2 Adaptive immunity
Adaptive immunity consists of two main arms: cell mediated immunity, which 
involves destruction of infected cells by cytotoxic cells, and humoral immunity 
which involves the production of antibodies against pathogen components.
Adaptive immunity is not an immediate early line of defence since it requires the 
expansion of antigen specific cells and their maturation into effector cells. However 
once this has occurred and the cells have expanded and cleared the infection, 
many of them die but some persist as memory cells, allowing the response to 
subsequent infection with the same pathogen to be quicker and larger (secondary 
response) than on first encounter (primary response). The major cell types involved 
are the T and B lymphocytes respectively. There is some cross over between 
these two lymphocyte subsets, as T cells are required to establish humoral 
immunological memory by B cells.
1.1.2.1  Antigen presenting cells (APC)
Antigen presenting cells (APC) are required to process and present antigens to T 
lymphocytes as T cells do no recognize cell surface antigens alone. T cells 
recognize short peptide fragments of proteins derived from pathogens that have 
been processed by the APC and presented in the context of a major 
histocompatibility complex protein (MHC) on the APC surface. This process is 
further discussed in section 1.1.2.3. When antigen is recognized by T cells on the 
surface of the APC, in order for an immune response to be initiated the APC must 
be in an activated state to provide co-stimulation for the T cells (Banchereau and 
Steinman, 1998).
29Dendritic cells (DCs) are professional antigen presenting cells and are widely 
credited with playing a central role in the immune system (Banchereau and 
Steinman, 1998). DCs link innate recognition of general “danger” signals, the 
presence of pathogen associated molecules such as double stranded 
ribonucleotides (dsRNA) and lipopolysaccharide (LPS), with the adaptive immune 
response (Gordon, 2002;Schulz et al., 2000).This is achieved by the presence of 
pattern recognition receptors both on the surface and within intracellular organelles 
of the DC. Pattern recognition receptors include the Toll like receptors (TLR). This 
family of proteins was initially identified in the fruit fly drosophila, and named Toll 
receptors (Barton and Medzhitov, 2002).
Over 9 different human TLR have been identified. The ligands for some, but not all 
of these TLR molecules have been discovered, along with their different sites of 
expression within a cell and cell subtypes. For example TLR4, which recognizes 
LPS, is expressed on monocytes and myeloid DCs and not on plasmacytoid DCs, 
where as TLR7 and TLR9, which are involved in the recognition of viruses, are 
expressed on the surface of plasmacytoid DCs but not on myeloid DCs (Reis e 
Sousa, 2004a;Reis e Sousa, 2004b).This shows a functional segregation of 
receptors as plasmacytoid DCs are high type 1   interferon producing cells which is 
the key cytokine involved in the immune response to viruses (Saint-Vis et al.,
1998).
DCs are distributed throughout most tissues and mucosal surfaces. They are 
constantly sampling the environment by internalizing molecules from the
surrounding area. This occurs through several processes including
30macropinocytosis. In this process, large volumes of surrounding fluid are taken up 
non -specifically along with receptor mediated phagocytosis of antigen by 
membrane bound molecules such as CD205 (DEC-205) and DC-SIGN (CD209) 
(Engering et al., 2002). DC-SIGN is also involved in the interaction between DCs 
and T cells by binding to ICAM-3 on the T cell surface (Geijtenbeek et al., 2000b). 
Interestingly DC-SIGN has been identified as a receptor for HIV entry into DCs 
(Geijtenbeek et al., 2000a). DCs display the processed antigen on their surface for 
recognition by T cells. However the DCs will only mature and migrate to lymph 
nodes if they have been activated by the recognition of pathogen derived 
molecules. DCs can then go on to secrete specific cytokines tailored to the type of 
immune response required to fight that pathogen. For example if TLR4 is ligated by 
LPS, this signals the presence of bacteria and so requires the production of T cell 
help in order for B cells to produce antibody. In contrast if TLR9 is ligated this may 
indicate the presence of a virus which would require a DC to produce type 1  
interferons, leading to increased expression of MHC class 1  on the cell surface and 
promoting production of cytotoxic T cells (CTL) which can kill virus infected cells 
(Saint-Vis et al., 1998). It is in this way that the innate and adaptive arms of the 
immune system are tightly linked, with the production of a specific signal by the 
DCs determining the fate of T cells (Barton and Medzhitov, 2002).
The T cells activated by contact with DCs will be those that have recognised 
antigen on the surface of the DC via their specific T cell receptor (TCR) and also 
receive co-stimulation from the up regulated co stimulatory molecules on the 
mature DC surface. This combined with the production of specific cytokines
tailored to the type of immune response required will stimulate previously naive T
31cells to develop into the necessary phenotype to fight the invading pathogen.  It is 
thought that without co-stimulation on the surface of the APC, T cells encountering 
antigen are not activated and therefore DCs also play a role in the maintenance of 
self tolerance in the periphery either by the induction of anergy in the T cells 
(Mahnke et al., 2002), or through the production of specific cytokines that induce 
the differentiation of a different population of T cells known as T regulatory cells 
(Treg) which themselves can modulate immune responses (Munn et al., 2002). 
This is further discussed in section 1.1.2.3.
As DCs are central to the immune response, several pathogens including measles 
virus (MV) (section 1.3) are able to modulate the action of DCs to their own 
advantage increasing the ability of the pathogen to successfully infect the host 
(Bhardwaj, 1997;Xu et al., 2001). This is mainly through the suppression of 
responses by the decreased expression of the Th1  inducing cytokine IL-12 by DCs 
during an MV infection (Atabani et al., 2001;Marie et al., 2001). Many other viruses 
also interfere with the functions of DCs including RSV (Bartz et al., 2003), HSV 
(Pollara et al., 2003) and Adenovirus (Jonuleit et al., 2000). The latter will be 
discussed further in chapter 6. Another mechanism that viruses may use to 
manipulate the immune system is to induce the production of T regulatory cells to 
effectively suppress the immune response that would otherwise clear the infection; 
this will also be discussed further in chapter 6.
1.1.2.2  B lymphocytes
B lymphocytes or B cells, (so called because they develop in the bone marrow then
mature in the periphery), can also act as antigen presenting cells. However there is
32a much reduced capacity for B cells to prime T cells and direct the nature of an 
immune response compared to DCs. Once B cells recognize antigen in its natural 
conformation via the B cell receptor (BCR) they can internalize this antigen via 
receptor mediated endocytosis and process this antigen and present it to T cells in 
the context of MHC molecules. This allows for the recruitment of antigen specific T 
cell help to the B cell. In the case of a primary response this can occur on the 
surface of a DC which provides cytokines and appropriate co stimulation to drive 
the appropriate immune response. However during recall memory responses the B 
cell can present antigen to and activate, the specific T cell. This in turn can 
produce cytokines and co stimulation to provide the second signal to help 
differentiation and antibody production by the B cell (Parker, 1993).This is the basis 
for the difference between so called T cell independent and T cell dependent 
antigens.  T cell dependent antigens require the T helper cell to provide the second 
signal for activation. T cell independent antigens bind the BCR and the second 
signal is provided by the antigen itself by recognition of a microbial cell constituent 
such as LPS (O'Rourke et al., 1997).
Although antibodies can be produced by B cells without T cell help which do 
provide some level of protection, (e.g. responses to polysaccharide antigens on the 
surface of capsulated bacterium), in order for the B cell to undergo proliferation and 
affinity maturation of their Ag specific receptor (surface Ig), T cell help is required 
(Parker, 1993). It is this phenomenon that can be manipulated using vaccination of 
polysaccharides conjugated to proteins to enhance memory and antibody affinity in 
the young (MacDonald et al., 1998). The initial phase of B cell activation usually
occurs when a specific B cell is trapped in the T cell zone of the secondary
33lymphoid tissue. This is a mechanism which ensures that the rare B and T helper 
cells which are specific for the same organism are more likely to come into contact. 
The primary phase of the B cell response involves proliferation of both T helper 
cells and B cells in what is known as a primary focus. After several days a 
proportion of these B cells will terminally differentiate into antibody secreting 
plasma cells, which migrate to the red pulp of the spleen. This provides a first wave 
of antibody responses that can disseminate into the periphery to help fight the 
infection. These plasma cells have a range of life spans: some may only persist for 
the duration of the infection, while others are very long lived and may account for 
the persistence of long term antibody responses (Manz et al., 1997).
Other B cells and T helper cells migrate to a primary lymphoid follicle where they 
form a germinal centre. This is where through successive rounds of somatic hyper 
mutation of Ig-coding sequences, and selection by antigen in germinal centres of 
the lymph nodes, affinity maturation of the B cells occurs (Berek et al., 1991). This 
is a very “resource expensive” process for the cell where at least 1   in 2 B cells will 
undergo apoptosis due to loss of affinity for antigen or through competition with 
higher affinity clones (Ziegner et al.,  1994). The process results in a few clones 
with much increased affinity for the antigen. With help derived from Th2 cells, B 
cells undergo isotype class switching to enable them to make different 
immunoglobulin (Ig) subclasses (IgG, A, E). This involves the combining of the 
variable gene with different constant region coding sequences, coded for 
downstream  which results in the progeny of one B cell having the ability to 
produce antibodies with the same specificity for antigen but of different isotypes.
These are further described later in this section. These cells then go on to
34terminally differentiate into Ig producing plasma cells or remain as B cell memory 
(Manz et al., 1997). This occurs both during the first encounter of the antigen as 
the primary response progresses and again during subsequent recall responses. 
This process is heavily reliant on the interaction between the cell surface proteins 
CD40 and CD40L. The process of signalling via CD40 to induce class switching is 
also dependent on cytokine production by T helper cells. This allows different 
pathogens to induce different proportions of the different isotypes. For example 
worms and parasites induce the IgE isotype possibly due to the production of 
cytokines such as IL-4 by Th2 cells.
On re-stimulation with antigen some of these memory B cells divide and 
differentiate quickly into plasma cells, while others return to the lymph nodes and 
undergo more rounds of affinity maturation (McHeyzer-Williams and Ahmed, 1999). 
Thus, unlike T cell memory, B cell memory increases in affinity on re-exposure to 
antigen. The main differences between memory and naTve B cells are the speed at 
which specific antibody can be produced, as well as an increase in affinity for the 
antigen and the Ig class of antibody produced. This changes from IgM at the start 
of the primary response to IgG and IgA later in the primary response and thereafter 
in the memory response (Ward and Ghetie, 1995).
The BCR is the membrane bound form of the antibody that the B cell will go on to 
secrete once it differentiates into a plasma cell. Antibodies are made up of four 
polypeptide chains, two heavy chains and two light chains. The light chains consist 
of two immunoglobulin protein domains, one variable and one constant. The heavy
chains consist of three constant and one variable domain, two domains either side
35of a flexible linker region. The variable domains arrange at the antigen binding 
region of the molecule to provide maximum antigen binding diversity as different 
heavy and light chain combinations can come together to give a variety of antigen 
specificity (Edelman,  1991). The variable domain is most variable in three regions 
which are the exposed loops between the immunoglobulin structural regions of the 
domain. These regions are specifically targeted for gene recombination and 
rearrangement combined with somatic hyper mutation that further diversifies the 
host repertoire of antibody (Fanning et al., 1996).
In germinal centres the gene rearrangements of the C regions of the heavy chain 
that result in an isotype switch occur. The first isotype of antibody produced by 
plasma cells is IgM. This is a low affinity antibody as B cells producing it have not 
undergone somatic hypermutation and affinity maturation. However since IgM 
molecules exist as pentamers, the overall avidity of the complex for antigen is high. 
For this reason IgM is found mainly in the blood, as pentamers are too large to 
diffuse into tissues. IgM is a potent activator of complement, so plays an important 
role in controlling blood borne infections. IgG, IgA and IgE are smaller in size and 
can therefore diffuse into the tissues they will have undergone affinity maturation 
and therefore act as monomers (IgA can exist as a dimer). IgG is the principal 
antibody isotype in the blood and can be further split into subtypes IgG 1-4. These 
subtypes relate to the nature of the response and pathogen and whether the 
response is Th1  or Th2 driven (Clark, 1997). IgG is a potent activator of 
complement, opsonization and sensitization for NK killing of cells. IgA is mainly 
present in secretions at mucosal surfaces, and as there are no complement
proteins or phagocytes in this environment, the main function of IgA is to neutralize
36invading pathogens and block binding to mucosal surfaces therefore preventing 
infection. IgG can also act as a neutralising antibody (Ward and Ghetie, 1995). IgE 
is present at low levels and is bound avidly by mast cells which reside beneath the 
skin and mucosa. Triggering of mast cell activation results in release of potent 
mediators such as histamine which results in coughing and sneezing aimed at 
expelling infectious agents. However it is this part of the immune system that can 
become over sensitized to the common environmental antigens and plays a large 
role in allergy.
1.1.2.3  T lymphocytes
T cell precursors arise in the bone marrow. These migrate to the thymus and 
undergo most of their development and selection there, hence the name T 
lymphocytes. The development of T cells involves both positive and negative 
selection to ensure that the rearranged T cell receptor (TCR) binds to self MHC 
(positive selection) but that the TCR is not reactive against self derived peptides 
(negative selection) (Gascoigne et al., 2001). It is for this reason that T cells in a 
specific organism are ‘MHC restricted’, meaning that they will only recognize 
peptides in the context of self MHC molecules. During development, thymocytes 
progress from a double negative (CD4-CD8-) to a double positive stage, ie when 
they express both the co receptors CD4 and CD8. If the TCR is reactive to MHC 
class I, it looses the expression of CD4 and if it binds MHC class II, it looses the 
expression of CD8. Thus mature cells in the periphery express either CD4 or CD8 
but not both (von Boehmer, 1988).
371.1.2.3.1 The T cell receptor (TCR)
The structure of the TCR and its interaction with MHC is central to the biology and 
function of T cells. The T cell receptor itself is made up of an a:(3 heterodimer 
structured homologous to an antibody molecule. Each chain consists of two 
domains, one constant and one variable. The membrane-distal ends of the 
molecule are exposed in order to recognize antigen. However this heterodimer 
alone cannot activate the T cell. The a:p heterodimer is part of the TCR complex 
which also contains two e chains, one 5 chain and one y chain which makes up the 
CD3 molecular complex. CD3 plays a role of stabilizing the TCR at the cell surface 
and in signalling (Davis et al, 1988; Chothia et al, 1988).
1.1.2.3.2 Signalling of the TCR complex
Also assocated with the crp heterodimer is a £ chain homodimer which is 
responsible for most of the signalling into the T cell. The £ chain homodimer has an 
intracellular domain that has six immunoreceptor tyrosine-based activation motifs 
(ITAMs). On TCR activation, due to antigen receptor binding the ITAM becomes 
tyrosine- phosphorylated and transmits the activation signal into the cell. Other 
chains within the CD3 complex also have ITAMs and can play a roll in signal 
transduction. Also associated with the CD3 complex is either CD4 or CD8 which 
act as co-receptors as they recognize and bind to either MHC II or MHC I 
respectively. The cluster of MHC molecules and co-receptors binding to the TCR 
and its associated molecules is known as an immunological synapse (Sidney et al.,
2001). The TCR complex is shown in figure 1.2; the interaction is shown in figure 
1.3a).
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Figure 1.2: Schematic diagram of the T cell receptor complex showing the different 
chains and the signalling ITAMs and the CD4 and CD8 co receptors only one of 
which is expressed on either T helper or cytotoxic T cells, respectively.
1.1.2.3.3 Activation of the T cell- co-stimulation
Binding of the TCR complex to the MHC peptide complex is not sufficient to 
activate the T cell; a second signal resulting from the ligation of co-stimulatory 
molecules such as CD28 and CD80 is also required. This prevents activation of T 
cells to foreign peptides that are not associated with danger such as food derived 
antigens. Innate mechanisms which activate and up regulate co-stimulatory 
molecules as discussed in section 1.1.2.1 are responsible for activating the APC to 
give the second signal required for appropriate T cell activation.
391.1.2.3.4 Major Histocompatibility Complex (MHC)
The TCR complex only recognizes antigen in the context of a major 
histocompatibility complex (MHC) molecule. In humans the MHC alleles are known 
as HLA (human leukocyte antigen) A, B and C for MHC I and HLA-DR, DP and DQ 
for MHC II. This gives a possible combination of six MHC I and six MHC II alleles, 
two for each locus, one from each parent. MHC molecules are composed of a 
heterodimer. In the case of MHC I (figure 1.3) this is the combination of an a chain 
or heavy chain, with three domains, combined with the stabilising non variable 
molecule fe microglobulin.
Figure 1.3: Ribbon diagrams of a) HLA-A2*0201- Heavy chain in purple, (32 
microglobulin in blue and peptide in red being recognized by an antigen specific 
TCR in yellow and green and b) the MHC class I binding groove as seen from 
above.  Created in Chimera and reproduced with the kind permission of Barry 
Flutter.
40The a1  and a2 domains form a cleft which is known as the peptide binding groove 
(Bjorkman et al., 1987). The groove is sealed at both ends allowing only peptides 
of specific lengths (8-12 amino acids) to bind and be presented to T cells. The 
peptide groove is formed at its base by a p pleated sheet of protein secondary 
structure while the sides of the groove are made up of two a helices one from the 
a1  an one from the a2 domain of the heavy chain of the MHC I molecule. Binding 
of a peptide as part of the trimeric complex is required for the MHC molecule to be 
stable at the cell surface (Elliott et al., 1991;Townsend et al., 1990). This is shown 
in figure 1.3 for MHC I.
MHC II is also a heterodimer of an a and p chain. However each has two domains 
and the a1  and p1 domains combine to form the peptide binding groove. This 
results in a more open conformation and MHC II molecules can bind peptides of 
between 13-17 amino acids long. The individual binding grooves associated with 
each allele expose different amino acid side chains within the groove which while 
allowing a wide range of peptides from many organisms to bind, will only bind 
peptides with a specific motif that will fit in the binding groove. The important 
residues in each motif are known as anchor residues (Sidney et al., 2001).
1.1.2.3.5  T cell functions
The functions of cells expressing CD4 and therefore recognizing MHC II
molecules, and CD8 therefore recognizing MHC I molecules, are very different.
CD4 T cells are known as T helper (Th) cells which provide co-stimulation and
cytokines to drive the differentiation of B cells and activation of other cells in the
immune system. This will be further discussed later in this section. CD8 T cells are
41known as cytotoxic T lymphocytes (CTL) and can directly kill virus infected or 
abnormal cells. For this reason the antigens that each type of T cell recognizes are 
derived from different sources. In health, only phagocytic cells such as 
macrophages, B cells and dendritic cells express MHC II. This is because peptides 
presented in the context of MHC II are derived from extra cellular antigen which 
enters the cell via endosomes and is degraded into peptide fragments before being 
loaded on to MHC II molecules in the endoplasmic reticulum and transported to the 
cell surface for recognition by CD4 T cells, this is shown in figure 1.4 (Pieters,
2000).
MHC I is expressed on the surface of most nucleated cells in the body. Expression 
of intra cellular proteins as peptides on class I MHC on the cell surface acts as a 
monitoring system for what is occurring inside the cell. The proteosome degrades 
intra cellular proteins which are then loaded on to MHC I molecules for 
presentation at the cell surface. This occurs with the cooperation of a variety of 
peptide loading proteins which are beyond the scope of this thesis (Flutter B,
2004). Therefore if the cell is infected with an intracellular pathogen the peptide 
presented derived from that pathogen will be recognized as foreign by a CTL and 
the infected cell will be destroyed halting the spread of the infection.  This process 
is also shown in figure 1.4.
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Figure 1.4: Diagram to show the different pathways of antigen presentation by 
MHC molecules. In blue is antigen from the cytoplasm digested in proteosomes 
and resulting peptides loaded onto MHC I molecules. In green is external antigen 
being engulfed and digested in endosomes and resulting peptides loaded onto 
MHC II molecules and presented at the cell surface.
1.1.2.3.6  Cross presentation
This system is complicated by the fact that some exogenous antigens such as 
viruses from cells that have undergone lysis, and intracellular proteins from dead or 
dying cells can also be presented to CTL. Thus a process known as cross 
presentation occurs in specialised antigen presenting cells such as DCs where 
there is a specific pathway which delivers extracellular proteins into the MHC I 
presentation pathway in order to allow presentation of exogenous antigens to CTL 
(Lizee et al., 2003;Rodriguez et al., 1999;Ulmer et al., 1994).
431.1.2.3.7 CD8T cells
After recognition of a presented peptide fragment in the context of MHC, provided 
the correct co-stimulation is present, T cells are activated. In general TCR ligation 
and T cell activation leads to proliferation and differentiation into either effector or 
memory cells. The function of CD8 T cells is detection and destruction of cells 
presenting abnormal peptides derived from cytoplasmic proteins. These peptides 
may be derived from intracellular pathogens or abnormalities due to mutations, as 
in cancer. These peptides are presented in the context of MHC Class I and once 
they are detected CTL kill infected or mutated cells by the release of granules 
containing perforin and other cytotoxic mediators, or Fas-Fas ligand induced 
apoptosis of the target cell. Cytokines released by CTL include IFNy, which 
activates macrophages and acts as a “warning” to surrounding cells inducing up 
regulation of MHC Class I in surrounding cells to enable easier detection of 
infection in those too (Stout and Bottomly,  1989).
1.1.2.3.8 CD4T cells
There are three types of CD4 T helper cells, defined as Th1, Th2  and ThO cells 
(Kamogawa et al., 1993). It is thought that Th1 and Th2 cells are driven to 
differentiate from ThO cells, however at which point during differentiation this 
becomes a permanent change is still unclear (Grogan and Locksley, 2002). Th1 
cells are induced by cytokines such as IL-12 and IFNy, and themselves produce 
IFNy and IL-2. These cytokines inhibit the development of Th2 cells and are 
produced in response to viruses and other intracellular pathogens (Nakamura et 
al.,  1997). Thus the cellular branch of the immune system is stimulated, activating
44macrophages and providing help for the production of effector CTL responses 
(Machy et al., 2002). In contrast, production of cytokines such as IL-4 and IL-10 
can push CD4 ThO cells into Th2 type cells, which are associated with a humoral 
response. Th2 cells through production of IL-4, IL-5 and IL-10 are very important 
for humoral immunity, stimulating B cells and playing a central role in antibody (Ab) 
class switching (Stavnezer, 1996), they also fail to activate macrophages (Stout 
and Bottomly, 1989).
1.1.2.3.9  ‘Natural’ T regulatory cells
There is another sub set of cells that are thought to be generated in the thymus 
and are characterised by a CD4+ CD25 high phenotype. These cells are known as 
regulatory T cells (Treg) and can suppress immune responses. Several 
populations of Treg have now been characterised. 'Treg were first recognised as a 
subset of cells that could decrease the severity of autoimmune disease (Asano et 
al., 1996;Read et al., 2000;Sakaguchi et al., 1996). It was subsequently shown that 
these cells also played a role in the control of immune responses to pathogens 
(Suvas et al., 2003). Cell contact is required to mediate the suppression by CD25+ 
Treg (Nakamura et al., 2001). In addition to this subset of cells, other suppressive 
cells have been identified. Some of these are thought to be generated in the 
periphery during the course of an immune response that are antigen specific and 
are derived from the memory pool of cells, but they can act in a non specific 
manner when suppressing other responses (Akbar et al., 2003). “Classical” Treg 
can also induce the production of secondary Treg in the periphery which act via 
cytokines such as TGFp and IL-10. These cells have been called Th3 and Tr1,
45respectively.  It also appears that DCs can induce the production of Treg (Levings 
et al., 2005;Roncarolo et al., 2003). This will be discussed further in chapter 6.
1.1.2.4 T cell memory
Once an infection has been detected by the immune system, specific cells are 
activated and proliferate. Thus a large expansion of antigen specific effector T cells 
occurs. Once the pathogen has been cleared, this primary response comes to an 
end and the effector cell pool contracts leaving a small population of memory cells 
(Badovinac et al., 2002). Unlike B cells there is no affinity maturation of the T cell 
response after the first encounter with antigen; however due to competition for 
antigen the higher affinity T cells have an increased chance of survival and 
therefore become dominant in the response (Blattman et al., 2000). There is 
evidence to suggest that memory T cells can persist for the lifetime of an organism 
this is shown in the case of vaccinia virus, where 90% of individuals vaccinated 
against smallpox had recall memory responses presumably in the absence of 
antigenic re-stimulation within the last 25 years (Hammarlund et al, 2003).
The current model of T cell memory subsets reflects the heterogeneity of both 
homing potential and function of memory T cells in the periphery. The T cell 
memory subsets are broadly separated into two populations termed central 
memory and effector memory (Geginat et al., 2003;Sallusto et al., 1999). In 
general, naTve cells, once they experience antigen, go from expressing the CD45 
isoform; RA, to expressing the smaller isoform CD45RO which can therefore be 
used as a marker of memory cells (Merkenschlager et al.,  1988). However in the
46CD8 population differentiated memory cells may also ‘revert’ to expression of 
CD45RA which will be discussed later.
1.1.2.4.1 Central memory T cells
Central memory cells are distinct from naive cells due to the increased sensitivity 
to TCR cross linking, they are therefore quicker to divide on encounter with specific 
antigen and due to expansion, are at higher frequencies within the T cell pool than 
naive cells. Central memory cells can also differentiate into effector cells, albeit 
slower than effector memory cells (Sallusto et al., 1999). Central memory T cells 
express CD62L (L-selectin) this is in common with naive cells; they also express 
the chemokine receptor CCR7 which is responsible for the central memory cells 
homing to lymph nodes.
1.1.2.4.2 Effector memory T cells
In contrast, effector memory cells can rapidly mature into effector cells and secrete 
large amounts of cytokine shortly after re-stimulation (Sallusto et al., 1999). These 
cells do not express CD62L or the chemokine receptor CCR7 therefore the cells do 
not home to lymph nodes. Some of them do however express receptors for 
inflammatory cytokines and chemokines. In the case of CD4 memory cells, CXCR5 
(the receptor for CXCL13, a chemokine present in B cell follicles) (Moser et al,
2002)  is expressed, making these cells specialised for quickly entering inflamed 
tissues at the start of an infection (Mackay et al., 1992).
Recent data has shown that both central and effector memory cells are generated
during the same immune response -i.e. both central and effector memory T cells
47are generated that either home to lymph nodes or are more activated and home to 
tissues (Lanzavecchia et al, 2005). Work in mice has shown that for CD8+ T cells 
responding to LCMV infection, memory cell precursors were present at the peak of 
the immune response but did not display the functional phenotype of memory cells. 
These functions such as self renewal, and survival were gradually acquired during 
pathogen clearance. It was also found that expression of the IL-7Ra chain could be 
used to isolate the memory precursors at early time points during the effector 
phase of the response and these cells could confer protection in other animals 
upon adoptive transfer (Kaech et al, 2003).
Another phenomenon associated with the development of memory T cells is that 
there appears to be the ability to imprint on to a T cell the tissue to which it should 
preferentially home, this has been demonstrated using DC taken from either gut or 
skin, to prime a T cell response and results in effector T cells with specific homing 
abilities (Campbell et al, 2001, Dudda et al,  2004).
1.1.2.4.3  Maintenance of T cell memory
Recent work has measured the rate of division of different memory T cell 
populations. This is very exciting and novel data as it is the first in vivo human data 
to be generated of this nature. The turn over of CD4+ cells was measured using 
heavy glucose incorporation into DNA. Effector memory cells divided at a rate of 
4.7% per day, central memory cells at 1.5% per day and naive cells at 0.2% per 
day. This shows that memory cells especially effector memory cells are shorter 
lived cells than the naive population and therefore are actively replenished through 
division (Macallan et al, 2004).
48There is also a debate about what mechanisms maintain T cell memory in an 
organism and how long this memory lasts. There is an increasing amount of 
evidence that suggests that IL-7 and IL-15 are important for resting homeostasis of 
the T cell pool (in particular CD8+ T cells) and interferons (IFN) are important for 
reactivation and proliferation on re-stimulation (Hamann et al., 1997;Tuma and 
Pamer, 2002). It appears that in CD8+ T cells IL-15 mediates proliferation and IL-7 
enhances survival. In humans it has been shown that both central and effector 
memory T cells proliferate in response to IL-7 and IL-15 (Geginat et al, 2003). One 
of the main controversies in this area is whether the central and effector memory 
subsets are stable or whether they can feed into one another. In vitro experiments 
have shown that central memory cells in response to IL-7 and IL-15, can loose 
CCR7 expression and acquire tissue homing receptors thus raising the possibility 
that the central memory pool might divide and differentiate into effector memory T 
cells (Geginat et al, 2003). However more work must be done in humans to further 
investigate the effector/central memory T cell relationship.
1.1.2.4.4  Phenotypic markers of memory
Although the distinction between naTve and antigen experienced cells applies to 
both CD4+ and CD8+ T cells, in that the isoform of CD45 expressed on the surface 
of the cells changes form CD45RA to CD45RO, there are other phenotypic 
markers which can be used to follow the maturation and differentiation of memory 
cells.  For example Appay et al and others (Posnett et al., 1999) have identified 
different levels of differentiation in the CD8+ T effector memory cell population by
the markers CD27 and CD28, CD27+CD28+ being the early T cell pool which can
49differentiate into CD27+CD28- cells, which progress further to CD27-CD28- cells. 
CD28- cells have been shown to be perforin positive and less sensitive to death by 
apoptosis (lower expression of CD95-Fas than CD28+ counterparts) (Posnett et 
al., 1999).
Related to this are reports that a revertant population of antigen experienced cells 
that re-express CD45RA  is present within the T cell memory pool (Hamann et al., 
1997;Dunne et al., 2002;Faint et al., 2001;Okumura et al., 1993;Wedderburn et al.,
2001). Therefore it can be said that within the population of CD8+ T cells, a 
CD45RA+CD27-CD28- CCR7- phenotype, which correlates well with expression of 
perforin and high cytolytic activity with no prior re-stimulation, represent the effector 
CTL population (Hamann et al., 1997;Hislop et al., 2001;Tomiyama et al., 2002).
Interestingly it has been shown that in the case of these chronic infections, the 
effector cells described above which are present in large numbers have an inability 
to respond to the homeostatic cytokines IL-7 and IL-15 probably due to the fact that 
they do not acquire the expression of memory markers such as IL-7Ra described 
earlier in section 1.1.2.4.3. This may explain the inability of these cells to exist long 
term and also points to a fundamental difference in both phenotype and function of 
CD45RO+ effector memory T cells, which exist independently of antigen 
stimulation and chronically stimulated CD45RA revertant effector T cells, which 
require antigen for survival (Harari et al 2004, Wherry et al 2004, Lang et al 2005, 
Lanzavecchia et a12005).
50This situation is generalised for memory cells against a transient infection, 
compared with individual studies in chronic infections. One study has compared 
immunological memory to persistent viruses such as EBV, CMV and HIV. There is 
evidence that in these chronic situations different subsets of cells within the 
memory T cell population are driven to divide and differentiate in different ways, 
depending on the virus. Thus it was concluded that a more specific approach 
should be taken when analysing responses to different viruses and one should be 
careful of applying observations made in the case of one virus, to other immune 
responses to different organisms (Appay et al., 2002)
Up until recently it has been difficult to mirror the studies in T cell memory 
phenotype on CD8+ T cells with similar studies on CD4+ T cells. This is because 
many of the studies addressing the resting phenotype of memory cells have relied 
heavily on the use of MHC tetramers. These have been manufactured successfully 
for MHC I however reagents using MHC II have been more of a challenge to 
produce (Cameron et al., 2002). However some data have emerged showing that 
the progression of CD4+ memory cells through the different stages of expressing 
CD27 and CD28 mirrors that which is seen in the CD8+ population for the same 
infection (EBV). This is in contrast with the CD4+ response seen to CMV which has 
CD4+ T memory cells accumulating in different stages of differentiation to those 
seen with EBV (Amyes et al, 2003). This again confirms that the progression of 
cells through the phenotypes outlined above may apply differently in different types 
of infection each of which must be investigated individually.
511.2  Manipulating the immune system (vaccination)
1.2.1  History of manipulation of immune responses
Edward Jenner is widely considered to be the founder of modern day vaccinology.
It had already been discovered that the process of variolation in which a small 
amount of dried material from a smallpox pustule was inoculated into a patient, 
caused a mild disease in most cases and protected the patient from subsequent 
infection with smallpox. However 3% of cases would go on to develop fatal 
smallpox; therefore this was not a feasible strategy for controlling disease. Jenner 
made the observation that during smallpox outbreaks, dairy-maids had a lower 
incidence of disease and that when servants milked cows with cowpox -infected 
udders they suffered inflamed spots on their hands. Jenner then inoculated the 
servants with smallpox and showed that they did not show any symptoms of the 
disease. Then in 1796 in a pioneering (but ethically dubious) experiment Jenner 
injected matter taken from the hand of a cowpox infected dairy maid into the arm of 
a boy named William Summers. One week later he noted that the boy was 
“perceptibly indisposed”: however he recovered and two weeks after the initial 
inoculation Jenner challenged the boy with smallpox, taken from varioles on a 
patient with smallpox and showed that the boy had no symptoms of smallpox 
infection at all. Jenner called this process vaccination after the cowpox vacinnia 
virus. This was the birth of vaccination, although it was almost 100 years later that 
Louis Pasteur developed a weakened strain of chicken cholera for the inoculation 
of chickens. In honor of the work of Jenner he named the process vaccination. He 
also developed a weakened strain of rabies for vaccination of humans.
52Since the first pioneering work by Jenner and Pasteur, at least nine major diseases 
in man have been controlled to a certain extent in humans using vaccination. 
Vaccination is considered to be one of the most important and most cost effective 
public health interventions alongside clean water. As well as the immeasurable 
benefit of saving lives and preventing disability, vaccination for just two common 
childhood diseases, measles and Haemophilus influenzae type B (HIB) is 
estimated to have saved the US public health authority $900 million per year since 
adequate coverage of the vaccines was achieved (Cutts et al., 1999;Peltola, 2000).
1.2.2  Successes of vaccination
The most obvious success of vaccination has been the worldwide eradication of 
Smallpox in 1979, which was estimated to have killed 500 million people worldwide 
in the 1900’s alone (Fenner, 1998). Although the vaccine was available throughout 
the 1800’s it was only used sporadically and it was not until the 1950’s that the 
suggestion was made that with increased efforts smallpox could be eradicated.
This was not taken seriously until 1965 when the intensified smallpox eradication 
programme came into effect which not only used vaccination but also incidence 
reporting and containment of outbreaks along with advances in vaccine delivery to 
achieve its goal (Mahalingam et al., 2004). In the early 1900’s the BCG vaccine for 
tuberculosis was introduced in the West, however access was restricted to the 
wealthy, while the most susceptible poorer communities continued to experience 
outbreaks of vaccine preventable diseases. Probably the next large achievement in 
the West was the great reduction of poliomyelitis through development of the oral 
polio vaccine which due to affordability and ease of administration achieved wide
coverage. However what is probably the biggest failure of vaccination to date is
53that while countries with the greatest resources and political infrastructure can 
reduce disease burden and achieve regional elimination of the diseases, in other 
countries almost 2 million children die every year as a result of diseases that are 
preventable with the use of cheap vaccines. For example 90,000 children develop 
paralytic polio each year which could be prevented with an efficient vaccination 
programme (WHO, 2005). Table 1.1  shows a selection of vaccines introduced for 
use in humans over the last 200 years (Centers for Disease Control and 
Prevention, 1999).
Date Disease Date Disease
1798 Smallpox 1962 Oral Polio Vaccine (OPV)
1885 Rabies 1964 Measles
1897 Plague 1967 Mumps
1923 Diphtheria 1970 Rubella
1926 Pertussis 1981 Hepatitis B
1927 Tuberculosis (BCG) 1987 HIB conjugate
1927 Tetanus 1999 Meningococcus conjugate
1935 Yellow Fever 2000 Pneumococcal conjugate
1955 Injectable Polio Vaccine (IPV)
Table 1.1: Dates of introduction of vaccines against a variety of diseases since 
Jenner’s work in 1798 a selective list adapted from (Plitkin S. A and Mortimer E.A., 
1994).
From the example of smallpox it is obvious that with international cooperation, as 
well as efficient vaccination and containment strategies, it is possible to eradicate
54diseases. To this end in 1974 the WHO created the expanded programme on 
immunization (EPI) which identified six diseases that had affordable vaccines that 
would be targeted for eradication. These were tuberculosis, diphtheria, neonatal 
tetanus, whooping cough, polio and measles. This has resulted in many countries 
virtually eliminating these diseases, but it is clear that in order to completely 
eradicate certain diseases an international effort is required as small pockets of low 
vaccine coverage and high disease rates act as reservoirs that lead to constant 
reintroduction of disease into areas that have controlled it (WHO, 2005).
1.2.3  Problems associated with vaccine development
Vaccine development has not been without problems. Several instances of 
vaccination resulting in abnormal manifestations of the disease have been 
reported. These have mainly been caused by a vaccine primed immune response 
causing increased disease severity in measles (MV), dengue and respiratory 
syncytial virus (RSV). The manifestation of atypical measles occurred after patients 
were immunized with formalin inactivated measles vaccine (Fulginiti et al., 1967). 
This vaccine was withdrawn. Subsequent analysis on the immune pathology 
caused by the vaccine and infection with MV has been carried out in rhesus 
macaques by Diane Griffin’s group. This has shown that atypical measles may be 
caused by the priming of a non protective Th2 biased immune response without 
priming for CTL (Polack et al., 2002). Antibodies are also involved and immune 
complex deposition at sites of infection and recruitment of eosinophils contribute to 
pathology contradicting previous predictions that infection could be due to low 
levels of anti MV fusion protein antibody (Polack et al., 1999). However the
antibodies produced against MV were of low avidity and therefore had reduced
55neutralising capacity. Affinity maturation did not occur in formalin inactivated 
vaccine recipients and the antibodies were non protective but induced complement 
resulting in atypical measles (Polack et al., 2002). The RSV vaccine was also 
formalin inactivated and the more severe form of RSV claimed the lives of two 
children. This has also been attributed to the induction of an inappropriate Th2 
skewed immune response which contributes to the lung pathology observed 
(Openshaw et al., 2001). Interestingly vaccines have recently begun to be credited 
with non specific positive effects on children in high mortality regions. The exact 
mechanisms of this are still being investigated (Aaby et al., 2003;Stensballe et al., 
2005).
A more recent problem has been encountered in developed countries where 
adverse publicity surrounding vaccines specifically the MMR (measles mumps and 
rubella) has reduced take up rates of the vaccine to dangerously low levels. 
Vaccine coverage in some areas of the UK has fallen to below 65% therefore it is 
highly likely that there will soon be an epidemic like that in Ireland in 2000 leading 
to deaths that could have been prevented (Coughlan et al., 2002). The claims 
surrounding the MMR have failed to be verified by many new studies however it 
appears the damage has been done (Chen et al., 2004;Honda et al., 2005;Miller et 
al., 2005;Peltola et al., 1998;Taylor et al.,  1999). Although vaccine coverage rates 
are rising again there remains a substantial population of parents that are not 
willing to have their child vaccinated. This highlights the very important point that 
public confidence must be established in any preventative intervention or herd 
immunity provided by high coverage rates of the vaccine will be lost and
susceptible individuals will suffer (Jansen et al., 2003).
56The majority of severe childhood illness occurs within the first eighteen months of 
life, the so called “window of opportunity”. Very young children are protected from 
infection by the presence of IgG antibodies that are passed from the mother across 
the placenta during pregnancy. This is further maintained during breast feeding, by 
the transfer of IgA antibodies through the breast milk. These antibodies begin to 
wane as the child’s immune system matures and breast feeding ends; however, 
there is a window of time when the child may not be fully protected. This may be of 
increased significance as it appears that vaccine induced antibodies from the 
mother wane more quickly than antibodies induced by natural infection. Therefore 
as the proportion of mothers that had the natural infection decreases, the age at 
which infants loose their maternal antibodies may decrease, causing susceptibility 
to infection to occur at an earlier age (Redd et al., 2004).
This contributes to another factor that continues to be a problem for the efficient 
use and development of vaccination programmes. This is the increasing evidence 
that an immature immune system in very young children contributes to the lack of 
or inappropriate response to vaccines. Initially it was believed that persistence of 
maternal antibodies neutralized the vaccination challenge and therefore prevented 
seroconversion of the infant (Albrecht et al., 1977;Osterhaus et al.,  1998). This is to 
a certain extent true and maternal antibodies do indeed play a role. However work 
by Hayley Gans and colleagues has shown using measles and mumps vaccination 
of 6, 9 and 12 month old children that independent of maternal antibody levels 
there is an age dependent deficiency of the humoral response in young compared
to older infants (Gans et al., 2001;Gans et al., 1998). They subsequently showed
57that there appears to be no deficiency in the cellular immune response to measles 
vaccine in early life and in fact maternal antibody levels have no effect on the 
induction of this response. These data seem to indicate that it is possible to 
vaccinate in the presence of maternal antibodies and induce the cellular arm of the 
immune response which may protect against viruses and other intracellular 
pathogens during the window of opportunity between the waning of maternal 
antibodies and the full maturation of the immune system (Gans et al., 2003). 
However it seems this phenomenon may be disease- and precise vaccination 
formulation- specific, and also may only apply to CTL responses. Other groups 
have shown that efficient CTL responses can be produced in early life, by human 
babies with HCMV (Marchant et al., 2003) and efficiently stimulated by DCs from 
cord blood (Salio et al., 2003). However with respect to the T helper subset of cells 
there are several other reports of a skewing of the infant immune response towards 
a Th2 rather than a Th1  phenotype which predominates in later life. Studies have 
shown that DCs from cord blood are intrinsically deficient in production of IL-12 
which is a cytokine vital for Th1 differentiation, thus potentially skewing the immune 
response in early life towards Th2 (Langrish et al., 2002). This has been 
demonstrated functionally in studies of vaccination against polio and hepatitis B 
(Ota et al., 2004;Vekemans et al., 2002) when compared to responses in adults. 
Although this may be a normal consequence of exposure to such antigens and the 
conclusion that responses in early life are Th2 skewed may be a result of the 
influence of findings in experiments in mice and may not hold true in future human 
studies. However it does appear to be possible to induce Th1  responses as has 
been demonstrated in studies of vaccination of infants with the BCG vaccine 
(Marchant et al., 1999).1.2.4  New challenges for vaccine development
Along with the development of vaccines for emerging diseases such as HIV and 
diseases that still cause huge morbidity and mortality such as malaria, the other 
major challenge is to supply and distribute the vaccines to the countries in the third 
world which need them most. This is of utmost importance if the WHO is to achieve 
the aim of complete eradication of diseases such as measles and polio. In 
countries where vaccination rates are high such as the USA the indigenous 
measles transmission has been eliminated; however, there are still intermittent 
outbreaks from imported cases of measles showing that in any long term goal of 
either eradication or regional elimination, must involve helping less developed 
countries to vaccinate which will in turn reduce imported cases and aid the efforts 
of more developed countries in controlling infectious disease (Cutts et al., 1999).
To this end, there has been a huge drive recently with measles vaccination in 
Africa to try to halt the spread of this highly infectious disease. In southern African 
countries which already had good vaccination coverage, from 1996 to 2000 in an 
attempt to regionally eliminate measles, a catch up campaign was implemented. 
This targeted children from 6 months to 14 years and then was enforced by follow 
up campaigns every 3 years after in 9-59 month olds. The results of this were very 
encouraging. Reported cases fell from 60,000 in 1996 to just 117 in 2000, deaths 
declined from 166 to zero during the same period (Biellik et al., 2002). Therefore 
this shows that increased efforts combined with catch up campaigns and 
surveillance can have a huge impact on decreasing transmission and disease 
burden caused by measles (Biellik et al., 2002).
59However as previously discussed it is the children under one year that are most at 
risk, yet routine vaccination cannot occur under 9 months of age due to the chance 
of vaccine failure due to maternal antibodies (Osterhaus et al., 1998). Therefore if 
a method of vaccination could be devised that was to bypass maternal antibodies 
and therefore could be given at birth to provide some protection mediated by CTL 
until the MMR could be administered, vaccine coverage could be even higher and 
the goal of measles elimination even closer. Such a vaccine could also be of 
importance to boost the immunity of adults as it is known that the response to the 
vaccine is less robust than the response to MV infection, as secondary vaccine 
failures have been documented where individuals responded well to the vaccine 
yet still contracted measles (Markowitz et al., 1990). There is also evidence that 
CD4+ T cell memory in vaccinated subjects decreases after 20 years however CTL 
levels appear to be stable over this time. The significance of this for protection is 
unclear (Naniche et al., 2004). Therefore there is fear that immunity in general to 
measles may be waning, as it is unclear as yet if vaccine induced immunity is life 
long (Osterhaus et al., 1998). It has been shown recently that 92% of patients 
vaccinated 26-33 years previously still had protective plaque reduction 
neutralization levels (PRN) (Dine et al., 2004).
There is a further issue concerning the measles vaccine, which being a live
vaccine, requires cold storage until use. This creates a logistical problem in remote
areas and inappropriate storage can lead to vaccine failure. It also significantly
increases the cost per dose due to the increase in transport costs associated with
cold storage. A component vaccine could potentially overcome these problems. If
the immunodominant peptides within the measles virus could be identified, and a
60subunit vaccine made that would be stable at room temperature, this could 
potentially advance the cause of measles control (Putz and Muller, 2003). Related 
to this is the issue of consumer confidence. It is possible that a non live vaccine 
would be more acceptable to parents especially in light of the recent controversy. 
Finally, there is the need to address the fact that in the future the eradication of 
measles may become a reality and therefore vaccinating with a live virus (even 
attenuated), may no longer be desirable or acceptable (although vaccine derived 
attenuated measles spreading between humans has never been reported). It is 
therefore believed that development of an alternative measles vaccine to the live 
attenuated one currently used, is an important task both because of the worldwide 
benefits measles eradication would bring, but also since the process of developing 
new vaccines should improve our knowledge of the interaction between the human 
immune system and this highly infectious virus (Putz et al., 2003).
Many different strategies have been employed in the search for an alternative 
measles vaccine. Most of the work on experimental vaccines has so far been 
carried out in mice and non human primates. Vaccines based on viral or bacterial 
vectors containing recombinant viral proteins, DNA or peptide epitopes have been 
developed and are reviewed extensively in (Putz et al., 2003). Single MV proteins 
have been used and have shown priming of antiviral CTL in mice (Etchart et al.,
2001).Two different groups have published work on DNA based vaccines which 
protect Rhesus macaques despite the presence of neutralising MV antibodies at 
the time of vaccination (Polack et al., 2000;Premenko-Lanier et al., 2004). Despite 
encouraging early reports that DNA vaccines induced potent Th1  responses
(Martinez et al., 1997), more recent studies have shown that the MV
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(Polack et al., 2003), obviously undesirable following the investigations into atypical 
measles.  The MV Fusion (F) protein, despite the identical routes of administration 
skewed towards a Th1  response identifying the complex nature of host/ vaccine 
antigen interaction (Polack et al., 2003) and that a combined approach to 
component vaccines may give a more balanced immune protection. Other novel 
strategies include the expression of MV proteins in carrots which retain 
conformations that induce neutralising antibodies when injected. The benefits of 
this are two fold, firstly antigen can be produced and purified for injection in the 
country of distribution lowering costs and secondly as carrots can be eaten raw, if it 
was shown that effective immune responses could be induced to measles via the 
oral route of administration as with polio, both production and administration costs 
and safety concerns would be significantly reduced (Bouche et al., 2002;Bouche et 
al., 2003).
1.2.5  Peptide based vaccines
Another line of investigation into potential new vaccines uses the identification of 
epitopes -  the consecutive polypeptide regions of a protein that are recognised by 
either B cells or T cells. Vaccines of this type have been shown to be effective in 
animal studies whether delivered as peptides or as DNA coding for peptides 
(Livingston et al., 2002;Vuola et al., 2005)  and that multiple epitopes can be 
delivered at the same time without one response overwhelming the others due to 
immune dominance. There are several peptide based vaccines currently in trials in 
both animals and humans. A vaccine based on a single CTL epitope against the
MV related virus RSV was shown to elicit an effective CTL response which did
62protect mice from establishing RSV infection but disease may have been enhanced 
by the same CTL (Simmons et al., 2001). A peptide based vaccine has also been 
trialed in humans as a therapeutic HIV vaccine used in an attempt to boost host 
responses to the virus and reduce the need for antiviral therapy (Asjo et al., 2002). 
There has also been some success with peptide vaccines against malaria where 
studies have successfully shown immunogenicity of the vaccine in humans and 
have been both immunogenic and protective in animals (Kashala et al., 2002;Tsuji 
and Zavala, 2001).
1.2.6  Identifying specific peptides
There are several different techniques that have been used to identify viral 
epitopes. These include initial studies with cells lines deficient in certain molecules 
important for the loading of peptides. MHC I surface expression is reduced in these 
cells lines as the MHC I is no longer stabilised at the cells surface. If exogenous 
peptide is added to these cells that can bind to HLA-A2*0201 the measurable MHC 
I on the cell surface increases. This technique has been used to identify epitopes in 
both influenza (Nijman et al., 1993) and EBV and HIV (Stuber et al., 1992). Other 
strategies have used microcapillary high performance liquid chromatography- 
electrospray ionization-tandem mass spectrometry to identify peptide motifs (Hunt 
et al., 1992) and in the specific case of measles by the same protocol comparing 
MV infected cells with uninfected cells. This allowed the identification of naturally 
processed CTL epitopes one of which proved to be immunogenic in transgenic 
mice (van Els et al., 2000). Another technique that Goulder et al have used to 
identify HIV epitopes is the use of overlapping synthetic peptides that are 15 amino
acids long and overlap by 10 amino acids. These are used in pools to stimulate
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15mers can be identified and further analysed to identify the dominant sequence 
(Goulder et al., 2001). This is a high throughput and fast assay, which may be of 
great benefit when working in the field. It also requires less starting material than 
other methods which involve growing cell lines or bulk cultures, and which can be 
difficult to interpret (Rodda, 2002).
1.2.7  Measuring immune responses to infection and vaccines
The release of IFNy is considered to be an effector function of re-activated effector 
CTL and occurs within hours of re-encounter with antigen. This can be measured 
in a variety of ways to assess CTL frequency and response to vaccines and virus 
antigens. This is further discussed in chapter 3. The ability to measure such 
responses depends on the precursor frequency of T cells specific for a certain 
antigen. Numbers of antigen specific cells have been measured in a variety of 
different infections. In order for efficient detection of responses, the assay must be 
sensitive enough and the precursor frequency of cells high enough to reproducibly 
allow measurement of responses over background. Using limiting dilution analysis 
and cytotoxic T cell assays one group found responses to hepatitis C virus (HCV) 
to be in the region of 10 responders per million PBMC compared to up to 40 
responders per million PBMC against the Influenza matrix peptide (Rehermann et 
al.,  1996). Further analysis of the influenza matrix peptide has shown that the 
precursor frequency to this epitope is in the region of 30 responders per million 
cells as shown by ELISpot (Jameson et al., 1998). However in a chronic infection 
such as HIV where the T cells are constantly stimulated with antigen, responses of
between 75 and over 1500 responders were seen per million PBMC (Goulder et
64al., 2001). This finding was verified in another chronic virus Epstein Barr Virus 
(EBV) where up to 2,500 responders to one peptide could be detected per million 
PBMC in infected patients (Tan et al., 1999).
1.2.8  Peptide epitopes in Measles
A peptide based vaccine could potentially address many of the current problems 
associated with MV vaccination as outlined in section 1.2.4. A vaccine which 
stimulated all parts of the immune system would be most desirable as antibodies 
are the current measure of protection although CTL and Th cells are obviously 
important (section 1.3). MV B cell epitopes have been identified, these are usually 
seen in the context of the folded protein and are therefore not consecutive peptides 
within the sequence of the protein however some are and have been shown to be 
protective in animal models (Atabani et al., 1997;EI Kasmi et al., 2000). More 
recent work by Putz et al has identified further B cell epitopes within the MV H 
protein the response to which is not neutralized by MV antiserum they are currently 
using bacterial toxin conjugates to develop candidate vaccines (Putz and Muller, 
2003).
The identification of potential MV T cell epitopes has also been a priority. Several 
proof-of-principle studies have found both CTL and Th epitopes in mice that when 
used as vaccines have proved to be protective to re-challenge with rodent adapted 
MV strains (Beauverger et al., 1994;Obeid et al., 1993;Schadeck et al.,  1999). 
Despite MV being widely studied, relatively little is known about its recognition by 
the human immune system, and specifically the peptide epitopes that human T
cells recognise. Studies have seen proliferative responses to predicted Th MV
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MV epitopes (Nanan et al., 1995). These putative CTL epitopes were further 
analysed by van Els et al using microcapillary high performance liquid 
chromatography- electrospray ionization-tandem mass spectrometry and were not 
found to be epitopes processed by MV infected B cells for presentation at the cell 
surface (van Els et al., 2000). They did however identify 3 other epitopes one of 
which from the core protein was expressed at very high density (C84-92). Further 
analysis showed that this epitope was responded to very strongly in naturally 
infected children with acute infection; however responses appeared not to persist 
to memory (Jaye et al., 2003). These predicted epitopes are all HLA-A2*0201 
restricted as this is the most common HLA-A allele, with 40% of the Caucasian 
population carrying it. Herberts et al identified another CTL epitope which was 
HLA-B*2705 restricted (Herberts et al., 2001). Despite the large amount of work 
involved here and the identification of several putative CTL epitopes little work has 
been done to examine to what extent these play a role in the human response to 
both natural measles infection and vaccination. The work outlined in this thesis 
initially attempts to further this work by investigating the T cell memory responses 
of immune individuals (MV seropositive) to previously identified MV CTL epitopes 
using the strategy used by Goulder et al to identify interferon y (IFNy) producing 
cells in the enzyme linked immunospot assay (ELISpot) in response to MV 
peptides (Goulder et al., 2001).
661.3  Measles virus (MV)
1.3.1  Measles Virus background
Measles is a highly communicable viral disease transmitted by aerosol from person 
to person with humans as its only natural reservoir. One measure of transmissibility 
of a virus is the Ro value. This indicates the number of secondary cases one 
individual index case can cause, for measles the value is 10 one of the highest for 
any virus reported (Rima, 2001, Edmunds et al, 2000). Due to this high infectious 
nature, any vaccination strategy requires between 95 and 99% of the population to 
be protected in order to halt viral transmission. In most cases measles causes 
fever, conjunctivitis and a cough. It can be identified through the characteristic red 
blotchy rash (figure 1.5), which appears on the third day of illness.
Measles is frequently associated with middle ear infection or diarrhoea due to 
opportunistic infections that are established due to transient immunosuppression 
elicited by the measles virus (section 1.3.8).  In 1846 Peter Panum made the 
important observations of the infectious nature of the virus, the 14 day incubation 
period from exposure to the onset of the rash and the fact that despite the lack of 
re-exposure after infection immunity was life long (Panum P.L., 1989- a re­
publication of the original paper). This was done making observations in the Faroe 
Islands where measles infection had been reintroduced after 60 years. Older 
members of the community were still immune whereas everyone who had not been 
previously exposed became infected, the disease being most serious in younger 
children.
67Figure 1.5 Child displaying the typical measles rash, kindly provided by Prof. John 
Stephenson (LSTHM)
1.3.2  Measles virus complications
Measles is not only responsible for the rash seen during infection. The secondary 
infections that occur due to the transient immune suppression elicited by MV 
infection can be devastating. This is best illustrated by statistics from the pre 
vaccination era in the USA where health care and support facilities were good. 4 
million children were infected per year -essentially the whole birth cohort. This 
resulted in an estimated 500 deaths, 48,000 hospitalisations, 100,000 cases of 
otitis media often associated with hearing damage, 4,000 cases of encephalitis 
1,000 cases of which resulted in permanent brain damage and 150,000 cases of 
respiratory complications often associated with secondary pneumococcus infection 
(White et al., 1985). These figures show that 10% of measles cases result in 
serious complications, this figure being far higher in developing countries along 
with the death rate in those countries estimated to be as high as 2% (MMWR,
1990;White et al., 1985). There is also a more rare complication of measles
68occurring in between 1   in 100,000 and 1   in 300,000 cases (Rima, 2001). This is 
sub acute sclerosing pan encephalitis (SSPE). SSPE occurs on average 8 years 
after infection and is the result of a persistent MV infection which causes 
demyelination and neuronal infection. Depending on the neuronal systems infected 
this leads to severe and progressive neurological deficits and death within 3 to 9 
months after the onset of symptoms (Rima, 2001).
1.3.3  Vaccination strategies
The majority of measles vaccines are based on the Edmonston strain of measles, 
so called after the patient from whom it was isolated in the 1950s, vaccine 
production soon followed (Katz, 1959).  The Edmonston B vaccine was developed 
by Enders and Peebles by passaging the Edmonston strain 24 times in primary 
kidney cells and 28 times in human amnion cells (Enders, Peebles, 1954). The 
strain was then adapted to chicken embryo cells for 6 passages. This attenuated 
measles virus was licensed as a vaccine in the United states in 1963. This vaccine 
was associated with a high rate of rash and fever although the more severe 
symptoms of measles were avoided. It was found that co-administration of 
immunoglobulin reduced adverse reactions by 50% (Krugman, 1963; Stokes,
1961)
It is on this original strain that most other vaccines available today are based, 
having been further attenuated. Most notable of these are the Schwarz; attenuated 
by passaging Edmonston A in chicken embryo fibroblasts, the Moraten strain; 
attenuated in a similar way from Edmonston B and the Edmonston-Zagreb; derived
69from Edmonston B and adapted for passage in the human diploid cell line WI-38 
(Plotkin and Orenstein, Vaccines 3rd edition).
The Moraten vaccine (Attenuvax, Merck) is the only vaccine used in the United 
States and the Schwarz vaccine is the one that predominates elsewhere. Other 
vaccines not derived from Edmonston are also in use around the world including 
CAM-70 and TD97 isolated from Tanabe strain and used in Japan (Hirayama, 
1983). The Shanghai-191 strain used for vaccination in China and the Leningrad- 
16 strain used in Russia and Eastern Europe (Peradze, 1983).
Since 1971 the measles vaccine has been combined with two other live virus 
vaccines for mumps and rubella known as the MMR vaccine although this was not 
implemented as a vaccine strategy until much later. This vaccine contains no less 
than 1000 TCID (Tissue culture infectious doses) of measles (Moraten strain in US, 
and Enders in UK) 5000 TCID mumps (Jeryl Lynn strain) and 1000 TCID of rubella 
vaccine virus (RA27/3 strain). Worldwide there are different formulations containing 
different MV and other virus strains depending on the strains that had been used to 
vaccinate in the individual vaccines. For example Japan uses the ALK-C measles 
strain, the Hoshino mumps strain and the Takahashi rubella virus (Plotkin and 
Orenstein, Vaccines 3rd edition).
Production of the different vaccine strains is in general carried out in the same way.
The vaccine strain of virus is cultured in primary chick embryo cells. The cultures
are inoculated with the Moraten strain of MV, and this is then incubated for several
days at 32°C. The cultures are then washed to remove FBS and the medium
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albumin. While cells are maintained at the same temperature, medium containing 
virus can be removed periodically. This medium is frozen and viral titre is 
determined. Once quality checks have been completed the frozen cell 
supernatants are dispensed into vials at the correct dose and lyophilised. To 
stabilise the formulation at this stage, sorbitol and hydrolised gelatine are added. 
This lyophilised product is then reconstituted with sterile distilled water immediately 
prior to injection (Elliott, 1984).
Before measles vaccination was introduced in the 1960’s (USA) and 1980’s (UK) 
measles epidemics occurred regularly every 2-5 years. Crowded urban settings are 
ideal for outbreaks and the larger the community the shorter the time between 
epidemics. The success of vaccination strategies in developed countries such as 
the USA is impressive, with a reduction in measles cases by 99% between 1963 
and 1989 (Markowitz et al., 1989). However as discussed in section 1.2.4 although 
the MV vaccination programme has been one of the most successful and 
economic, there is still the need to both increase current efforts especially in 
developing countries, and increase research into the immunology of measles if 
eradication of this disease is to be achieved.
As outlined in section 1.2.4 the reason that the advent of the measles vaccine has 
not had as significant an effect in developing countries, (aside from some areas 
with low vaccine coverage and potential vaccine storage problems) is the age at 
which children are most susceptible to MV infection. This is around 9 months of
age. Vaccinating this early can mean failure of the vaccine due to maternal
71antibodies (Markowitz et al., 1990).  Since T cell mediated immunity plays a central 
role in clearance and protection from MV, an ideal solution to this would be the 
development of a vaccine that stimulated cellular immunity possibly via a combined 
peptide approach thus bypassing maternal antibodies and potentially allowing 
vaccination at birth. A peptide subunit vaccine would be ideal for this function as 
discussed in section 1.2.5.
1.3.4  MV structure
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Figure 1.6: Diagram of the measles virus showing the major structural proteins and 
the RNA genome protected by the nuclear protein. H-Haemagglutinin, F-Fusion, L- 
Large, M-Matrix, NP- Nucleoprotein, P-phosphoprotein.
72Measles virus (MV) is a large enveloped single stranded negative sense RNA virus 
and is approximately 100-250nm in diameter (figure 1.6). The MV genome is 
approximately 16Kb in size which is divided into six transcription units separated by 
3 nucleotide long intergenic sequences (Rima, 2001). MV is a member of the 
Paramyxoviridae family. This family is divided into two subfamilies known as the 
Pneumovirinae of which the human pathogen RSV is a member and 
Paramyxovirinae (Bellini et al., 1994). Within the Paramyxovirinae are three 
genera, Respirovirus (human parainfluenza 1   and 3), Rubulavirus (Mumps) and 
Morbillivirus (MV). Other members of the Morbillivirus genus include the animal 
viruses, rinderpest and canine distemper virus (Rima, 2001).
1.3.5  Structure and function of measles virus proteins
The MV genome codes for at least eight different proteins. The MV virion consists 
of six of these proteins. There is an outer lipoprotein envelope and an internal 
nucleocapsid (figure 1.6). Three viral proteins are associated with each of these 
structures, the Fusion (F), Haemagglutinin (H) and Matrix (M) proteins associate 
with the envelope and the Nucleo (NP), phospho (P) and large (L) protein protect 
the 16Kb RNA genome in the nucleocapsid (Schneider-Schaulies and Meulen, 
2002). Other proteins include the Core (C) protein and V (V) proteins which are 
generated from the gene encoding the P protein but have unknown non structural 
functions although are thought to play a role in virulence as further discussed in 
section 1.3.5.4.
731.3.5.1  Haemagglutinin (H)
The MV H protein is the protein which mediates binding of the virion to the cell 
surface prior to entry into the cell. It is a 617 amino acid long, type 2 membrane 
glycoprotein, and is positioned protruding from the envelope along with the F 
protein, forming the spikes.  It is thought that it is present as a homotetramer in the 
virion (Ogura et al., 1990). In order for the virus to enter the cell, H protein must 
bind to the host cell but also be free to interact with the F protein as this is critical 
for cell fusion. This has been shown by mapping binding sites of neutralising 
antibodies (Wild et al., 1991). It has also been shown that the H protein is 
important for tropism of the virus to different cells types. This is presumably due to 
the different receptors (see section 1.3.6) that H can use on the cell surface, and 
the affinity of the H in the different MV strains for receptors preferentially expressed 
on certain cell types (section1.3.6 and figure 1.7).  Another difference between the 
wild type and vaccine strains of virus is the ability of the H protein to activate cells 
via TLR2. The wild type strains can do this yet it appears that the mutation that 
prevents this in vaccine strains is the same mutation that allows vaccine strains to 
bind to CD46. Consequences of TLR2 ligation include the up-regulation of CD150 
which may be another mechanism by which the wild type strains have increased 
viral spread-by up-regulation of the receptor required for cell entry (Bieback et al.,
2002)
1.3.5.2 Fusion (F)
The MV fusion protein is a 550 amino acid long, type 1   membrane protein, that as
its name would suggest is responsible for fusion of host cell and virion membranes.
This process occurs at neutral pH and results in the release of the viral capsid into
74the cytoplasm of the cell. The F protein is synthesised in the cell as a precursor 
protein FO this is the cleaved and therefore activated into the F1-F2 heterodimer. 
This becomes a homotrimer of the F1-F2 dimer on the surface of the virion. When 
the H protein binds to its receptor a conformational change is induced in the F 
protein leading to insertion of the hydrophobic fusion domain of the protein into the 
target cell membrane (Wild et al., 1994). The MV F protein is also responsible for 
some of the immunosuppression seen in MV infection. This process does not 
require cell fusion and merely requires the presence of the F1-F2 heterodimer. This 
can either be on the virion itself or on the surface of an infected cell, thus 
suppressing the proliferation of T cells that may have recognised MV antigen on 
the cell surface (Weidmann et al., 2000).
1.3.5.3  Nucleoprotein (N)
The MV NP protein is a 525 amino acid long phosphoprotein. It binds to the RNA in 
the virion protecting it from degradation and aiding in its replication once inside the 
cell (Zhang et al., 2002;Zhong et al.,  1999). The NP protein has been shown to 
have immunoregulatory functions in its own right, aside from the functions in 
replication and maintenance of the RNA genome of the virus. MV NP has been 
shown in mice to directly inhibit IL-12 production by DCs (Marie et al., 2001) 
through direct binding to the FcyRII on the surface of cells. Through the same 
interaction, NP can also bind human B cells but not T cells, and this interaction 
reduced production of CD40 by 50% thus inhibiting the production of antibodies 
and contributing to immunosuppression (Ravanel et al., 1997). The functional 
domain of the protein has been mapped to the C terminus and had been found to
bind a variety of cells via a different and as yet un-characterised receptor. The
75result of this is the arrest of those cells in the GO phase of the cell cycle and thus 
suppression of proliferation (Laine et al., 2003). Not only is NP derived from lysed 
cells available to act in this way but it also appears to enter the late endocytic 
compartment, couple with the FCyR and be expressed on the surface of infected 
cells, and be secreted into the extracellular compartment to interact with uninfected 
cells (Marie et al., 2004).  However, despite the profound suppressive ability of NP, 
Etchart et al have shown that NP can be immunogenic and can recruit DCs to the 
site of injection and prime CTL when used as a vaccine antigen (Etchart et al., 
2001).
1.3.5.4  Other MV proteins
The P (507aa) and L proteins (2183aa) are known to combine with the NP protein 
to form the nucleocapsid. These two proteins are also thought to form the RNA 
polymerase which is required for the replication of the genome and enabling mRNA 
to be made and the viral proteins produced in the host cell (Hamaguchi et al.,
1983). The M (335aa) protein is involved in the coordination of assembly of the 
new virions from infected host cells. A MV mutant lacking M also has an increased 
ability to promote cell fusion, this may be a feature of strains that cause SSPE, 
allowing the MV strains defective for M to penetrate further into the brain 
(Cathomen et al., 1998). The V (300aa) and C (186aa) non structural proteins are 
thought to act as virulence factors. Studies in transgenic mice expressing CD46 
which allow them to become infected with MV (see section 1.3.6), have shown that 
although equally immunogenic, MV strains lacking V or C proteins have reduced 
spread and pathogenesis in the mice, with viral load significantly reduced
(Patterson et al., 2000). The V protein has also been shown to inhibit STAT1 and
76STAT2 phosphorylation in human cell lines which resulted in reduced expression of 
type 1   IFN, contributing to the immunosuppression elicited by MV (Takeuchi et al.,
2003). The C protein was also found to be necessary for viral replication in human 
PBMC but not in vero cells where as the V protein was not necessary in either 
setting for viral replication to occur. Both defective viruses efficiently inhibited T cell 
proliferation to the same level as wild type virus therefore the C and V proteins are 
not necessary for the immunosuppressive effect (Escoffier et al., 1999)
1.3.6  Receptor binding and entry to cells
The vaccine strains of MV stimulate an effective immune response in vaccinated 
individuals, however these strains are significantly attenuated compared to wild 
type strains, indicated by the absence of most of the clinical symptoms caused by 
wild type MV infection. Several studies have investigated the genomic differences 
between wild type and attenuated MV strains and have found variation in all of the 
major proteins (NP, P, M, F, H and L) (Bankamp et al., 1999;Parks et al., 
2001;Takeda et al., 1999). As discussed in section 1.3.5, mutations in the H and F 
proteins may account for the differences in virulence between the strains and the 
lack of V and C proteins has been shown to inhibit virus spread in mice. Therefore 
mutations inhibiting the functions of these proteins could play a role in reduced 
pathogenesis.
The differences in the immune response between circulating wild type virus strains 
and the Edmonston vaccine strain could be due to mutations that have been driven 
by the passage of virus in non human cell lines such as chicken embryo fibroblasts
and dog and sheep kidney cells (Parks et al., 2001). Wild type MV enters cells
77through binding to its receptor, signalling lymphocyte activation molecule (SLAM) 
or CD150 (Erlenhoefer et al., 2001;Hashimoto et al., 2002). This is different to the 
Edmonston strain which preferentially enters via CD46 but can also use CD150 
(figure 1.7). Work in the cotton rat model has identified a point mutation in the H 
protein that allows MV strains carrying it to enter the cell via CD46. The same 
study found that viruses using exclusively CD150 caused strong 
immunosuppression and had increased spread than strains using CD46 (Pfeuffer 
et al., 2003).
CD150 is a CD2 family member, a defining characteristic of which is the presence 
of ITSM (immunoreceptor tyrosine based switch motif) on the cytoplasmic tail. This 
enables these molecules to be regulated by small adapter proteins within the cell 
and ligation of CD150 can mediate different effects depending on the availability of 
the different downstream effector molecules. One of the key functions of ligation of 
CD150 is the production of IFNy: several viruses have ways to subvert the function 
of CD150 (Sidorenko and Clark, 2003). Studies have found that despite this the 
contact mediated suppression of T cell proliferation seen in MV infection is not due 
to the down regulation of CD150 or CD46 (Erlenhoefer et al., 2001). CD46 is a cell 
surface glycoprotein that was first identified as a member of the regulation of 
complement activation family of molecules. These molecules bind activated 
complement components C3b and C4b preventing deposition on the cell surface 
and therefore complement lysis of the cell. The Edmonston strain can down 
regulate CD46 from the host cell surface post infection, which can lead to 
increased susceptibility of the cells to complement lysis thus reducing viral
78replication and spread in the host (Manchester et al., 2000;Schneider-Schaulies et 
al., 1995).
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Figure 1.7; Binding of MV to receptors CD 150 (all strains) and CD46 (vaccine 
strains) results in MV fusion and entry into target cell. CD 150 is expressed on 
activated lymphocytes, NK cells and mature DCs where as CD46 is expressed on 
all nucleated cells. Molecules known to be involved in signalling are shown. 
Tyrosine phosphorylation of the CD46 cytoplasmic domain occurs in a SRC kinase 
dependent manner in response to MV infection. Signalling after CD 150 ligation is 
dependent on SAP (SLAM associated molecule) in T and NK cells and EAT-2 in 
APC. Consequences of ligation of receptors are shown at the bottom of the figure 
with the effects proven to also occur in MV infection shown in red. Adapted from 
(Schneider-Schaulies and Meulen, 2002)
Interestingly recent studies have found that wild type MV can infect cells that do 
not express CD150 and this is not blocked using anti CD46 antibodies proving that 
there are as yet other unknown receptors for MV (Hashimoto et al., 2002). It has 
also been recently documented that wild type virus but not the vaccine strain 
activated Toll like receptor 2 (TLR2) on DCs via the H protein resulting in
production of IL-6 in response to viral infection. This provides a mechanism by
79which the immune response to the two strains differs in the stimulation of response 
(Bieback et al., 2002).
1.3.7  Immunity to measles
The immune response to measles consists of both B and T cell responses. After 
natural infection antibodies are made against N, F, H and M proteins. These can 
be neutralising meaning that they render the virus un-infectious. The antibody 
levels peak after 14 days and they correlate with clinical protection against 
measles (Griffin et al., 1994). Interestingly patients with cellular immune 
deficiencies such as severe combined immunodeficiency (SCID) are susceptible to 
severe even fatal measles infection as a result of giant cell pneumonia. However in 
contrast patients with an antibody deficiency such as X-linked 
agammaglobulinaemia (XLA) can still develop protective immunity to measles 
(Burnet, 1968). Thus as mentioned previously T cell responses may well be central 
to protective immunity to MV.
Natural MV infection and vaccination both lead to CD4 and CD8 T cell responses
(Jaye et al., 1998a). Several groups have documented the importance of the CD8
T cell response to MV infection. Large expansions of CD8+ CTL clones could be
detected up to a month after viral infection (Mongkolsapaya et al., 1999). The same
was found in a larger study of children in the Gambia which also showed that both
CD4+ and CD8+ T cells play a role in CTL mediated killing (Jaye et al.,  1998a).
More recently work in Rhesus monkeys showed that disease was much worse and
lasted longer in CD8+ cell depleted animals. This correlated with a marked
increase in viral titre again showing the importance of CD8+ T cells controlling viral
80replication (Permar et al., 2003). The same group went on to show that depletion of 
B cells prior to infection had no effect on the rate of clearance of the virus and did 
not produce any unusual symptoms. It would be interesting to investigate in this 
model the consequences of re-challenge in these animals, comparing animals who 
had a B cell response on primary infection with those who did not in order to 
investigate the roles of CTL and antibodies in protection from re-infection (Permar 
et al., 2004).  Another useful model that has been developed is a transgenic mouse 
expressing human CD8 and MHC I molecules. This model was shown to develop 
CTL with the same specificity for a HLA-B27 epitope as humans. If this could be 
adapted for HLA-A2 and other common human HLA alleles it may be an even 
more useful tool to identify MV specific epitopes (Tishon et al., 2000). T helper cells 
have also been shown to be involved in the response to MV infection. Moss et al 
demonstrated early type 1   responses in T cells with IFNy production followed by a 
switch to IL-4 and IL-13 in later responses, they also showed a prolonged 
production of IL-10 in the plasma of infected individuals which may contribute to 
the immune suppression seen after MV infection (Moss et al., 2002). Another study 
also showed Th1 type cytokine production in immune donors to MV antigens in 
vitro (Howe et al., 2005). ELISpot and intracellular staining techniques have also 
showed T cell responses to measles infected B cell lines with IFNy production 
(Nanan et al., 2000). It is clear that Th responses are important for both antibody 
production and CTL generation in response to MV. Proliferative responses and 
cytokine production by T cells was shown to correlate with the amount of antibody 
made in response to MV vaccination (Ovsyannikova et al., 2003). The same group 
has also shown an association between MHC II alleles and the failure to respond 
to vaccination against MV (St Sauver et al., 2003).1.3.8  Measles virus immunosuppression
As previously  discussed despite the success of vaccination programmes, measles 
is still the leading cause of vaccine preventable deaths, causing almost 1  million 
deaths annually (WHO, 2002). Pneumonia accounts for 60% of measles related 
deaths, as it is the transient immunosuppression elicited by measles that allows 
secondary opportunistic infections to establish themselves. The 
immunosuppression elicited by MV is paradoxical in that while a successful 
immune response is mounted to clear the infection there is a marked transient 
decrease in cellular immune responses as demonstrated by reduced delayed-type 
hypersensitivity reactions (Pabst et al., 1997;Von Pirquet C., 1908) and reduced 
cytokine production by, and proliferation of lymphocytes (Atabani et al.,
2001 ;Schneider-Schaulies and Meulen, 1998). This leads to increased 
susceptibility to bacterial infections. This has been tested in transgenic CD46 mice 
infected with MV and then challenged with Listeria monocytogenes. Compared to 
mice that were not infected with MV, the MV infected mice had increased 
susceptibility to infection with Listeria monocytogenes, had a decrease in 
macrophage and neutrophil counts and a decrease in IFNy production and 
proliferation in T cell subsets. This was not due to increased apoptosis but a 
decrease in proliferation in both adaptive and innate arms of the immune system 
(Slifka et al., 2003).
The mechanism of this immunosuppression is still debated; however it appears 
likely that there may be several different pathways and individual MV proteins that
play a role (Moss et al., 2004). Suppression of IL-12 production by MV has been
82reported up to several months after infection in humans in vivo (Atabani et al.,
2001) and in response to LPS stimulation in vitro (Karp et alM  1996). However the 
ability of DCs to produce type 1   IFN and mature in response to MV infection 
remains intact (Klagge et al., 2000). This reduction in IL-12 production could in 
some part caused by the increased production of IL-10 (Moss et al., 2002) which 
may be produced by the induction of T regulatory type 1   (Tr1) cells via activation of 
CD4+ cells through CD3 and CD46 (Kemper et al., 2003), but this suppression of 
IL-12 production is also via the direct action of individual proteins. As discussed in 
section 1.3.5.3, MV NP has been shown in mice to directly inhibit IL-12 production 
by DCs (Marie et al., 2001) and is implicated in several other mechanisms of 
immune modulation including direct inhibition of antibody production by B cells and 
contact dependent inhibition of cell proliferation through cell cycle arrest (Laine et 
al., 2003;Marie et al., 2004;Ravanel et al., 1997). There is also a suppressive effect 
mediated by the MV glycoproteins H and F which as outlined in section 1.3.5.1 act 
together to induce a state of unresponsiveness in responder cells (Schlender et al.,
1996)  or apoptosis of bystander cells (Vuorinen et al., 2003). This is thought to be 
via disruption of the Akt kinase signalling pathway (Avota et al., 2001). Expression 
of these MV glycoproteins on the surface of infected DCs suppresses proliferation 
of T cells despite a mature DC phenotype (Dubois et al., 2001;Klagge et al., 2000). 
There also are non specific effects of immune modulation by MV. The MV infection 
causes changes in the intra cellular expression of type 1   IFN inducible protein and 
Hsp90 resulting in presentation of self epitopes and activation of autoreactive T 
cells in acute MV infection. MV infection of DCs can also induce Fas mediated 
apoptosis thus further disabling the immune response (Servet-Delprat et al.,
2000a) and it has also been reported that both DCs and T cells in human cocultures undergo massive apoptosis after exposure to MV (Fugier-Vivier et al.,
1997). These diverse immunosuppressive effects of whole MV on human DC make 
it difficult to work with both live MV and individual proteins to study T cell responses 
in vitro, as proliferative responses may be hard to detect in light of the suppressive 
ability of the virus. In particular the apoptotic effect both wild type and attenuated 
MV has on DCs is of concern when attempting to present naturally processed MV 
antigen. This will be further discussed in chapter 4.
1.4  Project aims
The aim of this study was to characterise T cell epitopes in the MV, by 
demonstrating IFNy production in response to measles peptides in immune donors 
and then in recently vaccinated adult volunteers. Peptides were initially chosen 
from reported epitopes for HLA-A2*0201 which had stimulated proliferation of T cell 
lines and been naturally processed but no direct ex vivo quantitation of responses 
had taken place (chapter 3). If this was successful it could then be used to look at 
responses in recently vaccinated children. In order to further map the T cell 
response to MV a series of overlapping peptides, spanning the different MV 
proteins were used in immune donors and recently vaccinated individuals in order 
to identify specific peptides that would warrant further investigation (Chapter 3 and 
4). This approach has been successfully used to map the major T cell epitopes of 
HIV (Goulder et al., 2001).
When studies in chapters 3 and 4 were inconclusive, a system was developed by
which individual MV proteins could be delivered to DCs with the use of adenoviral
vectors this was to allow processing and presentation of MV proteins which would
84more closely mimic the route of natural infection and avoid the cytopathic effects 
that MV has on antigen presenting cells. DCs infected with adenoviral vectors 
containing the coding sequences for MV proteins would then be used to stimulate 
autologous T cells in order to grow short term T cell lines. This would significantly 
increase the precursor frequency of antigen specific T cells, which were re­
stimulated in the ELISpot assay with peptide pools specific for the protein to which 
the T cell line had been grown, in order to identify MV specific epitopes.
During the course of these experiments, an interesting observation was made. T 
cells proliferating in the presence of adenoviral infected DCs had reduced 
proliferation when compared to T cells proliferating in the presence of mock 
infected DCs. This phenomenon was further investigated, firstly to establish if the 
effect was due to an adenoviral induced defect in the antigen presentation capacity 
of the DCs or if the effect was due to an active suppression by the adenoviral 
infected DCs. Supernatant transfer, transwell and cytokine blocking experiments 
were used in order to determine a mechanism for the observed suppression of 
proliferation. This work is detailed in chapter 6.
During the course of this project, the opportunity arose to utilise the same methods
used throughout the other sections in order to investigate the nature of the T cell
response to a different pathogen. This was N. Meningitidis B. The aim of this
section of the work was to characterise the T cell response in individuals
vaccinated with an outer membrane vesicle (OMV) based vaccine and to
determine the nature of this response. This was done using methods that had been
shown to be effective in other studies such as proliferation assays, and also
85ELISpots to detect both IFNy and IL-5 release in response to re-stimulation of 
PBMC from vaccinated individuals with OMV. This section of the work is discussed 
in chapter 7.
86Chapter 2 General materials and methods
All cell culture work was performed using endotoxin free sterile reagents, in a 
Gelaire® BSB 4A Category 2 fume hood, local safety regulations were followed at 
all times.
2.1 Volunteers
2.1.1 Vaccination study volunteers
Full informed consent was obtained from all individuals who took part in the 
studies. For both the Meningitis B and the MMR vaccine trials, healthy adult 
volunteers were selected from the Institute of Child Health, London. All studies had 
full ethical approval from the Great Ormond Street Hospital/ Institute of Child 
Health regulatory ethics committee.
2.1.2 Other volunteers
Healthy volunteers for other parts of this project were selected from within the 
Immunobiology, Rheumatology and Molecular Immunology units at the Institute of 
Child Health, London. On recruitment these individuals were assigned an AW 
(Adult Well) number and were typed for the presence or absence of HLA-A2 
protein expression (see section 2.5.7).
2.2 Blood Samples
2.2.1  Preparation of Peripheral Blood Mononuclear Cells (PBMC)
Blood samples were collected into universals containing 35U of preservative free 
heparin (CP pharmaceuticals Ltd. Wrexham) and processed within 6 hours of 
collection. PBMCs were isolated from venous blood by Lymphoprep™ (Axis-Shield,
87Nycomed, Oslo, Norway) gradient centrifugation. Whole blood was diluted with and 
equal volume of RPM11640 medium (Life technologies, Paisley, Scotland) 
supplemented with 2mM L-glutamine (Life technologies) and 
Penicillin/Streptomycin (100Uml'1 /100ngmr1  conc.) (Life technologies)(RPMI). Half 
the final blood volume of Lymphoprep™ was put in a falcon tube and the blood was 
layered on top using a pipette. The blood samples were spun at 800g for 30mins in 
either an IEC Centra-8R centrifuge or a Beckman Coulter, Allegra™21R centrifuge 
with the acceleration and deceleration low. The resulting interface layer of PBMCs 
was removed with a pastette into a clean falcon tube.  The volume was then at 
least doubled with RPMI and spun again at 500g for 10 minutes. The supernatant 
was removed and the cells re-suspended in 50|J RPMI by gentle flicking then 
made up to the required volume for counting with RPMI (usually the same volume 
of blood originally taken). The cells were then spun again at 300g for 10 minutes 
and re-suspended in the desired volume of either complete medium (CM) (RPMI 
10% v/v foetal calf serum (FCS) (Insight Biotechnology), freezing medium if to be 
frozen (see 2.2.4) or RPMI 5% AB human serum (Sigma, St Louis, Missouri, USA) 
for all  DC work.
2.2.2  Preparation of serum samples
For some volunteers 1ml of blood was taken for storage as serum to look at 
antibody and cytokine levels at a later date. This involved 1ml blood incubated in a 
serum tube with no anti-coagulant in a 37°C water bath for 30 minutes. After clot 
formation, the liquid fraction was spun at 10000rpm to remove any cells and the 
supernatant removed before being stored in 200/J aliquots at -70 °C.
882.2.3 Counting viable cells
10jnl of cell suspension was added to 10jul of trypan blue 0.4% (Sigma) in a U 
bottomed plate well for 1   minute. 10jxl of this was then placed on to a Neubauer 
counting chamber and counted under a microscope. All unstained, therefore live 
cells were counted in the specified 25-box field. Blue cells were noted but not 
counted and cells were routinely > 97% viable. The total number of cells was then 
calculated by multiplying by 2 to account for the trypan blue dilution and then by 
104 to calculate the number of cells per ml.
2.2.4 Freezing cells
All cells were cryo-preserved in liquid nitrogen for long-term storage. After counting 
cells were spun and re-suspended at 10 x 106 cells per ml in freezing medium 
(FM), FCS supplemented with 10% v/v Dimethyl sulphoxide (DMSO) (Sigma). 
Between 0.5 and 1ml of this solution was then transferred in to cryovials (NUNC, 
Roskilde, Denmark) and these were placed into a freezing pot with isopropanol 
coolant then placed at -70°C (thus cooling at 1°C per minute) for 24hours before 
being transferred to liquid nitrogen. The only exception to this was freezing the 293 
cells and Thp1 cells, which are sensitive to DMSO. In this case glycerol was used 
in the place of DMSO in the FM.
2.2.5 Thawing cells from liquid nitrogen
Cryo-preserved cells were removed from liquid nitrogen and rapidly thawed in a 
37°C water bath. Cells were then transferred to 2ml of pre warmed 37°C FCS in a
89drop wise fashion. The universal was then filled up with warmed medium and spun 
at 300g for 10 minutes before being counted.
2.3  Summary of cells and culture medium
2.3.1 Summary of different cells and culture medium
A summary table of the different cells and culture medium used throughout this 
project is outlined in table 2.1. All reagents are from GIBCO BRL unless otherwise 
stated. Penicillin at lOOUml'1, Streptomycin at lOOjugmf1  and 2mM L-glutamine was 
added to all media and is indicated below as P/S/glu. Foetal Calf Serum (FCS) 
(Insight Biotechnology, lot no A01120-650) throughout the project was the same lot 
number that had been batch tested previously.
2.3.2 Cell line culture
Cell lines were routinely thawed into and cultured in a T75 flask (Corning Life 
Sciences, UK) at 37°C 5% CO2 in a humidified incubator (Jencons-PLS, Beds, UK) 
then transferred after 24 hours to a T225 (Corning Life Sciences) for further 
amplification prior to use. The same incubator was used throughout the project.
2.3.3 Splitting adherent cell lines
All adherent cell lines were grown to approximately 90% confluence before being 
split. This was done by removing the old medium and washing gently twice with 
PBS Dulbeccos (Life Technologies) then adding enough 37°C Trypsin/EDTA 
(Gibco) to cover the monolayer of cells. The flask was then placed back into the 
37°C incubator for 5 minutes or until the monolayer had floated off. 20ml of
90medium was then added to halt the reaction and the cells were spun at 300g for 10 
mins then re-suspended in the appropriate amount of fresh medium and 
transferred to new culture flasks.
Cell
type
Medium Supplements Origin Use in 
project
Comments Publications
PBMC RPMI
1640
P/S/glu 10% 
FCS
Human
volunteers
Ex vivo 
assays for 
memory to 
antigen
Media 
called CM 
in further 
methods
PBMC RPMI
1640
P/S/glu 5% 
Human AB 
serum 
(Sigma)
Human
volunteers
Growing 
Dendritic 
cells (DC)
293 MEM P/S/glu 
20mM 
HEPES, 1% 
100x ne aa 
(Sigma)
Human
embryonal
kidney
Permissive 
cell line for 
amplifying 
viral stocks
Freeze in 
FCS.  10% 
glycerol
(Fooks et al., 
1995a)
Vero DMEM P/S/glu 10% 
FCS
African
Monkey
Kidney
Cell line for 
growing and 
titrating MV
(Prasad and 
Mnere,  1980)
U937 RPMI
1640
P/S/glu 10% 
FCS
Human
histiocytic
lymphoma
Monocytic 
cell line for 
optimising 
DC protocol
Exhibits
early
monocytic
phenotype
(Sundstrom 
and Nilsson, 
1976)
Thp1 RPMI
1640
P/S/glu 10% 
FCS
Human
monocytic
leukaemia
Monocytic 
cell line for 
optimising 
DC
methodology
Start up in 
15% FCS 
Freeze in 
10% 
glycerol
(Tsuchiya et 
al., 1980)
T2 RPMI
1640
P/S/glu 10% 
FCS
Fusion of 
.174 B cell 
line and 
CEM T cell 
line
TAP deficient 
line used as 
APC in 
ELISpots
(Zweerink et 
al., 1993a)
K562 RPMI
1640
P/S/glu 10% 
FCS
Human
Lymphoma
Original cell 
line, used as 
control in 
ELISpots for 
K562-A2
Low MHC 
class I 
expression 
used as NK 
cell target
(Andersson 
et al., 1979b)
K562- 
A2
RPMI
1640
P/S/glu 10% 
FCS 10mM 
HEPES
Human 
Lymphoma 
transfected 
with human 
HLA-A2*02
APC in 
ELIspots
Keep at low 
passage to 
avoid 
loosing A2 
expression
(Britten et al., 
2002b)
Table 2.1 Summary of cell lines and media used in project
912.4  Enzyme Linked Immuno-spot assays (ELISpots)
2.4.1  IFNy ELISpot
96 well polyvinylidine diflouride (PVDF) (Millipore, Bedford, MA, USA) plates were 
coated for 2 hours at 37°C/5%C02 with 50^1 per well of 15figml'1  anti-human IFNy 
mouse lgG1  (clone D1K, Mabtech, Sweden). This was diluted in PBS (w/o Mg and 
CaHCOa, GIBCO™, USA) from the stock. Following incubation the wells were 
washed x8 in 200pl PBS 1% FCS in sterile conditions using a vacuum pump to 
aspirate (Vaccubrand GmbH, Wertheim, Germany). 100jnl complete medium (CM) 
(RPMI plus 10% v/v FCS) was then added to each well and incubated for 1  hour at 
37°C/5%C02 to block non specific binding sites. This medium was aspirated out 
and PMBC (either fresh or thawed) were re-suspended at either 1  or 2.5 x 106 ml"1  
in CM. IOOjliI was transferred to each well (i.e. 1  or 2.5 x 105 cells per well). 100jul 
of antigen was diluted in CM to 2x final concentration and added to the relevant 
wells in either triplicate or quadruplicate. If peptide pulsed antigen presenting cells 
were being used these were pulsed for 3 hours with peptide at a concentration of 
10pM, washed and re-suspended and added per well in an APC: PBMC ratio of 
1:4. The plates were then incubated for 16 hours at 37°C/5%C02. Following 
incubation the cells were discarded and wells were washed x8 in PBS as before. 
50|ul of 1pgml"1  biotinylated mouse lgG1 anti human IFNy (clone 7-B61 , Mabtech) 
was transferred to each well and the plate was incubated for 2 hours at 
37°C/5%C02. The plate was washed x8 with PBS and 50pl of 1pgml'1  streptavidin 
alkaline phosphatase (Sigma) added to each well. The plate was incubated again 
for 1  hour at 37°C/5%C02 and was washed again x8 with PBS. For detection of 
cytokine production the wells were developed using 5-bromo-4-chloro-3-indolyphosphate and nitroblue tetrazolium (BCIP/NBT) substrate (BioRad, Hemel 
Hempstead, UK). This was combined just prior to use as per the manufacturer’s 
instruction and diluted in substrate buffer. 100pl of this was added per well and 
incubated at room temperature for 5 minutes or until dark blue spots appeared in 
the positive control wells. Running the plate under tap water for 3 minutes stopped 
the development of colour.
2.4.2 IL-5 ELISpot
The protocol was the same as for the IFNy ELISpot with the following exceptions. 
PVDF plates were coated with rat anti human/mouse IL-5 (clone TRFK5, 
Pharmingen) at a concentration of 10j^gml'1  overnight at 4°C. Once the cells were 
added the plate was incubated at 37°C/5%C02 for 48hours. The secondary 
antibody biotinylated rat anti human/mouse IL-5 (clone JES1-5A10 Pharmingen) 
was added at a concentration of 1pgml"1.
2.4.3 IL-10/ IL-12 ELISpot
The protocol is as for IFNy ELISpot with the following exceptions. PVDF wells were 
coated with rat lgG1 anti human IL-10 (Clone 9D7 Mabtech) or mouse lgG1  anti 
human IL-12 (code IL-12 I Mabtech) at lOpgml'1  for 2 hours at 37°C/5%C02. On 
addition of the cells the plate was incubated for 24 hours before development. The 
secondary antibodies were either rat lgG2a biotinylated anti human IL-10 (clone 
12G8 Mabtech) or Mouse lgG1  biotinylated anti human IL-12 (antibody code IL-12 
II Mabtech) used at a concentration of 1pgml1  and incubated overnight at 4°C.
932.4.4 ELISpot positive controls
2.4.4.1  Phorbol 12-Myristate 13-actetate (PMA)
PMA (Sigma) is a Phorbol ester and a specific activator of protein kinase C. Stocks 
of PMA were prepared in ethanol and stored at 1mgml"1  at -20°C. PMA was used 
at a final concentration of 1pgml'1.
2.4.4.2 Lipopolysaccharide LPS
LPS (Sigma) was stored in RPMI at a concentration of 1mgml'1  at 4°C and used at 
a final concentration of lOOngml"1  unless otherwise stated.
2.4.4.3 Dust mite antigen
As a positive control for the IL-5 ELISpot plate (since not every donor responded to 
LPS), PBMC from an atopic donor were used on each plate. This donor was known 
to be highly allergic to dust mite and so would produce high levels of IL-5 in 
response to the Dermatophagoides Pteronyssinus antigen (Aquagen, ALK- 
ABELLO, Denmark) used at a final concentration of 100 SQ-Umf1.
2.4.5 ELISpot data analysis
i
After air-drying the developed plates over night at room temperature, the spots 
were counted using a video analyser (BioReader 3000, BioSys, GmbH, Karben, 
Germany).  Pre-optimised reading methods, created for the project using the 
BioSys software were utilised. Each triplicate or quadruplicate was read and the 
mean number of spots determined per condition. The mean background value in 
control wells was either included on the graphical representation of the results, or
94when comparing samples from different time points, was deducted from the mean 
test well values.
2.5  Fluorescence Activated Cell Sorting (FACS)
All antibody staining was carried out on ice, using cold reagents and wash buffers.
2.5.1 Buffers and solutions
FACS Buffer is PBS 1% FCS and 0.1% sodium azide (Sigma).
FIX Buffer is FACS buffer containing 1% formaldehyde (Sigma).
PERM Buffer is FACS buffer containing 0.1% saponin (Sigma).
PFA is PBS with 4% paraformaldehyde (Sigma) dissolved in it (by heating in fume 
hood to 65°C for 45 minutes then cooling and freezing in appropriate aliquots for 
use later).
2.5.2 Staining for surface markers
Cells were re-suspended to a concentration of 106mr1  in cold FACS buffer and 
100pl per condition to be stained for was added to one well on a round-bottomed 
96 well plate (MERCK, Germany). The plate was then spun at 300g for 5 minutes 
at 4°C. The supernatant was flicked off and the plate vortexed briefly to loosen the 
cell pellet. The cells were re-suspended in FACS buffer to 10O jLtl per well and spun 
again. Having removed the supernatant and vortexed briefly, the cells were re­
suspended in 25jnl of FACS buffer containing the appropriate antibodies at the 
specified dilution (see table 2.3). This was incubated on ice in the dark for 30 
minutes. After the incubation the cells were washed x3 in FACS buffer as outlined 
above before being re-suspended in 100pl per well of FIX buffer and transferred to
95LP2 tubes (A1  Lab supplies, UK). For two layer staining instead of adding FIX 
buffer, the second antibody was added and the protocol was repeated.
2.5.3 Staining for intra-cellular proteins
Cells were prepared as outlined above. Before the antibody was added the cells 
were fixed in 50^il per well of PFA for 10 minutes at room temperature. They were 
then washed twice with PBS as above and then once in PERM buffer. This 
permeabilised the cells enabling the antibodies to enter and bind to the specific 
protein. After spinning and removing the supernatant the cells were re-suspended 
in 25jLtl of PERM buffer containing the appropriate antibody at the dilution outlined 
in table 2.3. This was then incubated on ice for 30 minutes in the dark before being 
washed twice more in perm buffer and once in FACS buffer, then re-suspended in 
100jil FACS buffer and transferred to LP2 tubes. Again if two-layer staining was 
necessary instead of re-suspending in FACS at the end the cells were re­
suspended in the secondary antibody and the process was repeated.
2.5.4 Antibodies used throughout the project
Most monoclonal antibodies were used as direct conjugates, conjugated to 
Fluorescein Isothiocyanate (FITC), R-Phycoerythrin (PE), CY (cychrome) or QR 
(Quantum Red). For any antibodies that were unlabelled a “second layer” 
conjugated reagent specific for the IgG of the relevant species was used. In some 
cases, no monoclonal antibody was available and polyclonal serum was used from 
immunised animals (rabbit, mouse) or a human patient suffering from SSPE. The 
antibodies used throughout the project are shown in table 2.3.
96Target Species Clone Conjugate Company Cone.
Human CD3 Mouse - FITC Pharmingen 1/10
Human CD3 Mouse UCHT-1 QR SIGMA 1/25
Human CD3 Mouse UCHT-1 PE BD 1/50
Human CD4 Mouse Q-4120 FITC SIGMA 1/25
Human CD4 Mouse T-310 PE DAKO 1/40
Human CD4 Mouse Q-1420 QR SIGMA 1/50
Human CD8 Mouse LEU-2A FITC BD Bioscience 1/25
Human CD8 Mouse UCHT-4 PE DAKO 1/25
Human CD8 Mouse LEU-2A QR SIGMA 1/10
Human CD11a 
(LFA-1)
Mouse - FITC Immunotech 1/25
Human CD11c Mouse - FITC Pharmingen 1/10
Human CD13 Mouse - PE Pharmingen 1/25
Human CD14 Mouse - Cy5 SEROTECH 1/25
Human CD19 Mouse - PE Pharmingen 1/25
Human CD28 Mouse LEU-28 PE BD 1/25
Human CD40 Mouse - FITC Caltag 1/10
Human
CD45RA
Mouse F8-11-13 FITC SEROTECH 1/25
Human
CD45RA
Mouse F8-11-13 PE SEROTECH 1/25
Human
CD45RO
Mouse UCHL-1 PE DAKO 1/25
Human CD80 Mouse - QR Pharmingen 1/20
Human CD83 Mouse - FITC Pharmingen 1/25
Human CD86 Mouse - FITC SEROTECH 1/25
Human CCR7 Mouse - PE R&D Systems 1/25
Human DC 
SIGN
Mouse - FITC R&D Systems 1/50
Human DR 
(MHC class II)
Mouse HK14 PE SIGMA 1/25
Human IL-6 Mouse - PE BD Bioscience 1/10
Human IL-10 Rat - PE Pharmingen 1/25
Human IL-10 
(blocking ab)
Mouse 23738 - R&D Systems 10pg/ml
Human IL-12 Mouse - PE Pharmingen 1/25
Human TGFB 
(blocking ab)
Mouse 1D11 - R&D Systems 10pg/ml
Human TNFa Mouse - PE BD Bioscience 1/10
Human IFNy Mouse - PE Pharmingen 1/10
Human HLA- 
A2*0201
Mouse BB7.2 - Provided by Dr 
Bin Gao*
1/100
Table 2.3: Antibodies used in this project
97Measles Mouse Serum - LSHTM** 1/50
Measles Human Serum LSHTM** 1/50 
(1/100 
0 WB)
Measles Rabbit Serum Kindly provided 
by Dr Kenth 
Gustaffson*
1/100
Measles NP Mouse 22E1 - Abeam 1/100
Measles NP Mouse - - LSHTM** 1/100
Measles NP Mouse A - Fabien Wilde*** 1/200
Measles NP Mouse B - Fabien Wilde*** 1/200
Measles NP Mouse C - Fabien Wilde*** 1/200
Mouse IgG Rabbit - PE SIGMA 1/400
Mouse IgG Rabbit - FITC SIGMA 1/200
Mouse IgG Rabbit HRP SIGMA 1/20,0
00
(WB)
Human IgG Goat - HRP Caltag 1/5000
(WB)
Human IgG Goat - PE Caltag 1/200
Human IgG Goat - FITC Caltag 1/200
Table 2.3 continued: Antibodies used in this project.  * Institute of Child Health, 
University College London (ICH, UCL).  **London School of Hygiene and Tropical 
Medicine.  ***Lyon, France.
Where LSHTM is mentioned in table 2.3, Professor John Stephenson from the 
London School of Hygiene and Tropical Medicine (LSHTM) kindly donated these 
reagents.  Where Fabien Wilde is mentioned these antibodies were kindly donated 
by Professor Fabien Wilde, Lyon, France. Dr Bin Gao and Dr Kenth Gustaffson are 
from Institute of Child Health, University College London (ICH, UCL). Where 
antibodies were used at different concentrations for western blot, this is denoted in 
table 2.3 by (WB).
2.5.5  Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE)
For analysis of phenotype of proliferating cells that responded to specific stimuli 
CFSE was used to stain cells and then to gate on the divided cells which had lowerlevels of CFSE after division. CFSE was from SIGMA and was made to 5mM in 
DMSO before being aliquoted and stored at -20°C until use. To stain cells PBMC 
were washed to remove any serum, then counted and re-suspended in 10ml RPMI 
(for 106 to 5 x 107  PBMC). CFSE was added to a final concentration of 1pM and 
then the sample was incubated for 10mins at 37°C before 40ml of serum 
containing RPMI was added and the cells were washed 3 times before being re 
suspended at 3 x 106 cells per ml. 3 x 106 cells were added to a 24 well plate well 
for each condition with antigens made up to 2x in RPM110% FCS added 1ml per 
well. After the culture time, cells were harvested, washed in FACS buffer and 
stained with the appropriate antibodies before being analysed by flow cytometry.
2.5.6 Positive controls for proliferation assay
2.5.6.1  Phytohaemagglutinin (PHA-P)
PHA (Sigma) is a lectin extracted from the kidney bean and is a mitogen, which 
causes T cell proliferation. PHA was prepared in ethanol at a stock concentration 
of 1mgml“1  and was stored at -20°C. It was used at a final concentration of 1pgml'1.
2.5.6.2 Tetanus Toxoid (TT)
Tetanus toxoid (TT, kindly donated by Aventis Pasteur, Marcy I ’Etoile, France) 
was at a stock of 2.947mgml*1  at +4°C and used at a concentration of lOpgml-1.
2.5.7 HLA typing using flow cytometry
To HLA type different AW donors in this project for the expression of HLA-A2, the 
unconjugated A2 specific antibody BB7.2 (Parham and Brodsky, 1981) was used
99with a second layer to stain a known positive and a known negative donor 
alongside the unknown donors. The cell staining protocol was followed as for 
surface protein staining outlined above. The antibody was kindly provided by Dr 
Bin Gao.
2.5.8  Data analysis for Flow cytometry
All samples were run according to standard operating procedures on a Becton 
Dickenson FACScan with CellQuest™ software. Live cells were gated according to 
their light scattering properties and typically 10,000 events were collected for each 
condition with the exception of proliferation assays using CFSE where 150,000 
events were collected per condition. All gating was set compared to either an 
isotype matched control antibody or baseline staining on a comparative condition.
2.6  Monocyte derived dendritic cell (DC) culture
2.6.1  Culturing DCs
All DC work was done with RPMI media containing 5% AB human serum (Sigma) 
as optimisation experiments showed that this was better than FCS at maintaining 
healthy DC cultures. Whichever technique used to isolate the precursor population 
(see below), the resulting 6 day culture was performed in a 6 well tissue culture 
plate (NUNC) with 2ml RPMI 5% human AB serum containing 50ngml'1  
recombinant human IL-4 (R&D Systems Inc, MN, USA) and 100ngml"1  recombinant 
human GM-CSF (R&D Systems Inc) at 37°C/5%C02. The cytokines arrived as 
lyophilised powders and were re-suspended in sterile filtered PBS 1  % tissue 
culture grade BSA (Sigma) to a 100x concentration then stored at -70°C.
1002.6.1.1 Adherence technique
After separation of PBMC from whole blood, cells were re-suspended in RPMI 5% 
AB human serum at a concentration of 3.3x106ml"1. 3ml of this cell suspension was 
added to each well on a 6 well plate and incubated at 37°C/5%CC>2 to adhere for 2 
hours. After this incubation the non-adherent cells were removed with 3 rounds of 
washes with RPMI. In general these were frozen down for use as responder cells 
at a later date. Then 2ml of the relevant culture medium containing GMCSF and IL- 
4, was added per well and the cells incubated at 37°C/5% C02  for 6 days.
2.6.1.2 CD14 bead monocyte isolation
An alternative method of deriving DCs is to use magnetic bead separation to 
isolate DC precursors. This was done to compare the populations obtained by the 
two different methods. After isolating PBMC from whole blood cells were re­
suspended in 20ml MiniMacs buffer (MMB)(2mM EDTA (from stock 0.5M pH8), 
0.5% BSA in PBS, filtered and degassed for 30mins) and pelleted with a gentle 
spin. This was repeated and cells were re-suspended in 480jil MMB plus 1^1 of anti 
CD-14 beads (Milteyni Biotech, Germany) per 1.5x106 cells. This was then 
incubated at 4°C for 15 minutes with agitation every 5 minutes. 20ml MMB was 
then added and the cells were pelleted again at 400g for 10 minutes. Cells were 
then re-suspended in 2ml MMB and passed through a pre-equilibrated LT 
MiniMacs column (Milteyni Biotech) as per the manufacturer’s instructions. Once 
the magnet was removed 2x 1ml of MMB was allowed to drip through the column 
and was collected then 3ml of MMB was plunged through and collected, the cells
101were counted re-pelleted and re-suspended in the culture medium as outlined 
above at 0.75x106ml'1  and 2ml of this was seeded onto one well of a 6 well plate.
2.6.1.3  DC maturation
After 6 days in culture in GMCSF (lOOngml'1 ) and IL-4 (50ngml1 ) the monocyte 
derived DCs were ready for use. To stimulate cytokine production and phenotypic 
maturation, between 1  and 100ngml'1  LPS was added directly to the culture well. If 
looking at cytokine production using flow cytometry, Brefeldin A (Sigma), a golgi 
block was also added at S^igml"1. Brefeldin A was reconstituted to a stock 
concentration of 5mgml1  in DMSO then used at 1/1000 (final concentration of 
5pgml"1 ) in the cultures for 14 hours. For work involving DCs used as stimulators 
the DCs were matured for 14 hours prior to use with lOngml'1  TNFa (Sigma), 
10ngml'1  IL-1 p (Peprotech), 10ngml'1  IL-6 (Sigma) and 1pgml"1  prostaglandin E2  
(Leen et al., 2004). All cytokines were reconstituted from lyophilized powder 
according to the manufacturer’s instruction then diluted to a 100x working stock 
and stored at -20°C.
2.7  Adenoviral constructs
The recombinant adenoviral constructs (Rad) used in this project are based on the 
replication deficient E1a and E3 genome deletion adenoviral vectors and were 
kindly provided by Professor John Stephenson (LSHTM). They were produced by 
recombination of the pJM17 plasmid (McGrory et al., 1988) with plasmids 
containing the cDNA sequences of the relevant proteins. The cDNA sequences for 
the proteins are each under the CMV promoter (see section 6.1.2). Rad68 is the
102construct containing the cDNA of MV Nucleoprotein (NP), Rad88 contains the 
cDNA coding for MV Haemagglutinin (H) and Rad95 contains the cDNA coding for 
MV Fusion (F). Rad35 is the construct containing the cDNA for the reporter gene p- 
galactosidase which is used for all the verification of infection and effect of infection 
on DC phenotype and function studies. Being replication deficient the predominant 
proteins to be made by the host cell once the virus has infected will be the proteins 
of interest. As discussed further in chapter 5 this is because in the adenoviral 
constructs the E1 and E3 regions are deleted and this is the region of the 
adenoviral genome coding the transcription factors responsible for the transcription 
of the rest of the genome. In light of the suppressive capacity of the constructs 
described in chapter 6, the constructs were tested for mycoplasma and found to be 
negative.
2.7.1 Adenovirus amplification
All work involving growing adenovirus in 293 cells was carried out in a category 2 
laboratory.
2.7.1.1  Infecting 293 cells
293 cells were grown, split the day before use and allowed to grow to 80% 
confluence over night in 4x T225 per viral prep. The medium was then removed 
and the monolayer washed gently twice with PBS. The monolayer was then 
covered with serum free medium and incubated at 37°C/5%C02 for 1   hour. 
Following this the medium was removed and fresh serum free medium containing 
1/500 dilution of the viral stock (see below) was added.  The flasks were then
103incubated for a further 4 hours when this inoculum was removed and replaced with 
serum containing medium. These were incubated for 3 days at 37°C/5%C02  or 
until the monolayer started to float off.
2.7.1.2 Virus purification
Once the 293 cells were beginning to show the cytopathic effects of the virus, the 
flasks were agitated to make a cell suspension. This cell suspension was 
transferred to 50ml Falcon tubes and pelleted at 2000g for 5 minutes at 4°C. Each 
pellet was re-suspended in 2ml of cold PBS and re-pelleted. The pellets were re­
suspended again in cold PBS and an equal volume of 1,1,2,trichlorotrifluoroethane 
(Sigma) was added and vortexed. The solution was then re-spun for 10 minutes 
and the aqueous layer (containing virus particles) was retained. Again an equal 
volume of the fluorocarbon was added and the spin repeated. The aqueous layer 
was then removed and divided into 300pl aliquots before being frozen for storage 
at -70°C. The virus preparations were kept at -70°C for at least 24 hours before 
titrating.  To control for impurities in the preparation uninfected 293 cells were 
scraped off the flask and treated in the same manner to obtain a mock virus 
preparation which was used as a control in all the adenovirus experiments.
2.7.1.3 Plaque assays
For each viral stock to be titrated, 12 10cm diameter culture dishes were seeded 
with 293 cells and cultured until confluent. The medium was removed from each 
well and replaced with 2.5ml of serum free medium. Cells were incubated for 1  
hour at 37°C/5%C02 then the medium removed and replaced with 0.5ml of
104inoculum. The inoculum was added in duplicate at 5 different dilutions and one 
mock infection of medium alone. The dilutions were 1   in 105, 106, 107, 108  and109. 
The plates were then returned to the incubator for another hour and were rocked 
every 10 minutes.  An agar overlay was prepared consisting of 50% v/v 2% noble 
agar (Sigma), (an agar designed to be very pure with low salt and mineral content 
so can be used as a gelling agent for specifically defined media) and 50% v/v 2x 
minimal essential medium w/o phenol red (GIBCO) 3% FCS. 3ml of this was 
layered gently into each well and left to set at room temperature for 15 minutes 
before being transferred to 37°C/5%C02 for 5 days. After 5 days a second overlay 
was prepared by the same method as the first, but containing 0.45% of 33.3% 
neutral red (Sigma). 3ml of this was then added to each well and allowed to set 
before being transferred to 37°C/5%CC>2 for a further 24 hours after this time the 
plaques could be counted as areas of no staining in the now red stained 
monolayer. The plate was left at 37°C/5%C02 for a further 10 days checking for 
the emergence of any new plaques. Routinely the most easily counted dilution was 
the 106-fold dilution and it contained approx 50 plaques. After taking into account 
the dilution factors, this gave a stock concentration of approx 108 PFU per ml 
(figure 5.4).
2.7.1.4  Infecting other cells
The virus preparation was added directly to cells in culture at approximately 100pfu 
per cell (e.g. 100pl per well of DCs).
1052.7.1.5  Mycoplasma testing of virus preparation
Both mock and adenovirus preparations were tested for mycoplasma. Alongside 
PBMC from 3 individuals were mock or adenovirus infected and cultured for 4 days 
in RPMI 10% FCS without penicillin and streptomycin. The supernatants were then 
harvested and tested for mycoplasma. This was done using the MycoAlert 
Mycoplasma detection kit (Cambrex Bio Science Ltd, Belgium) according to the 
manufacturers instructions. Briefly the assay measures the activity of 
mycomplasma specific enzymes which through conversion of ADP to ADP can be 
measures using luciferase and measuring the luminescence of the samples, the 
level of ATP is measured before and after the addition of the MycoAlert substrate, 
resulting in a ratio value that if under 1  confirms the absence of mycoplasma. All of 
the samples tested were considered to be mycoplasma negative.
2.7.2  Verifying infection by adenoviral constructs
2.7.2.1  Flourescein di(B-D-glucuronide) (FDG) assay
In order to detect efficient protein expression of the protein contained in the viral 
DNA in Rad35 infected cells (which contain the full length p-galactosidase cDNA), 
a substrate of p-galactosidase (p-gal), FDG (Sigma) was used. This substrate is a 
colourless compound that when cleaved by p-gal becomes fluorescent and can be 
detected using flow cytometry in the FI1 channel. FDG was re-suspended from 
lyophilised powder in a 1:1  ratio of DMSO and water to give a 200jaM stock 
solution. This was then stored at -20°C. For working stock 10jLtl of this solution was 
added to 990jnl water and incubated in a 37°C water bath for 10 minutes to 
dissolve. This working stock was again stored at -20°C. Cells were incubated with
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suspended in 5ml cold assay buffer (PBS 4% FCS 10mM HEPES pH 7.3) and 
pelleted again. The supernatant was removed and the cells re-suspended in 50pl 
assay buffer and incubated in a 37°C water bath for 10 minutes to recover. Then 
50jnl of FDG was added and the suspension put back in the water bath for 1   minute 
and 15 seconds (to force FDG into cells, by osmotic pressure).  1ml of ice-cold 
assay buffer was added and the cells left on ice for at least 3 hours before 
measuring using flow cytometry. While optimising this assay it was observed that 
cells left overnight gave a more clear difference between positive and negative 
cells, due to an amplification of the signal by the enzyme and this method was 
therefore used.
2.7.2.2  Propidium Iodide (PI)
Alongside the FDG staining of cells, 10jul Propidium Iodide (PI) (Sigma) was added 
to each tube to a final concentration of 25pgmr1  to measure cell death. Dead cells 
have permeable membranes therefore allow PI through the membrane. These cells 
can then be detected in the FI2 channel using flow cytometry. This protocol was 
used to investigate any association between cell infection with adenovirus and cell 
death.
2.7.2.Z 5-Bromo-4-Chloro-3-indolyl p-D-Galactopyronoside (X-gal)
In order to directly visualize infected cells and to verify the FDG staining, the 
substrate X-gal was used. X-gal (Sigma) was dissolved in DMSO at a
107concentration of 20mgmr1  this was stored at -20°C until use. This was then further 
diluted tolmgml"1  in a solution of PBS containing 5mM Potassium Ferricyanide, 
5mM Potassium Ferrocyanide and 2mM MgCI2  to make the working solution. 
Infected cells were harvested and washed twice in PBS and fixed in 4% 
paraformaldehyde as in section 2.5.3. The cells were then washed with PBS twice 
more before being resuspended in 2ml of X-gal working solution and placed in a 
well of a 24 well plate. The cells were then incubated for 24 hours at 37°C/5% C02  
before viewing under a light microscope.
2.7.2.4 FACS staining for NP protein
The standard dual layer antibody labelling protocol was used to detect the NP 
protein by flow cytometry; this was using the Measles specific antibodies and 
appropriate top layers as outlined in table 2.3.
2.7.2.5 Western Blotting 
Buffers and reagents.
2x SDS loading Buffer: (Tris-CI pH 6.8, 4% w/v SDS, 0.2% w/v bromophenol blue 
(Sigma) and 20 % v/v glycerol)
Lysis Buffer: 1% Nonidet P-40 (Sigma) in PBS plus 10% protease inhibitor cocktail 
(Sigma)
Run Buffer: 0.025M Tris, 0.192M Glycine, 0.1% SDS (Flowgen)
Transfer Buffer: 0.02M Tris, 0.15M Glycine, 20% Methanol (Flowgen)
PBST: PBS, 0.05% Tween (Sigma)
Enhanced Chemiluminescence fluid (Pierce): 1ml Super signal Dura West luminal
enhancer solution, 1ml stable peroxide buffer.
108Protoflow gel: 30% Acrilamide, 0.8% w/v Bis acrilamide stock solution 
Protoflow gel Buffer: 1.5M Tris HCL, 0.4% SDS, pH 8.8 
Protoflow gel stacking Buffer: 0.5M Tris HCL, 0.4% SDS, pH 6.8
Samples were prepared as follows. Cells were re-suspended in lysis buffer (1% 
Nonidet P-40 (Sigma) in PBS plus 10% protease inhibitor cocktail (Sigma)) to a 
final concentration of 108 cells per ml. This was incubated for 10 minutes on ice 
then spun at 13,000rpm for 15 minutes in a micro centrifuge (Eppendorf centrifuge 
5415R). The samples were then diluted 1   in 2 in 2x SDS loading buffer (Tris-CI pH 
6.8, 4% w/v SDS, 0.2% w/v bromophenol blue (Sigma) and 20% v/v glycerol 
(Sigma) and boiled for 5 minutes at 94°C. 10pl samples were added to the wells of 
12% SDS protein separating gels made using the Flowgen Protogel system 
(Flowgen). 12% acrilamide gels were prepared by adding 6ml of protoflow gel to 
3.9ml of protoflow gel buffer, 5ml of deionised water, 50pl of 10% ammonium 
persulphate and 10pl of NNNN tetramethyl ethylene diamine (TEMED). 4% 
acrilamide stacking gels were made by adding 1.3ml of protoflowgel to 2.5ml of 
protoflow gel stacking gel buffer, 6.1ml deionised water, 50pl 10% ammonium 
persulphate and 10pl TEMED. Once loaded gels were run in an Xcell SureLock 
mini Cell and Blot module (Invitrogen) according to the manufacturer’s instructions 
for 1   hour at 200V or until samples had travelled sufficiently. A High Molecular 
Weight Rainbow Marker was run alongside the samples to allow analysis of the 
size of the detected protein (New England Biolabs).
109The blotting of the gel was again carried out in the Xcell sureLock module at 25V 
for 2 hours.  This was on to Hybond C Extra membrane (Amersham). The 
membrane was then blocked at room temperature in 5ml PBST (PBS 0.05%
Tween (Sigma)) and 2.5% Marvel (Premier International Foods, UK) on a Gyro 
rocker (Gyro Rocker STR-9, Stuart). The membrane was washed 3 times in PBST, 
then the primary antibody (either rabbit, mouse or human anti measles serum at 
1/1000 dilution or monoclonal anti NP at a 1/100 dilution, see table 2.3 for details) 
was added diluted in PBST 2.5% Marvel. This was then incubated on the rocker for 
1   hour at room temperature. The membrane was washed 3 times in PBST then the 
secondary antibodies either anti mouse (Sigma), anti human (Caltag) or anti rabbit 
(Sigma)- Horse radish peroxidase (HRP) at a 1/5000 dilution in PBST 2.5% Marvel 
were added for 1   hour on the shaker at room temperature. The membrane was 
washed 5 times in PBST and then developed using Super signal west Dura luminal 
enhancer solution and stable peroxide buffer (Pierce). The membrane was dabbed 
dry with a paper towel and 2ml of enhanced chemiluminescence fluid was added 
evenly to the membrane. After 5 minutes the fluid was pipetted off and the 
membrane dabbed dry. The membrane was then wrapped in parafilm and attached 
to one side of an exposure box with tape. This was then used to expose Kodak X- 
Omat AR films (Sigma) for between 30 seconds and 2 hours.
The gels were also done in duplicate so protein content could be verified using a 
coomassie blue stain to ensure isolation of protein and migration of that protein 
through the gel. The gels were stained in 0.05% w/v coomassie blue (Sigma) 
solution in 50% methanol, 10% acetic acid, for 2 hours then de-stained overnight in
110a 30% methanol, 10% acetic acid solution before visualization and image capture 
using AlphaEase software (Alphalnnotech).
2.7.2.S  Polymerase Chain Reaction (PCR)
1pl of either Rad35 or Rad68 stock virus solution was used as a template in a total 
reaction volume of 50jnl consisting of the reagents outlined in table 2.4. The 
primers were designed from the known DNA sequence of the MV NP cDNA and 
were custom made and desalted by Sigma Genosys Ltd.
The sequences were:
NP forward: 5’ ATGGCCACACTTTTAAGGAG 3’
NP reverse: 5’ GTCTAGAAGATTCTGTCATT 3’
The annealing temperature used was 56°C with 30 PCR cycles on a GeneAmp 
PCR System 9700 (PE Applied Biosystems).
Reagent Stock Concentration Volume (pi) Final
concentration
PCR buffer (Tris-CI 
(pH 8.4), KCI)
10X (200mM, 500mM) 5 1x (20mM, 
50mM)
MgCb 50m M 1.5 1.5mM
DNTP (Invitrogen) Each at 5mM 2 0.2mM
Primer 1 12.5pM 1 0.25pM
Primer 2 12.5pM 1 0.25pM
Taq DNA polymerase 
(Invitrogen)
5U(xr1 0.2 1   unit
H20 38.3
Total 50
Table 2.4 Reagents for PCR master mix
111Negative control wells were run in parallel, omitting DNA template or primers. Gel 
electrophoresis of 10pl PCR product alongside 1Kb DNA ladder (New England 
Biolabs) was performed on 1.5% agarose Tris-borate EDTA (TBE) (1M Tris-EDTA, 
0.9M Boric acid, 20mM EDTA pH 8 is a 10x solution) gel at 100V for 40 minutes. 
The gel was then stained in 0.5pgml"1  Ethidium bromide (Sigma) in TBE and 
visualized by ultraviolet illumination and image capture using AlphaEase software 
(Alphalnnotech).
2.7.2.7 Staining for analysis by confocai microscopy
Monocyte derived DCs (see section 2.6) were harvested and counted after 6 days 
of culture. These were re-suspended at106ml'1  in RPMI 5% human AB serum and 
1  ml per well plated onto sterile cover slips (Western Lab Supplies) in 24 well plates 
(Corning). These were then infected with either control or test adenoviral 
preparations and incubated overnight at 37°C/5%C02. The cover slips were then 
removed and placed facing up in a fresh 24 well plate. These were gently washed 
with wash buffer (PBS 0.5% BSA) by pipetting and aspirating 1  ml x4. The cover 
slips were then fixed in 1:1 acetone: ethanol for 15 minutes at room temperature. 
The fixing solution was aspirated off and the cover slips allowed to air-dry for 5 
minutes. The cells were re-hydrated with 1ml of wash buffer for a further 15 
minutes. The cells were then blocked on ice for 15 minutes with 200pl per well of 
FcR blocking reagent (Miltenyi Biotech) diluted 1/100 in wash buffer. The cells 
were then washed x4 as before and incubated for 30 minutes on ice with either anti 
measles human serum or control human serum at 1/10 dilution in wash buffer. The 
cells were washed x4 as above and then incubated for 30 minutes on ice in the
112dark with 200pl per well of anti human IgG FITC antibody at a 1/200 dilution in 
wash buffer. The cells were washed x4 as before and incubated for 20 minutes on 
ice in 200pl of ToPro (1/500, 1pM, Molecular Probes) and phalloidin-Rhodamine 
(1/100 Sigma) in wash buffer. ToPro stains the nucleus by binding to DNA and the 
phalloidin stains the F-actin cytoskeleton. The cells were washed again x4 as 
before and then removed from the wells and put face down on microscope slides 
with a drop of fluorescent mounting medium (Dako Coporation) on them. The 
mount was allowed to set for 1   hour at 4°C before the edges were sealed with clear 
nail varnish. The slides were stored at -20°C before being studied on a Leica 
confocal microscope.
2.8 Statistical analysis
On the data from the vaccine study, the students paired t test was performed, 
comparing each time point to pre vaccination. This test was also used to test the 
statistical significance of the difference in responses of fresh and frozen cells.  The 
students paired t test was also used to analyse the data from the adenovirus 
studies. Due to the non-parametric nature of the cytokine production data, where 
statistical analysis was performed a Wilcoxon paired assigned rank test was 
performed.
113Chapter 3 Detecting measles specific responses in immune 
donors
3.1 Introduction
3.1.1 Detecting T cell memory
The main purpose of an immunisation protocol is to mimic the natural infection of 
the specific pathogen thus stimulating an immune response, which results in the 
appropriate memory production that is subsequently protective. The ability to study 
and quantify the response to both natural infection and vaccination is an essential 
step to better understand and develop new vaccine strategies. There are many 
different ways of detecting memory T cells to a specific antigen, all of which use a 
different parameter as a measure of memory and therefore give different 
information on the nature of the response.
One of the first methods to be widely used was the proliferation assay, which 
defined memory as the ability of cells to proliferate to a given antigen. This method 
used radioactive thymidine incorporation into newly synthesised DNA of 
proliferating cells as the read out (Mayer et al., 1996). The proliferative response 
can now be further defined by using carboxyfluorescein diacetate succinimidyl 
ester (CFSE) labelling, in which cells are labelled with a fluorescent dye, which 
gets divided between daughter cells on division and therefore halves in brightness, 
which can be detected by flow cytometric analysis (Lyons, 2000).  This method has 
the benefit of being able to combine other staining of surface markers to phenotype 
the responding cells.
114Another assay is the chromium release assay which measures the ability of 
amplified or fresh cells (typically CD8+ T cells, or NK cells) to kill antigen pulsed 
target cells, which have been loaded with chromium, that can be detected in 
supernatants, allowing killing levels to be calculated (Brunner et al., 1968).
There are several flow cytometric methods for detection of antigen specificity. One 
of these is tetramer staining, where a fluorescently labelled tetramer of MHC 
molecules loaded with a specific peptide is used to stain T cells (Appay and 
Rowland-Jones, 2002;Lechner et al., 2001). This often results in higher counts of 
antigen specific cells than other methods, on average 4.4 fold higher than levels 
detected by ELISpot although the two methods correlate well (Tan et al., 1999). 
This is likely to be because the affinity of the TCR for the tetramer may be enough 
to bind in the assay but not enough to promote an effector function in vivo and that 
the ELISpot relies on production of IFNy as a readout which may not be the only 
effector function of antigen specific cells. An alternative method is intra cellular 
cytokine staining which detects the cells that have produced cytokine in response 
to the stimulus.
The benefit of flow cytometric methods is that the cell type involved in the response 
can be characterised with the use of surface marker staining. However these 
methods can be labour intensive both in laboratory work and in the data analysis, it 
may also require large cell numbers, therefore may not be as suitable for routine 
analysis as other cytokine detection methods, if only quantification of responding 
cells is required. The Enzyme linked immunospot assay or ELISpot is an ideal
assay of this kind (Schmittel et al., 1997). The ELISpot is based on the Enzyme
115linked immunosorbant assay (ELISA). However, instead of measuring levels of 
soluble cytokine in supernatants, the ELISpot enables quantification of the number 
of cells producing the cytokine. This is a direct read out of effector cells as the 
assay is typically 16 hours long, making this a quick and high throughput method 
for measuring specific cytokine responses to antigen in several cell types, not only 
T cells (Schmittel et al., 2001).
The ELISpot assay combined with intracellular cytokine staining were the methods 
used throughout this project to detect memory cells to both vaccines and natural 
infection. These were combined with other readouts such as proliferation assays to 
allow comparison with data from other groups, and CFSE staining to analyse 
phenotype of responding cells.
3.2  Specific Materials and Methods
3.2.1  Peptide antigens
Initially, predicted epitopes (section 3.2.1.1) were used as peptide antigens. This 
was subsequently followed by a more general approach, of using overlapping 
peptides from three of the major MV proteins as antigens.
3.2.1.1  Predicted epitopes
Table 3.1 shows the amino acid sequences of the peptides used in this project. 
Each peptide was allocated a code consisting of the letter representing the protein 
of origin and the number of the amino acid within the protein that the peptide 
started at. The peptides were received from Research Genetics, Huntsville, USA
as lyophilised powder and were re-suspended in DMSO to a stock concentration of
11610mM. For routine use these were then diluted 1/1000 (final concentration 10pM). 
The only exception to this was M58, which was hydrophobic and would only 
dissolve at 1mM so was used in assays at 1/100. Peptides were selected which 
were predicted to be efficiently presented by HLA-A2*0201, using a combination of 
reported sequences and an algorithm search (http://bimas.dert.nih.gov:80/). They 
were then manufactured by Research Genetics, Huntsville, USA.
Abbreviation Origin Protein AA sequence
N210 Measles Nucleo (NP) RLERKWLDV
N226 Measles Nucleo (NP) DLSLRRFMV
H30 Measles Haemagglutinin LMIDRPYVL
C84 Measles Core KLWESPQEI
M211 Measles Matrix QLPEATFMV
M58 Influenza Matrix GILGFVFTL
T368 Human Tyrosinase protein YMDGTMSQV
G77 HIV -1 Gag SLYNTVATL
Table 3.1 Peptides used in this study and abbreviation used in subsequent figures.
3.2.1.2  Responses to control and recall peptides
To show that antigen specific T cells could be detected efficiently in this system 
alongside PMA as a positive control for IFNy release, the well characterised Flu 
matrix peptide M58 (Bednarek et al., 1991) was used as an antigen specific 
positive control, and either the HIV-1 Gag peptide or the human tyrosinase peptide 
which are both A2 binding peptides were used as negative controls.
1173.2.1.3 Peptide pools
HPLC purified lyophilized overlapping 15mer peptides from the MV proteins 
nucleoprotein (NP), Fusion (F) and Haemagglutinin (H) were used. These peptides 
were kindly donated by Prof. Mike Steward at the LSTHM. The peptides span the 
majority of each MV protein and overlap each other by 5 amino acids. The 
sequences of the peptides are shown in tables 3.2 (NP), 3.3 (F) and 3.4 (H).
1 MATLLRSLALFKRNK 26 AEMICDIDTYIVEAG
2 FKRNKDKPPITSGSG 27 IVEAGLASFILTIKF
3 TSGSGGAIRGIKHII 28 LTIKFGIETMYPALG
4 IKHIIIVPIPGDSSI 29 YPALGLHEFAGELST
5 GDSSITTRSRLLDRL 30 GELSTLESLMNLYQQ
6 LLDRLVRLIGNPDVS 31 NLYQQMGKPAPYMVN
7 NPDVSGPKLTGALIG 32 PYMVNLENSIQNKFS
8 GALI Gl LSLFVESPG 33 QNKFSAGSYPLLWSY
9 VESPGQLIQRITDDP 34 LLWSYAMGVGVELEN
10 ITDDPDVSIRLLEW 35 VELENSMGGLNFGRS
11 LLEWQSDQSQSGLT 36 NFGRSYFDPAYFRLG
12 QSGLTFASRGTNMED 37 YFRLGQEMVRRSAGK
13 TNMEDEADQYFSHDD 38 RSAGKVSSTLASELG
14 FSHDDPISSDQSRFG 39 ASELGITAEDARLVS
15 QSRFGWFENKEISDI 40 ARLVSEIAMHTTEDL
16 EISDIEVQDPEGFNM 41 TTEDLISRAVGPRQA
17 EGFNMILGTILAQIW 42 GPRQAQVSFLQGDQS
18 LAQIWVLLAKAVTAP 43 QGDQSENELPRLGGK
19 AVTAPDTAADSELRR 44 RLGGKEDRRVKQSRG
20 SELRRWIKYTQQRRV 45 KQSRGEARESYRET  G
21 QQRRWGEFRLERKW 46 YRETGPSRASDARAA
22 LERKWLDWRN11AE 47 DARAAHLPTGTPLDI
23 NIIAEDLSLRRFMVA 48 TPLDIDTASESSQDP
24 RFMVALIEDIKRTPG 49 SSQDPQDSRRSAEPL
25 KRTPGNKPKIAEMIC 50 SAEPLLSCKPWQESR
Table 3.2: MV NP 15mer peptides. Each pool contained 5 peptides,  when pooled 
pool 1 contained peptides 1,11,21,31 and 41, pool 2 contained 2,12,22,32 and 42 
and so on with pool 10 containing peptides 10, 20, 30, 40 and 50.
1181 IGWGIGSASYKVMT 23 GGDLLGILESRGIKA
2 YKVMTRSSHQSLVIK 24 RGIKARITHVDTESY
3 SLVIKLMPNITLLNN 25 DTESYFIVLSIAYPT
4 TLLNNCTRVEIAEYR 26 IAYPTLSEIKGVIVH
5 IAEYRRLLRTVLEPI 27 GVIVHRLEGVSYNIG
6 VLEPIRDALNAMTQN 28 SYNIGSQEWYTTVPK
7 AMTQNIRPVQSVASS 29 TTVPKYVATQGYLIS
8 SVASSRRHKRFAGW 30 GYLISNFDESSCTFM
9 FAGWLAGAALGVAT 31 SCTFMPEGTVCSQNA
10 LGVATAAQITAGIAL 32 CSQNALYPMSPLLQE
11 AGIALHQSMLNSQAI 33 PLLQECLRGSTKSCA
12 NSQAIDNLRASLETT 34 TKSCARTLVSGSFGN
13 SLETTNQAIEAIRQA 35 GFSGNRFILSQGNLI
14 AIRQAGQEMILAVQG 36 QGNLIANCASILCKC
15 LAVQGVQDYINNELI 37 ILCKCYTTGTIINQD
16 NNELIPSMNQLSCDL 38 IINQDPDKILTYIAA
17 LSCDLIGQKLGLKLL 39 TYIAADHCPWEVNG
18 GLKLLRYYTEILSLF 40 VEVNGVAIQVGSRRY
19 ILSLFGPSLRDPISA 41 GSRRYPDAVYLHRID
20 DPISAEISIQALSYA 42 LHRIDLGPPISLERL
21 ALSYALGGDINKVLE 43 SLERLDVGTNLGNAI
22 NKVLEKLGYSGGDLL 44 LGNAIAKLEDAKELL
Table 3.3: MV F 15mer peptides, when pooled pool 1 contained peptides 1-5, pool 
2 contained 6-10 and so on until pool 8 containing peptides 41-44
The peptides were pooled with five peptides in each pool for the initial probing of 
immune responses and then any positive pools were then split to identify potential 
epitopes. The individual peptides were made up in DMSO at a concentration of 
10mM and used at a final concentration of 10pM. The final concentration of each 
peptide in the pools was also 10pM. The NP peptides were pooled first in a way 
which separated the different overlapping residues into separate pools. However 
this was then deemed to be an unwise strategy as it would not allow for 
highlighting specific regions of the protein in specific pools, therefore the following 
two proteins, H and F were split into pools where consecutive peptides were 
included in each pool.
1191 LIGLLAIAGIRLHRAAIYTAEIH 29 DPVIDRLYLSSHRGV
2 SLSTNLDVTNSIEHQ 30 SHRGVIADNQAKWAV
3 SIEHQVKDVLTPLFK 31 AKWAVPTTRTDDKLR
4 TPLFKIGGDEVGLRT 32 DDKLRMETCFQQACK
5 VGLRTPQRFTDLVKF 33 QQACKGKIQALCENP
6 DLVKFISDKIKFLNP 34 LCENPEWAPLKDNRI
7 KFLNPDREYDFRDLT 35 KDNRIPSYGVLSVDL
8 FRDLTWCINPPERIK 36 LSVDLSLTVELKIKI
9 PERIKLDYDQYCADV 37 LKIKIASGFGPLITH
10 YCADVAAEELMNALV 38 PLITHGSGMDLYKSN
11 MNALVNSTLLETRTT 39 LYKSNHNNVYWLTIP
12 ETRTTNQFLAVSKGN 40 WLTIPPMKNLALGVI
13 VSKGNCSGPTTIRGQ 41 ALGVINTLEWIPRFK
14 TIRGQFSNMSLSLLD 42 IPRFKVSPYLFNVPI
15 LSLLDLYLGRGYNVS 43 FNVPIKEAGEDCHAP
16 GYNVSSIVTMTSQGM 44 DCHAPTYLPAEVDGD
17 TSQGMYGGTYLVEKP 45 EVDGDVKLSSNLVIL
18 LVEKPNLSSKRSELS 46 NLVILPGQDLQYVLA
19 RSELSQLSMYRVFEV 47 QYVLATYDTSRVEHA
20 RVFEVGVIRNPGLGA 48 RVEHAWYYVYSPSR
21 PGLGAPVFHMTNYLE 49 YSPSSFSYFYPFRL
22 TNYLEQPVSNELSNC 50 YPFRLPIKGVPIELQ
23 ELSNCMVALGELKLA 51 PIELQVECFTWDQKL
24 ELKLAALCHGEDSIT 52 WDQKLWCRHFCVLAD
25 EDSITIPYQGSGKGV 53 CVLADSESGGHITHS
26 SGKGVSFQLVKLGVW 54 HITHSGMEGMGVSCT
27 KLGVWKSPTDMQSWV 55 GVSCTVTREDGTNRR
28 MQSWVPLSTDDPVID
Table 3.4: MV H 15mer peptides.  When pooled pool 1  contains peptides 1-5, pool 
2 6-10 and so on until pool 11 containing peptides 51-55
3.2.2  Determining MV immunity
To determine if volunteers were immune to MV, as defined by serum antibody 
concentration, serum samples were prepared from each donor and kindly analysed 
by Dr Bernard Cohen at the Enteric, Respiratory and Neurological Virus Laboratory 
at the Health Protection Agency (HPA), London, for titres of anti MV antibody. 
Quantitative measurements of anti measles IgG were made using an ELISA kit
120made by the Dade Behring company which uses plate bound MV antigen and a 
standard ELISA method to measure anti MV IgG. This is compared to WHO 
standard serum to give ab titres in international units.
3.3  Results
3.3.1 Optimisation of the ELISpot.
The IFNy ELISpot protocol outlined in the materials and methods (chapter 2) was 
optimised as outlined in the experiments below. In all ELISpot data, data points 
represent the mean of triplicate wells with error bars showing the standard 
deviation (SD). The data are shown either alongside the control value (the number 
of spots produced in a well with no antigen or in later experiments using the 
tyrosinase control peptide, a self antigen which should not be recognized, or the 
HIV-1 peptide in volunteers assumed to be HIV-1  negative) for comparison, or in 
vaccine studies with the background subtracted to allow easier comparison of 
different time points. Each plate included a positive control well of PMA (data not 
shown). Typically positive control wells showed in excess of 250 spots per 250,000 
PBMC.
3.3.1.1 Optimising cell number
To ensure the optimal number of cells was being used per well, taking both low 
precursor frequency of reactive cells and background into consideration, titrations 
of cell number were carried out (figure 3.1). This showed that over a certain cell 
density, cells began to non-specifically release IFNy. Thus 250,000 cells per well 
were used in experiments using specific antigen, unless otherwise stated. In
121optimisation experiments using PMA the response was high enough to use only
100,000  cells per well as in figures 3.2 and 3.3.
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Figure 3.1 Titration of cell number per ELISpot well. Graph showing the number of 
spots produced by different numbers of PBMC from one donor; either un­
stimulated (pink) or stimulated (blue) with 1pgmf1  PMA in a standard ELISpot Data 
points represent mean spots in 3 wells with error bars representing the SD.
3.3.1.2  Primary antibody titration
The optimal concentration of primary antibody was first determined. Figure 3.2 
shows how the detection level falls off rapidly with increasing dilution. Thus, the 
primary antibody was used at a 1.5% of stock solution, which was equivalent to a 
1/66.6 dilution, a final concentration of 15pgmf1.
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Figure 3.2 Titration of primary antibody concentration.  100,000 PBMC from one 
donor were incubated with 1  fig  mf1  PM  A in a standard ELI  Spot except with 
increasing dilutions of the primary antibody from 0.75 to 1.5% of the stock solution. 
Data points represent mean spots in 3 wells with error bars representing the SD.
3.3.1.3  Titration of PMA
As this assay was a new protocol in the laboratory, experiments were carried out to 
ensure the assay could detect an increasing number of responder cells in a linear 
fashion in this setting. A titration of PMA was carried out the results of which are 
outlined in figure 3.3. This titration was performed using 100,000 cells per well 
using concentrations of PMA ranging from 0.1 to 1ngml'1. This experiment shows 
the assay to be both sensitive and reproducable over a wide range of number of 
responding cells.
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Figure 3.3 Titration of PMA in the ELI  Spot.  100,000 PBMC from one donor were 
incubated in a standard ELISpot with increasing concentrations of PMA, from 0 to 
1ngmr1 . Data points represent mean spots in 3 wells with error bars representing 
the SD.
3.3.1.4  Titration of DMSO
There was concern that DMSO (which was used as a diluent for peptide 
preparations) may have a toxic effect on PBMC. Therefore a titration (figure 3.4) 
was performed to assess any such effect. This measured spots formed in response 
to PMA with different concentrations of DMSO. The final concentration of DMSO in 
the cultures after addition of peptide was 0.1% (with the exception of 1% for M58 
and 0.5% for the peptide pools). Due to scale 5% DMSO was not included on the 
graph. However at this concentration of DMSO there was a marked decrease in 
spots formed (data not shown).
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Figure 3.4: DMSO titration in the ELI  Spot.  100,000 PBMC from one donor were 
incubated with 1pgmt1  PMA and an increasing concentration of DMSO (blue). 
Shown in pink is the number of spots made with no PMA in the presence of 2% 
DMSO. Levels of 5% DMSO did have a detrimental effect of the number of spots 
(data not shown). Data points represent mean spots in 3 wells with error bars 
representing the SD.
3.3.2  Preliminary ELISpot results
Once the ELISpot method had been optimised, the measles peptides and positive 
controls were assessed. All individuals used in the initial ELISpot experiments were 
shown to be HLA-A2*0201 positive by genotyping, and immune to MV as defined 
by positive serology. The results from 4 adult well (AW) volunteer ELISpots are 
shown in figure 3.5. Very little specific IFNy production could be detected to any of 
the peptides except the positive control M58 from influenza matrix protein in 3 of 
the 4 individuals, known to be recognised in the context of HLA-A2*0201 
(Bednarek et al., 1991).
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Figure 3.5: Preliminary measles peptide results. A standard ELISpot was carried 
out with 250,000 PBMC per well, stimulated with different peptides at a 
concentration of 10pM.  Comparing measles peptide responses with the negative 
control peptide T368 and the positive control M58 in 4 adult well (AW) donors. Bars 
represent mean spots in 3 wells with error bars representing the SD.
3.3.3  Long ELISpot
Given the lack of specific responses seen in response to predicted A2 epitopes 
derived from MV, possible explanations for these negative results were sought. It 
was possible that the response to peptides would require a longer incubation time, 
in order to make equivalent levels of IFNy as that made in response to PMA. 
Therefore to test whether this might be the reason for the lack of response seen to 
peptides (figure 3.5), a 48-hour ELISpot was performed (in which the incubation 
time of PBMC with peptide antigen was 48hr) instead of the usual 16 hour ELISpot. 
The results of this assay carried out in 4 healthy donors using 4 different peptides 
or DMSO alone are shown in figure 3.6. The only effect this had was an increase in 
background as shown in the control well with an increase in AW49 backgroundfrom 15 in spots (in figure 3.5) to 125 spots and no detectable specific response 
amplification (in figure 3.6). Therefore the standard 16-hour incubation continued to 
be used.
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Figure 3.6: Long ELISpot results. A standard ELISpot was performed with 250,000 
cells per well incubated for 48hrs rather than the usual 16hrs with 10pM of peptide 
antigen in the same 4 healthy donors as shown previously in a 16hr ELISpot. Bars 
represent mean spots in 3 wells with error bars representing the SD.
3.3.4  Using Antigen Presenting Cells (APC) to enhance responses.
Due to the lack of response seen in figure 3.5, the issue of efficient antigen 
presentation was raised. It was possible that low frequency of professional antigen 
presenting cells (APC) could limit the detectable responses, even though memory 
CTL frequencies were under investigation. Therefore several different cell types 
were tested in the ELISpot as APC, as described in 3.3.4.1-3.3.4.3.
1273.3.4.1 Autologous dendritic cells (DC)
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Figure 3.7: Human monocyte derived DCs.  Scatter plot (top left) and phenotype 
histograms of flow cytometric analysis of monocyte derived DCs pre (purple line) 
and post (green line) LPS induced maturation.  The results show up regulation of 
CD83, CD40 and HLA-DR, and down regulation of DC-SIGN on the surface of 
myeloid DCs,  consistent with maturation of the DC (Banchereau and Steinman, 
1998b;Renneson et a!., 2005). DCs were analysed before or after maturation with 
LPS for the surface markers as shown and antibody stained cells run on the flow 
cytometer. Histograms show cells gated as shown in the dot plot.
Monocyte derived DCs were generated by standard adherence to plastic method 
followed by 6 day culture in GMCSF and IL-4 (see section 2.6.1). This generated a 
homogeneous population of cells with high expression of DC-SIGN and MHC 
Class II (figure 3.7) and low expression of CD14 (data not shown). These cells, on
128receiving a maturation signal such as LPS, also up regulated markers such as 
CD40 and CD83 as shown in figure 3.7.
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Figure 3.8: Responses to peptide presented on autologous DCs. 200,000 PBMC 
were incubated with 50,000 DCs after peptide loading and without peptide in a 
standard ELISpot assay.  T368 is used as a self protein derived (tyrosinase), 
negative control peptide and M58 as a positive control peptide. Bars represent 
mean spots in 3 wells with error bars representing the SD.
Monocyte derived DCs were pre-incubated with peptide for 3 hours then washed 
and used at a 1:4, DC: PBMC ratio as described in section 2.4.1. This was with
200,000  cells per well from the non-adherent (containing T cells) fraction of PBMC 
which had been stored after the DC preparation. These numbers were chosen in 
order not to exceed the 250,000 cells per well limit (section 3.3.1.1). The results of 
this, from one donor (representative of 2 experiments) are shown in figure 3.8. 
While this method appeared to improve antigen specific responses detected to 
M58 and in the case of one MV peptide M211, it also increased background 
responses to the irrelevant tyrosinase peptide, T368. Also, the limitations imposed
129upon experiment size due to using blood samples from children (planned for the 
future) would mean that there may not be enough cells to carry out standard DC 
preparations. Therefore other methods of presenting antigen were investigated.
3.3.4.2 T2 cells as APC
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Figure 3.9: Responses (mean of 3 wells +/- SD) to peptide presented on T2 
cells.200,000 PBMC were incubated with 50,000 T2 cells after peptide loading and 
without peptide in a standard ELISpot assay.  T368 is used as a negative control 
peptide.
The T2 cell line is a cell line deficient in TAP the transporter gene for antigenic 
peptide (Zweerink et al., 1993). Therefore these cells are unable to process 
antigen and as such should have no MHC Class I on the cell surface as this 
molecule is unstable when no peptide is bound (Zweerink et al., 1993). T2 cells 
were pre-incubated for 3 hours with the different peptides at a concentration of
10pM, washed and then 50,000 peptide loaded T2 cells were added per well with
130200,000  PBMC in a standard ELISpot assay. The results of this approach for 3 
donors are shown in figure 3.9.
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Figure 3.10:  MHC Class I expression on T2 cells.  T2 cells were incubated with and 
without 10pM M58 peptide for 3 hours before being washed and stained with anti 
MHC I antibody W6-32 and an anti mouse FITC conjugated second layer then 
analysed using flow cytometry
Although the background response to T2 was low, the response when the control 
peptide was added increased as much as to the measles peptides, indicating that 
the PBMC were responding to other signals. Therefore T2 cells were analysed 
using flow cytometry (figure 3.10) to compare levels of MHC Class I expression 
both after incubation with 10pM M58 peptide and without. Although incubation in 
M58 did increase levels of MHC Class I, the T2 cells were seen to have a high 
level of MHC class I expression before exogenous peptide was added (figure 
3.10). Therefore, as the T2 cells did not facilitate the demonstration of MV specific 
T cell responses, this line of investigation was not pursued any further.
1313.3.4.3 K562 cells
The K562 cell line is a human lymphoma cell line that is usually used as an NK cell 
target due to the lack of MHC Class I expression on its surface  (Andersson et al., 
1979). Britten et al had transfected this cell line with HLA-A2*0201 to make K562- 
A2 cells (Britten et al., 2002). This new cell line was generously donated for use in 
ELISpot assays. Figure 3.11 shows a titration of wild type K562 cells used to 
stimulate 200,000 PBMC in an ELISpot, in 4 donors which shows that there is a 
response to wild type K562 cells.
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Figure 3.11: K562 cell titration. Standard ELI  Spots were earned out using 200,000 
PBMC per well with increasing numbers of wild type K562 wild type cell line, from 0 
to 100,000 cells per well.  This was done in 4 donors. Data points represent mean 
of 3 wells +/- 1SD.
Figure 3.12 shows the K562-A2 cells that had been pre incubated for 3 hours with 
7 different peptides at a final concentration of 10pM (5 MV derived peptides, the 
negative control tyrosinase peptide and the positive control flu matrix peptide). Due 
to the large background, the response to M58 the positive control became much
132less obvious in all of the donors tested. As with the T2 cells, the background 
response to K562 cells was found to be very high and so this cell line too was no 
longer used.
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Figure 3.12: Responses to K562-A2 cell lines (mean of 3 well +/- 1SD). Standard 
ELI  Spots were carried out with 200,000 PBMC per well and 50,000 K562-A2 cells 
that had been incubated with 10pM peptide and washed.  This was done for the 5 
MV derived peptides and the positive and the negative control peptides.
3.3.5  Responses to MV Peptide pools in normal MV immune control 
individuals
As a response had not been observed to the predicted peptides and efforts to 
enhance presentation of these peptides had not increased the response to the 
peptides over background responses, it was decided to use a different approach. 
Prof Mike Steward at the LSHTM kindly donated peptides that had been generated 
according to the sequences of 3 MV proteins, NP, H and F. These peptides were 
all 15 amino acids long and overlapped by 5 amino acids (table 3.2, 3.3 and 3.4). 
The peptides were pooled, with 5 peptides in each pool, giving 10 NP pools, 9 F 
pools and 11  H pools which could be used to probe the responses to the three
133proteins in immune individuals. Pools of peptides were used as antigen in standard 
ELISpot assays to stimulate PBMC for MV immune donors. This strategy uses the 
natural APC within the PBMC to present antigen to the T cells in the assay. This 
strategy has been previously used  to successfully identify HIV epitopes(Goulder et 
al., 2001). The results of this strategy are shown in figures 3.13-3.15.
3.3.5.1  Responses to pools of MV Nucleoprotein peptides
Firstly PBMC from 4 donors were tested in a standard ELISpot with the 10 NP 
peptide pools (figure 3.13). This identified three pools that appeared to be 
responded to more consistently between donors, these were pools 2, 6 and 10. 
These were investigated further by splitting the pools in two of the donors this is 
shown in figure 3.14. Pool 4 was also spit to ensure the low responses to this pool 
were also reproducible in the split pool assay.
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Figure 3.13: Responses of four healthy adults to MV NP pools (mean of 3 wells +/- 
1SD). Standard ELI  Spots were carried out stimulating 250,000 PBMC per well from 
4 MV immune donors with 10 pools of peptides derived from the MV NP protein, 
HIV negative control peptide and M58 positive control peptide at 10pM final 
concentration.
134In analysis of responses to peptides from MV NP, the pool that most individuals 
had consistently responded to was pool 6 and pool 2 (figure 3.13). However on 
splitting pool 2 no significant response was seen in more than 1  donor for more 
than 1  peptide. There was a peptide within pool 6 that all individuals responded to 
and this was peptide 6 (figure 3.14 and data not shown). The sequence of this 
peptide was LLDRLVRLIGNPDVS which interestingly on analysis contained a 
sequence that had similarity to the A2- binding motif of LXXXVXXVX, in this case 
LDRLVRLIG, the final valine being replaced with an isoleucine. However valine (V) 
and isoleucine (I) are similar in property and structure so it is possible that this 
peptide could bind to HLA-A2. The exact peptide epitope 9mer was manufactured 
by Peprotech and referred to as N77. Another 9mer was made that was frame 
shifted to the right so the sequence was DRLVRLIGN and was referred to as N78. 
The original peptide 6 15mer was also re-made as the initial stock was running low.
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Figure 3.14: Responses to split MV NP pools 2, 4, 6,  7 and 10 in 2 healthy adults 
(mean of 3 wells +/-1SD). Standard ELI  Spots were carried out in 2 donors splitting 
pools of peptides that had been responded to in previous experiments. Peptides 
were used at 10pM to stimulate 250,000 PBMC per well.
135When the new peptides were investigated in the ELISpot alongside the original 
peptides it was found that only the original peptide 6 produced a response (figure 
3.15) and neither of the 9mers produced a response either (figure 3.16). This 
suggested that the original peptide 6 may have been contaminated and that it was 
not a true antigen specific stimulation that was being observed. This hypothesis 
was strengthened by the observation that 4 non A2 donors also responded strongly 
to the original peptide 6 but not the new peptide 6 (data not shown).
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Figure 3.15: Comparison of responses to original and new peptide 6 in 4 healthy 
adult donors indicating the original peptide may have been contaminated. Standard 
ELISpots were carried out to compare responses of 250,000 PBMC per well from 4 
donors to the original peptide 6 15merwith the newly synthesized 15mer at 10pM. 
Values shown are mean spots in 3 wells, error bars represent one SD.
Thus, after initial data generated by dividing the NP peptide pools in healthy adults 
was interesting the final conclusion of this section of the work was that it did not 
highlight any one peptide as being dominant in several individuals tested.
136Therefore this approach did not allow confident identification of HLA-A2*0201 
restricted peptides from the MV NP protein.
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Figure 3.16: Response of 8 HLA-A2 positive individuals to the N77 and N78 MV 
peptides (mean of 3 wells+/-SD) in a standard ELISpot, showing no increase in 
response over background responses to HIV negative control peptide (Gag 
SLYNTVATL).
3.3.5.2  Responses to MV Haemagglutinin (H) protein peptide pools
As shown in figure 3.17 there was no significant increase in response in any of the 
peptide pools from MV H protein in any of the individuals tested (n=4) over 
background responses. Therefore it was decided not to split any of the pools or 
investigate these peptides any further in normal un- boosted individuals.
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Figure 3.17: Responses to pooled MV H protein peptides of 4 MV immune HLA-A2 
positive healthy adult donors in a standard ELISpot (mean of 3 wells +/-1SD). 
Compared with the M58 positive control peptide all peptides were used at a 
concentration of 10pM.
3.3.5.3  Responses to Fusion (F) protein peptide pools
Figure 3.18 shows the responses in four normal MV immune HLA-A2 positive 
individuals to the MV F protein peptide pools. It shows that peptide pools 6, 7, 8, 
and 9 might be interesting to divide and look at individual peptide responses. 
Therefore MV F protein pools 6, 7, 8 and 9 were split and individual peptides used 
to stimulate PBMC of the same 4 normal volunteers. This is shown in figure 3.19. 
The most obvious response to see in figure 3.19 is that to peptide 34 which has the 
sequence TKSCARTLVSGSFGN which does not contain any obvious HLA-A*0201 
binding motif sequences. On further investigation of the healthy adult volunteers all 
were found to also have C*0602 or 0702 in common. The binding motif for these 
alleles is still unknown. Peptide 27 which has the sequence GVIVHRLEGVSYNIG 
(figure 3.19) was also recognised. There is also no obvious A2 sequence in this 
peptide and no other peptides that induced a response in the individuals tested.
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Figure 3.18:  Responses to pooled MV F protein peptides of 4 MV immune HLA-A2 
positive healthy adult donors in a standard ELISpot (mean of 3 wells +/-1SD). 
Compared with the M58 positive control peptide all peptides were used at a 
concentration of 10pM.
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Figure 3.19 Responses to split pools of MV F protein peptides in 4 MV immune 
HLA-A2 positive healthy adult donors in a standard ELISpot (mean of 3 wells +/- 
1SD). Compared with the HIV negative control peptide all peptides were used at a 
concentration of 10pM.
1393.4 Discussion
3.4.1 Responses to measles peptides in the ELISpot assay
Previous exposure to measles is thought to induce lasting immunity to measles 
(Cutts et al., 1999). Re-exposure does not appear to be necessary to maintain 
protection at least for wild type measles (see section 1.3.1). The donors chosen for 
this study were naturally immune HLA-A2 donors as measured by a positive anti 
measles Ig titre. As such it was predicted that these donors would give a positive 
response to individual measles peptides in the ELISpot, however as shown in 
section 3.3 no response could be detected.
The lack of detection of antigen specific T cells could be due to several factors.
The precursor frequency of MV antigen specific T cells could be too low for the
sensitivity of the assay, possibly due to the current situation in the UK where MV
infections are rare and so there is minimal natural boosting of T cell numbers. As
discussed in section 1.2.7 typical precursor frequency of CTL specific for non
chronic viral infection is quite low. For example the influenza peptide used in these
studies as a positive control, is the most abundantly recognised epitope however
has still only 40 responders per million PBMC (Rehermann et al., 1996) although
this appeared to be slightly higher in the individuals tested in this study. When
taken into consideration that individuals will be regularly boosted with circulating
virus it seems that the precursor frequency of CTL to MV epitopes may be below
the sensitivity of the ELISpot assay. Furthermore, due to the central/peripheral
memory dichotomy discussed in chapter 1, it is possible that a large proportion of
memory cells may not be detected after only 16 hours in an ELISpot (which
measures rapid production of IFNy) as the central memory cells will take longer to
140mobilise. Use of other techniques such as the longer proliferation assay, may be a 
solution to this. This method was not investigated in the first instance however due 
to the lack of exact quantitation of precursor responder cell frequency that this 
method provides.
3.4.2 Improving in vitro responses to MV peptides
As shown in section 3.3, the efficiency of antigen presentation in the ELISpot 
assays was raised as a possible reason for the lack detectable response and was 
further investigated. Despite attempts to use different APC, the background 
responses increased as much as the positive controls and measles peptides, 
making these strategies unhelpful in improving detection of responses. Using 
autologous DCs however did seem worth pursuing as a line of investigation (see 
section 3.3.4.1). DCs have been used to amplify detection of other T cell 
responses in vitro, such as responses to adenovirus (Leen et al., 2004) although 
this was done by infecting DCs with adenovirus which due to the cytopathic effects 
of MV on human DCs as discussed in section 1.3.8 is not a viable strategy for 
expanding T MV specific T cells. DCs were not used in the first instance due to the 
initial project aim of looking at and quantifying responses in small paediatric blood 
samples, which would not allow for the production of DCs. However this strategy 
could be utilized in future studies aimed at identifying responses to specific 
peptides in adults, prior to quantification of these responses in vaccinated children.
3.4.3 Responses to MV peptide pools
Following the finding that no response could be detected to the predicted epitopes
despite some being identified in other assays to detect T cell memory, there was
141the possibility that the cells that responded to these peptides, responded by 
proliferating rather than the instant effector function of producing IFNy. Thus 
overlapping peptides spanning 3 of the major MV proteins were used in a more 
general approach to scanning for potential epitopes. Although some pools gave 
positive results, when the pools were split, most of them failed to identify a 
dominant peptide within the pool. Where a peptide was identified there was no 
obvious sequence that would bind in the groove of the HLA-A2*0201. Thus the way 
this work could be extended would be to synthesise overlapping 9mers within the 
peptides identified. The disappointing lack of obvious responses seen to the 
peptide pools again raised the issue that precursor frequencies within the 
individuals tested were too low for the sensitivity of the assay. Thus the next line of 
investigation involved the decision to vaccinate two of the HLA-A2 positive, MV 
seropositive individuals with the MMR vaccine, in an effort to boost the responses 
seen to the MV peptides in vivo. This strategy would also allow the monitoring of 
any changes in responses over time to assess if the predominant responses were 
the same straight after vaccination compared to 6 or 12 months later. This work is 
detailed in chapter 4.
142Chapter 4 In vivo boosting of responses to MV through 
vaccination
4.1  Introduction
A problem that may have been encountered when scanning for MV T cell epitopes 
(as described in chapter 3), was that the approach taken sought to detect 
responses in healthy immune individuals who may not have encountered antigen 
recently and therefore may not have been boosted for many years. Thus the levels 
of precursor T cells may have been below the detection levels of the assay. It is 
well known that for other viruses CTL precursor frequency may be very low even 
when immunity is effective and the individual may encounter antigen more 
regularly than with MV. For example, in Hepatitis C virus (HCV) responses to one 
epitope are thought to be in the region of 10 responders per million PBMC 
compared to up to 40 responders per million PBMC against the Influenza matrix 
peptide (Rehermann et al., 1996) (this is discussed in section 1.2.7). Given that the 
sensitivity of the ELISpot has been shown to be close to 100% when detecting 
beads and specific numbers of T cell clones (Schmittel et al., 1997), the detection 
limit of the assay is potentially 1/250,000 cells (the number of cells per well) 
depending on the background (non specific spot formation). In this system on 
average 3 non specific spots are seen in each well therefore statistically for a 
stimulation index of 3, 9 spots would have to be detected to be considered 
significant which requires 6 spots per 250,000 cells -24 per million to be antigen 
specific and this is about half the level of responders seen for influenza, a virus 
individuals encounter much more often than MV.
143Therefore in order to boost responses to MV, two volunteers were vaccinated with 
the MMR and sequential blood samples were taken and PBMC stored for analysis 
for response to the MV peptide pools. Wong-Chew et al have studied the effect of 
boosting previously immune adults with a measles vaccine (Wong-Chew et al., 
2003). This study showed a transient boost in T cell proliferation levels to MV 
antigen compared to no proliferation prior to vaccination (this despite high MV 
specific Ig titres prior to vaccination). This was therefore encouraging for the line of 
investigation used here. CFSE labelling of PBMC drawn at different time points 
post vaccination was used to measure proliferation of T cells to MV antigen.
4.2  Specific materials and methods
4.2.1  Vaccine and volunteers
The volunteers were fully consented and given one dose of the Aventis Pasteur 
MMR vaccine M.M.R. II in the presence of a physician and in a clinical area. The 
vaccine contains 1,000 tissue culture infectious doses 50 (TCID) of live MV,
Enders line of the Edmonston strain, 20,000 TCID50 of live mumps, Jeryl Lynn 
Level B strain and 1,000 TCID50 of Rubella, Wistar RA 27/3 strain. The vaccine 
was obtained through Great Ormond St Hospital pharmacy. Volunteers were 
allocated linked anonymised codes, MMR01 and MMR02 for labelling of all 
laboratory samples. Both volunteers were HLA-A2*0201  positive adult males (as 
confirmed by PCR genotyping) they also shared the alleles B*07 and C*0702. They 
were 45 and 32 years old respectively. MMR01  had had MV as a child approx 40 
years prior to this study. It is assumed that MMR02 has also suffered from MV as a 
child however could not remember. Neither of the volunteers had been previously 
immunized against MV.
1444.2.2 Bleeding schedule
50ml of blood was taken on each of the days indicated below in Figure 4.1, the 
PBMC were extracted and stored in 7.5x106 aliquots in liquid nitrogen.
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Figure 4.1 Bleeding schedule for MMR study (not to scale). Letters represent the 
codes that were allocated to the different time points e.g. pre vaccination MMR01A, 
2 weeks post vaccination, MMR01D.
4.2.3  Production of MV antigen
MV antigen was produced by infecting a 75% confluent Vero cell monolayer with 
MV Edmonston -Zagreb strain which is the attenuated MV strain used for 
vaccination (Gariy et al., 2001) obtained from the National Collection of Pathogenic 
Viruses (NCPV) at a multiplicity of infection (number of virus particles per cell) 
(MOI) of 0.1.  This was done by adding 10ml of virus containing serum free 
medium to the Vero cells and incubating for 2 hours at 37°C/5%CC>2 This inoculum 
was then replaced with 100ml of culture medium containing fetal calf serum (this 
was in a T225 flask). The viral antigen was harvested when the cytopathic effect of 
the virus as observed by standard microscopy was at 80-90% indicated by 
syncytium formation. This typically took 2-3 days at 37°C/5%C02  . Cells were 
harvested by scraping them off the flask, which resulted in approx 2.5 x 105  cells 
per ml of medium which was then ruptured by 6 rounds of freeze thawing, before 
the suspension was spun at 1000g for 5 minutes, aliquoted and frozen at -80°C 
until use. In parallel with this preparation, uninfected cells were prepared in the
145same way as a negative control for the presence of Vero cell derived proteins in
the virus preparation.  Proliferation to MV antigen was measured using CFSE
labelling of cells as described in section 2.5.5. The MV antigen preparation was
used at a concentration of 1/25 of the culture medium, the vero control antigen was
also used at this concentration.
4.3  Results
4.3.1  Serology of individuals at different time points
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Figure 4.2: Serum anti measles IgG antibody titres in MMR01 pre and at time 
points post vaccination. Titres were measured in an ELISA against MV antigen and 
were compared with the WHO standard to give values in International Units 
(lU/ml).
In order to determine the MV immune status of volunteers, anti MV IgG antibody
was measured for all the time points from both of the individuals vaccinated as
shown in figures 4.2 and 4.3 below. This was done as outlined in section 3.2.2 by
146comparing ab concentrations with an international standard in an ELISA.  Both 
individuals were considered immune before vaccination and both show a transient 
boost in antibody levels around 30 days after vaccination.  However the antibody 
levels are ten fold different between the two volunteers showing significant 
variation between individuals.
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Figure 4.3: Serum anti measles IgG antibody titres in MMR02 pre and at time 
points post vaccination.  Titres were measured in an ELISA against MV antigen and 
were compared with the WHO standard to give values in International Units 
(lU/ml).
4.3.2  Proliferation to whole measles
Whole measles antigen was prepared as outlined in section 4.2.3 and was 
compared in all proliferation experiments to Vero cell lysate prepared identically 
except without MV infection.  Responder cells were labelled with CFSE and 
incubated with Vero cell lysate for 5 days,  before being harvested and stained for 
CD3, CD8 and CD4.  Plots shown in figure 4.4 are gated on live, CD3 positive cells
147and the percentages shown are the percentage of CD3+, CD4+ or CD8+ cells that 
have proliferated to the antigen. Only the donor MMR02 is shown for the time 
points pre and 6 months post vaccination in the FACS plots however the same 
pattern is repeated in MMR01 where there is less proliferation to MV antigen post 
vaccination than before.  Proliferation to MV at all time points post vaccination for 
both MMR01  and MMR02 is summarised in figure 4.5, in which data are expressed 
as percentage of cells that have divided in each sub population.
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Figure 4.4: Proliferation of T cell subsets to MV antigen (CD3+CD4+ upper row, 
red proliferation to MV pink to control, CD3+CD8+ lower row blue proliferation to 
MV turquoise to control) to MV antigen or uninfected Vero control from volunteer 
MMR02 pre (left four panels) and 6 months post (right four panels)vaccination.
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Figure 4.5 Graphical representation of proportions of CD3+CD4+(red) and 
CD3+CD8+(blue) T cells proliferating to MV antigen over time post vaccination in 
a)MMR01 and b)MMR02.
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Time point4.3.3 Memory phenotype analysis
Obtaining serial samples post vaccination provided a unique opportunity to 
examine the populations of cells in the PBMC after vaccination. Although the 
immune system is highly homeostatic the use of flow cytometry to detect distinct 
populations of both T cells and other peripheral cell populations showed some 
small but interesting variations in frequency. Figures 4.6 and 4.7 show the 
proportions of different cell populations as a percentage of either total cells or of 
the population indicated changing over time post vaccination in both MMR01 and 
MMR02.
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Figure 4.6: Changes in lymphocyte sub populations in PBMC over time post 
vaccination in MMR01. Data generated by analysis of three colour staining of 
PBMC run on the flow cytometer. Cells were gated on a lymphocyte gate and then 
on the sub population indicated in the legend. Five time points in the vaccination 
schedule were analysed (as shown in figure 4.1).
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Figure 4.7; Changes in lymphocyte sub populations in PBMC over time post 
vaccination in MMR02. Data generated by analysis of three colour staining of 
PBMC run on the flow cytometer. Cells were gated on a lymphocyte gate and then 
on the sub population indicated in the legend. Five time points in the vaccination 
schedule were analysed (as shown in figure 4.1).
All analysis of phenotypes was carried out using flow cytometry as outlined in 
section 2.5. CD19 was used to stain B cells and CD3 to stain T cells. The T cells 
are then split into CD4 and CD8 positive cells indicating T helper cells or Cytotoxic 
T cells. CD25 high, CD4 positive cells could indicate a population of recently 
activated or T regulatory cells in the CD4 population (Kuniyasu et al., 2000). The 
CD8 population is then split into two cell populations expressing either the CD45 
isoform CD45RA or CD45RO. These two populations at one time were believed to 
represent either naive T cells (CD45RA) or antigen experienced cells (CD45RO). 
However recent studies both using TCR analysis and MHC tetramer staining have 
shown that the CD45RA+CD8+ population contains high numbers of antigen
151specific T cells thus must contain memory cells (Dunne et al., 2002). Further 
studies investigating integrin and chemokine receptor surface expression on cells 
have shown that the antigen experienced CD45RA+ cells express high levels of 
LFA1 and low levels of CCR7. This indicates a population of cells that home to 
tissues rather than lymph nodes (CCR7 being a receptor crucial for extravasation 
across the high endothelial venule (HEV) (Dunne et al., 2002;Faint et al., 2001), 
therefore entry to the lymph nodes. LFA1  is an adhesion molecule made up of 
CD11a and CD 18 that allows for homing to tissues, thus although the cells exhibit 
the low turnover rate of naive cells they home to tissues and can be activated on 
antigen encounter without the need for professional antigen presentation in the 
lymph nodes and may then become RO positive effector cells. As can been seen in 
figures 4.6 and 4.7, the populations do vary with time post vaccination in some 
cases up to 7 or 8% of a sub population. How much significance this has in vivo is 
hard to determine, and more individuals would need to be studied to determine a 
pattern and by comparison with variation over time in non-vaccinated controls. 
However in these two individuals it can be seen that although there is little change 
in the levels of CD3+CD4+ cells in one individual (MMR02) the proportion of CD3 
cells that are CD8 positive increases 10 days post vaccination from 31% to 40%. In 
the same individual there is also an increase in CD4+CD25+ cells which may 
indicate the presence of a regulatory population beginning to control the response 
at the 10 day time point or a population of activated, dividing cells up-regulating the 
IL-2 receptor. Perhaps more interestingly the percentage of CD8+ cells that are 
LFA1+ in both individuals, decrease at the 10 day time point as does the LFAIhigh 
CD45RO population which could be activation induced cell death of the effector
152cell population. It is also interesting to note the relationship between RO and RA 
cells being that when one increases the other decreases.
4.3.4  T cell responses to pools of MV peptides assayed by ELISpot
In order to investigate the MV peptides to which the MMR vaccinated individuals 
responded, and to demonstrate any similarities between the two donors over time, 
the pools of peptides from the three MV proteins NP, H and F (tables 3.2, 3.3 and 
3.4) were used to stimulate PBMC from all time points in the ELISpot assay. Where 
possible pools were then separated into their individual peptides and used to 
stimulate PBMC from specific time points, to try to identify specific peptides that 
were stimulating IFNy release. In order to allow easier comparison over time 
values have been normalized by subtracting the number of spots in the control 
wells at each time point and are expressed as spots per 250,000 cells per well.
The results of IFNy release in response to peptides derived from the MV NP 
protein are shown in figures 4.8 (MMR01) and 4.9 (MMR02).
4.3.4.1  Response of vaccinated individuals to peptides derived from MV NP 
protein
As can be observed in figures 4.8 and 4.9 there is a trend towards an increase in 
response to pool 1  and 2 in both individuals with pool 1  peaking late in the 
response at time point F (3 months) in MMR01. Responses to pool 4 appear to 
increase gradually in both donors peaking late at time point E (1  month). In MMR01 
responses to pool 5 peak at time point C (10 days) but not in MMR02. Responses 
to pool 8 rise at 2 weeks in MMR01 and 1  month in MMR02. Responses to pool 9
gradually increase over the time to peak at 1  year and those to pool 10 peak at 1
153month in both donors.  These data, especially where both donors show the same 
pattern of response highlight pools and time points that warrant more investigation 
by splitting the pools into their individual peptides and testing responses to these 
(see section 4.3.5).
A B C D E F G H  
Time point
NP Pool 1
NP Pool 2
NP Pool 3
NP Pool 4
NP Pool 5
NP Pool 6
NP Pool 7
NP Pool 8
NP Pool 9
NP Pool 10
Figure 4.8 Graph to show the response of MMR01 PBMC to MV NP peptide pools 
over time post vaccination. Standard ELI  Spots were earned out with 250,000 
PBMC per well stimulated with 10pM of each of 5 peptides per pool.  Values have 
been normalized to responses at each time point to the negative control HIV 
peptide. Letters represent the time points post vaccination as outlined in figure 4.1. 
Values are mean of 3 wells SD are not shown for ease of viewing but were typically 
as low as in previous experiments.
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Figure 4.9 Graph to show the response of MMR02 PBMC to MV NP peptide pools 
over time post vaccination. Standard EUSpots were carried out with 250,000 
PBMC per well stimulated with 10pM of each of 5 peptides per pool.  Values have 
been normalized to responses at each time point to the negative control HIV 
peptide. Letters represent the time points post vaccination as outlined in figure 4.1. 
Values shown are mean of 3 wells, SD are not shown for ease of viewing however 
were typically low as in previous experiments.
4.3.4.2  Response of vaccinated individuals to peptides derived from MV H 
protein.
As can be seen from figures 4.10 and 4.11  pool 1   of the H peptide pools appears 
to be the most interesting as it is consistently giving high responses in MMR02 and 
appears to peak at time point D (2 weeks post vaccination) in MMR01. The 
response to pool 2 appears to peak around 2 weeks post vaccination in both 
donors making this a potentially interesting pool to investigate further.  Responses 
to pool 7 peak late in both donors with a steady increase in response in MMR02. 
Responses to pool 9 also have an interesting pattern over time in both donors, with 
a peak response at 2 weeks which then gradually declines post vaccination.
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Figure 4.10 Graph to show the response of MMR01 PBMC to MV H peptide pools 
overtime post vaccination. Standard ELI  Spots were carried out with 250,000 
PBMC per well stimulated with 10pM of each of 5 peptides per pool.  Values have 
been normalized to responses at each time point to the negative control HIV 
peptide. Letters represent the time points post vaccination as outlined in figure 4.1.
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Figure 4.11 Graph to show the response of MMR02 PBMC to MV H peptide pools 
overtime post vaccination. Standard ELI  Spots were carried out with 250,000 
PBMC per well stimulated with 10pM of each of 5 peptides per pool.  Values have 
been normalized to responses at each time point to the negative control HIV 
peptide. Letters represent the time points post vaccination as outlined in figure 4.1.
1564.3.4.3  Response of vaccinated individuals to peptides derived from MV F 
protein.
Figure 4.12 and 4.13 show that as for the NP and H, proteins there are several 
peptide pools to which an interesting pattern of response was seen. Firstly pool 1  
which in both individuals gives high responses, which in MMR02 peaks at 2 weeks 
post vaccination. Responses to pool 7 have a peak at 2 weeks and are consistently 
high in MMR02. Finally responses to pool 10 rise towards the end of the time 
course of samples taken post vaccination (time point H 1 year post vaccination) in 
both donors.
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Figure 4.12: Graph to show the response of MMR01 PBMC to MV F peptide pools 
over time post vaccination. Standard ELI  Spots were carried out with 250,000 
PBMC per well stimulated with 10pM of each of 5 peptides per pool.  Values have 
been normalized to responses at each time point to the negative control HIV 
peptide. Letters represent the time points post vaccination as outlined in figure 4.1. 
Values are means of 3 wells, SD not shown for ease of viewing.
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Figure 4.13 Graph to show the response of MMR02 PBMC to MV F peptide pools 
overtime post vaccination. Standard ELISpots were carried out with 250,000 
PBMC per well stimulated with 10pM of each of 5 peptides per pool.  Values have 
been normalized to responses at each time point to the negative control FIIV 
peptide. Letters represent the time points post vaccination as outlined in figure 4.1. 
Values are mean of 3 wells, SD not shown for eas of viewing.
4.3.5 Splitting peptide pools
Once the response to the MV derived peptides pools had been investigated in the 
vaccinated individuals, the highlighted pools were then split into individual peptides 
and these were used to stimulate PBMC from the time points that had been 
positive in the previous experiments, in an ELISpot, in order to identify a specific 
peptide that the cells were responding to. Due to the limited amount of cells in the 
samples available from the volunteers, this could only be done for the NP protein 
pools in the first instance.  The results of this are shown in figures 4.14 and 4.15. 
For MMR01 the time points and NP derived peptide pools that were investigated 
were, C- pool 5, D pools 2 and 8, E pool 10, F pool 1  and G pool 2. Peptides 22
158a)
and 38 appeared to show some response over background (figure 4.14)
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Figure 4.14: MMR01 PBMC simulated by split MV NP peptide pools, a) MMR01G 
with split pool 2 b) MMR01D with split pools 2 and 8. Standard ELISpots were 
carried out where PBMC were stimulated with 10pM of individual MV NP peptides 
from identified peptide pools. A positive response was considered to be more than 
a doubling of responses to control HIV peptide which is shown for comparison. 
Values represent mean of 3 wells +/- 1SD.
159Response to the peptides was defined by at least a doubling of responses when 
compared to the control peptide. For this reason the responses to the control 
peptide are shown on figures 4.14 and 4.15 for comparison.
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Figure 4.15: MMR02 PBMC simulated by split MV NP peptide pools, a) MMR02F 
with split pool 2 b) MMR02G with split pools 2 and 8. Standard ELISpots were 
carried out where PBMC were stimulated with 10pM of individual MV NP peptides 
from identified peptide pools. A positive response was considered to be more than 
a doubling of responses to control HIV peptide which is shown for comparison. 
Values represent mean of 3 wells +/- 1SD.
160As these experiments could only be carried out once the increases observed were 
not statistically significant but served to identify individual MV NP peptides that 
warranted further investigation. For MMR02 the time points and NP peptide pools 
that were further investigated were, E -pools 8 and 10, F- pools 1  2 and 3 and G- 
pool 1. Of these split pools, peptides 1, 11, 3, 33, 22, 21 and 38 appeared to show 
some response over the response to the control peptide (figure 4.15).
The fact that peptide 22 was identified as a possible epitope was interesting as this 
contains one of the predicted epitopes N210 that was investigated in chapter 3.
The sequence of peptide 22 is LERKWLDWRNIIAF and the underlined section is 
all but one amino acid of the predicted A2 epitope N210 (RLERKWLDV). Also 
interestingly, H30 would be in Pool 1  in the pools of MV H peptides which is the 
poll of MV H peptides that is responded to most by both vaccinated individuals.
4.4  Discussion
4.4.1  Proliferative responses of PBMC to MV antigen after vaccination with 
the MMR vaccine
Figures 4.4 and 4.5 suggest that T cell proliferation to MV antigen is reduced 
following vaccination which is somewhat counter-intuitive. However as discussed in 
section 1.3.8, MV infection and to some extent the vaccine is associated with a 
transient immunosuppression which could explain these results (Hirsch et al., 
1981;Schneider-Schaulies and Meulen, 1998). One study in children receiving 
measles vaccines showed that proliferation of lymphocytes to mitogen after 
vaccination was reduced both 2 weeks and three months after vaccination
compared to pre vaccination levels. Interestingly it was also found that this
161suppression of lymphocyte proliferation negatively correlated with the levels of anti 
MV antibody, therefore the stronger the response to the vaccine the more 
suppression of lymphocyte proliferation to mitogen (Hussey et al., 1996). The 
Hussey et al study did not follow the vaccinated individuals after 3 months so it is 
possible that this vaccine induced immunosuppression extended beyond this time 
point (Hussey et al., 1996). This may support the observation seen in this study 
where reduced levels of proliferation to MV antigen are seen up to one year after 
vaccination. Ideally to determine if this phenomenon is reproducible these 
experiments should be repeated, both to ensure that the assay reproducibility is 
acceptable with these samples and that the changes seen in proliferation to MV 
antigen are significant. In addition to this the viability of cells prior to the 
proliferation assay could be tested further than analysis by trypan blue, with 
Annexin V staining, as it may be that cells from some time points are more prone to 
apoptosis than others. In contrast to these data, the investigation by Wong Chew et 
al concluded that T cell proliferation increased post vaccination (Wong-Chew et al., 
2003). However on further analysis of the methods used in the Wong study it was 
found that PBMC were stimulated with MV antigen but proliferation was measured 
by thymidine incorporation and so there was no verification that it was T cell 
proliferation that was being measured.
When data from this study were not gated on CD3, proliferation post vaccination 
was observed. However anti CD3, 4 and 8 staining showed this was not T cells 
proliferating. Attempts were made to identify the proliferating cells. However 
staining for both monocyte and B cell markers failed to identify a specific
population on the small number of cells available (data not shown).
1624.4.2 Memory phenotype post vaccination
In staining the PBMC stored from each time point in both vaccinated individuals it 
was interesting to see that some changes were detectable in the proportions of 
cells expressing certain markers despite the homeostatic nature of the immune 
system as a whole. The most interesting findings were the increase in CD4+CD25+ 
cells 10 days post vaccination which could indicate the emergence of a regulatory 
population of cells to control the response. Alternatively this could also indicate the 
activation and proliferation of the antigen specific cells. The decrease in CD8+ 
CD45RA+ LFA1 + cells post vaccination could either indicate the differentiation of 
these cells into a more immediate effector cell or activation induced cell death of 
this population due to antigenic stimulation. Due to the small numbers of 
vaccinees, it is impossible to determine how much significance these changes 
have, however this pilot study shows that it may be an interesting area to study in 
the context of larger vaccine trials in order to further characterize the effect of 
vaccination and further investigate the immune response as a whole. This could be 
then compared to the studies discussed in section 1.3.7 which describe the 
immune responses to wild type MV infection.
4.4.3 Dissecting peptide pools
Although several epitope candidates arose from this analysis, only two of the MV 
NP peptides produce a response in both MMR01 and MMR02. By using 15mer 
overlapping peptides the study might have identified not only HLA-A2 binding 
epitopes but also of identifying epitopes that bound to other HLA molecules on the 
surface of the cells including Class II epitopes. However as this study was
163restricted to just 2 individuals, it was decided to focus in on the original aim of 
identifying HLA-A2*0201 epitopes.
The two peptides that were responded to by both MMR01 and MMR02 were NP 
peptide 22 and peptide 38. Peptide 22 contains the initial N210 peptide that was 
investigated in chapter 3. On further investigation it was found that the initial 
predicted epitope H30 would be in Pool 1   in the pools of MV H peptides which is 
the H pool that is responded to most by both vaccinated individuals. This would be 
interesting to further investigate in the context of recently vaccinated individuals in 
future studies.
The other NP peptide identified by splitting the pools into individual peptides was 
NP 38 which has the sequence RSAGKVSSTLASELG this does not contain any 
immediately apparent A2 motif sequences. However both MMR01 and MMR02 
share two other MHC alleles, B*07 and C*0702, the binding motifs for which are 
XPXXXXXXL/F and XXXXXXXXY/F/L respectively. There are no potential binding 
sequences for B*07 in either peptide 38 or peptide 22 however both peptides 
contain sequences that may bind to the C*0702 allele, SSTLASEL for peptide 38 
and DWRNIIAF for peptide 22.
With regards to the initial predicted epitopes that had been identified by various 
techniques as outlined in chapter 1, it appears that the vaccinated individuals do 
respond to two of these peptides by producing IFNy. H30 was initially identified by 
Nanan and colleagues (Nanan et al., 1995;Nanan et al., 2000) firstly by
proliferation of T cells to the peptide and then by production of IFNy. It was also
164identified as a naturally processed epitope by MV infected B cells by van Els and 
colleagues (van Els et al., 2000). N210 was also identified by proliferation to the 
peptide by Nanan et al. It is important that these epitopes have been verified by 
other methods and it will be interesting to investigate the response to these 
epitopes in newly vaccinated naive individuals and in natural measles infection in 
order to further characterize the immune response to measles.
Although this method did identify several potentially interesting peptide sequences 
the responses seen were still very small and a slightly higher background spot 
level could change the interpretation of the data. This suggests that even after 
vaccination the precursor frequency of the CTL specific for these epitopes is very 
low. Even the largest responses over background were only 10 spots in 250,000 
cells which is 40 per million PBMC. This is within the same precursor frequency as 
the influenza matrix protein epitope M58 as discussed in section 1.2.7. Therefore a 
new strategy was adopted that mirrored the strategy used by van Els et al (van Els 
et al., 2000) in that by infecting antigen presenting cells the result would be a 
naturally processed epitope. In contrast to this work however, the aim was to grow 
T cells lines to the APC and therefore needed to overcome the cytopathic effects 
that MV has on DCs. Therefore an adenoviral vector system was used to express 
MV proteins in DCs, this strategy is discussed in chapter 5 where autologous DCs 
from one vaccinated individual, MMR02 were infected with adenoviral vectors 
containing single MV proteins and used to stimulate the T cells in order to grow T 
cell lines, with the hope of amplifying the specific T cells and providing a much 
larger specific cell population allowing a more detailed analysis for each protein.
165Chapter 5 In vitro boosting of responses using adenoviral 
constructs
5.1  Introduction
It has been shown that MV specific CTL can be detected in individuals vaccinated 
against MV. These were detected in a chromium release assay by killing of HLA 
matched allogeneic B cells (Jaye et al., 1998a). This is an assay known to 
correlate well with results observed in the ELISpot (Scheibenbogen et al., 2000). 
However in order to detect these cells it was necessary to expand them in vitro 
prior to use in these assays (Jaye et al., 1998b). Therefore it was decided to 
expand MV specific T cells in vitro prior to use in the ELISpot. It is well established 
that measles virus infection has a direct cytopathic effect on human dendritic cells 
in vitro and have a negative effect on T cells co cultured with these DCs this was 
discussed in sections 1.3.5 and 1.3.8. Therefore as an alternative strategy to 
provide measles antigens for presentation in in vitro assays, a replication deficient 
adenoviral vector containing cDNA coding for the full length MV NP protein was 
used (Rad68) alongside constructs containing full length cDNA’s coding for the F 
(Rad95) and H (Rad88) MV proteins, or a control construct, (Rad35) containing p- 
galactosidase. These constructs were shown to infect human cells using low 
enough levels of virus to be non-toxic to the cells. It was thought if these constructs 
could be used to infect human DCs, this would represent a more natural route of 
antigen entry, since antigens are typically presented on MHC I via the intra cellular 
antigen presentation pathway as outlined in section 1.1.2.3. Therefore processing 
and presentation would more closely mirror that of natural measles, while avoiding 
the cytopathic effects natural measles infection would have on the cells.
166Interestingly the NP protein itself has been reported to inhibit IL-12 production by 
DCs in vitro (Section 1.3.5) and may therefore have an immunosuppressive effect, 
which would be potentially overcome by the intracellular expression of the protein 
rather than it being added exogenously. These constructs would also allow the 
delivery of MV antigen into APC in a more natural route and therefore allow the 
expansion of MV specific T cells to use in further in vitro assays.
5.1.1  Adenovirus virology
The adenovirus is a member of the Mastadenovirus genus which infects mammals. 
It has a double stranded DNA genome which is encased within non-enveloped 
icosahedral particles which are between 60 and 90nm in diameter depending on 
the strain (Roy-Chowdhury and Horwitz, 2002). These are shown both 
schematically and in an electron-micrograph in figure 5.1.
a)  b)
Figure 5.1: a) Schematic representation and b) electron micrograph of adenovirus 
particles showing the penton structures on each comer. Adapted from 
http://www. uct. ac. za/depts/mmi/stannard/adeno. html.
167The wild type adenovirus causes mild respiratory illness and conjunctivitis in 
humans amongst other more serious symptoms such as gastroenteritis and 
pneumonia. The adenovirus family has been classified into six distinct sub groups 
A-F and then split further into at least 49 serotypes. This has been done on the 
basis of genetic variability, oncogenic potential and G-C content of DNA.(Li et al., 
1999). It is subgroup C isolates that are associated with upper airway infections of 
which the main two are serogroup Ad2 and Ad5. Ad5 is the serogroup on which the 
adenoviral vectors used in this study are based, although Ad2 has also been used. 
The Adenovirus is ideal for use as a vector, as its life cycle does not involve 
integration into the genome, instead replication is as episomal elements in the host 
cell nucleus which means there is minimal risk of insertional mutagenesis. 
Adenovirus has a large genome of 35Kb, up to 30Kb of which can be replaced with 
foreign DNA (Verma and Somia, 1997) again making the virus an ideal candidate 
for a vector system.
5.1.2  Mechanisms of infection by adenovirus
The adenovirus gains entry to the cells by using the penton structure which can be
seen as the projections in figure 5.1. Uptake of the adenovirus particle is a two
stage process involving the binding of the penton structure to receptors on the cell
surface. The major receptor to be described is the coxsackievirus and adenovirus
receptor (CAR) (Bergelson et al., 1997). However at high enough viral titres
adenovirus can enter cells that do not express CAR such as DCs and it is thought
that MHC I may also act as a receptor (Hong et al., 1997).The penton base protein
at the end of the penton spike nearest the virus particle then binds to integrins on
the cell surface allowing internalisation via receptor mediated endocytosis
168(Wickham et al., 1993;Wickham, 2003). Once in the phagocytic vacuole, the 
penton proteins have a toxic activity which is responsible for the rupture of the 
phagocytic membrane and release of the viral particle into the cytoplasm of the cell 
(Bergelson, 1999). The core of the virus then migrates to the nucleus where the 
DNA enters through nuclear pores where it is replicated and in wild type virus new 
viral particles are synthesised (Guy et al., 1995).
5.1.3  Use of adenoviral vectors for gene delivery.
With the recent increase in the use of viral vectors to deliver genes for gene
therapy and anti tumour therapy (Kanerva and Hemminki, 2004;Roy-Chowdhury
and Horwitz, 2002) there has become an increased need for studies addressing
the effect of such viral vectors, both on phenotype and function of the transduced
cells. Adenoviral vectors are being used in several trials in both animal models and
humans. A variety of strategies are being investigated, for example to target
therapeutic genes to cells lacking them (Raper et al., 1998;Raper et al., 2002), to
target suicide and toxic products specifically to cancer cells using modified vectors
(Breidenbach et al., 2005;Kanerva et al., 2004), for use in vaccination strategies
against HIV-1 (Barouch and Nabel, 2005) and to transfer tumour associated
antigens to components of the immune system to stimulate a systemic specific
immune response against tumour cells (Chen et al., 1996). Due to their pivotal role
in the immune response, DCs have been targeted for gene transfer of these
tumour associated antigens (Philip et al., 2000) with successful generation of
tumour specific immune responses which can clear tumour cells on re challenge.
From this body of work it appeared human DCs could be infected with adenoviral
vectors and the transgene efficiently expressed. However, before this specific
169system could be used verification of infection and protein expression was required 
(chapter 5) and the effects of the specific constructs used in this study needed to 
be investigated (chapter 6).
5.2  Specific materials and methods
5.2.1 Viral constructs
Recombinant adenoviruses containing the cDNA for MV proteins NP, F and H were 
kindly donated by Professor John Stephenson as discussed in section 2.7 
Virus was amplified using standard protocols as outlined in section 2.7. After 
preparation of adenoviral stock, an estimate of viral infectivity was made by 
counting plaque-forming units (PFU) on 293 cells. This was done as outlined in 
chapter 2 by performing serial dilutions of the virus in duplicate then counting the 
one dilution that had approximately 50 to 100 plaques. These 50 plaques arose 
from 0.5ml of virus implying a titre of 100 x 1,000,000 (108) PFU per ml of virus 
stock. In the experiments shown, a PFU to cell ratio of 50:1 was used to infect 
cells. The endotoxin level in the virus preparations was also measured. This was 
25pgml'1 , which is less than reported levels in “endotoxin free” reagents (data not 
shown). This was to ensure any effect observed on DCs was due to infection and 
not LPS stimulation.
5.2.2 Short term line culture
In this study human monocyte derived DCs were infected at the immature state 
and then matured before use in stimulation assays. We did not infect mature DCs 
(mDC), since previous reports have suggested that mDCs are less readily
170transduced due to low expression of the coxsackievirus and adenovirus receptor 
(CAR) (Bergelson et al., 1997;Rea et al., 1999).
5.2.2.1  Short term T cell lines stimulated with adenovirus infected DCs
T cell lines were grown using a previously described method (Leen et al., 
2004a;Leen et al., 2004b). Briefly, monocyte derived DCs were cultured as outlined 
in section 2.6. These were then infected with adenovirus, either Rad35 (control), 
Rad68 (NP), Rad88 (H), or Rad95 (F) on day 5 at an MOI of 50 (these constructs 
are further described n chapter 6). After 24 hours cells were then matured using 
100ngml'1  each of PGE2, IL-6, human recombinant (hr)TNFa (all from Sigma UK) 
and hrlL-1 p (Peprotech UK) for a further 24 hours. DCs were then counted and 
plated at a ratio of 1:10 (DC: T cell) with 2 x 106  autologous T cells in a 24 well 
plate in RPMI supplemented with 45% clicks medium (GIBCO) and 10% FCS. After 
10 days the cells were harvested and re-plated at 2 x 106 cells per well in a 10:1 
ratio of cell line to newly infected and matured autologous DCs. Half the media was 
changed every 3 days until day 18 when cells were harvested and re-plated in 
medium containing 50Uml'1  of human recombinant IL-2 (Roche) (figure 5.2).
Day 6: 
Infect DC
Day 0: 
Set up DC
Day 8: set up 
proliferation 
jys
Day 15: 
Infect DC#2
Day 7: 
Mature DC
Day 9: Set 
up DC#2
Day 17: Harvest 
lines and re-plate 
with 1|C#2
Day 37: Harvest lines and re- 
stimulate in ELISpot and 
proliferation assays
Day 16: 
Mature DC#2
Day 27: Harvest 
lines and re-plate 
with IL-2
On day 7 change half of the cell line medium and then repeat every 3 days.
Figure 5.2 Schematic diagram of protocol for the production of T cell lines using 
autologous DCs infected with adenoviral constructs.
1715.2.2.2 Re stimulation of T cell lines for proliferation assays
After a further 7-10 days in IL-2 the T cell lines were harvested and pooled, stained 
with CFSE, spun and re-suspended in fresh RPMI 10% FCS in half their original 
volume. The lines were then re-plated using 10Opil per well and were co-cultured 
for 5 days with either autologous PBMC infected for 24 hours with the same Rad, 
or Rad35 or uninfected PBMC. After 5 days cells were harvested and stained with 
anti CD3 as previously described and analysed for proliferation by flow cytometry.
5.2.2.3 Re-stimulation of lines in the ELISpot assay
After a further 7-10 days in IL-2 the T cell lines were harvested and pooled, 
counted and plated in triplicate ELISpot wells at an optimized number of 10,000 
cells per well in a 1:1  ratio with autologous PBMC that had been previously 
infected for 24 hours with the same Rad, control Rad or left uninfected. Peptide 
pools were used as previously described in chapter 3 with 40,000 cells per well of 
each line.
5.3 Results
5.3.1  Comparison of monocyte derived DCs prepared by different methods
It has been suggested that the phenotype, as detected by surface marker staining 
and the effect of maturation stimuli on these surface markers, is similar with either 
of the methods of DC preparation described in section 2.6.1, adherence to plastic 
or purification on magnetic beads.  However when cytokine production by myeloid 
DCs in response to LPS stimulation was measured, as shown in figure 5.3 for 2 
donors, the proportion of DCs producing cytokine was consistently less in DCs
prepared with magnetic bead sorting than those prepared using adherence.
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Figure 5.3: Comparison of cytokine production upon LPS stimulation in myeloid 
DCs prepared via adherence (red bars) or CD 14 bead sorting (blue bars) in two 
control healthy donors, AW5 (a) and AW75 (b). Myeloid DCs were stimulated with 
100ng/ml LPS for 18hrs with Brefeldin A added for the final 16 hours. Cytokine 
production was analysed by intracellular staining and flow cytometry data are 
expressed as the percentage of DCs producing cytokine.
There was a reduction in the percentage of DCs producing cytokine for all 4 of the 
cytokines tested, IL-6, IL-10, IL-12 and TNFa. The significance of this result was 
tested using the Wilcoxon paired rank statistical test and despite the small sample
size, these differences were significant, as a decrease in total number of cells
173producing all of the four cytokines in CD14 magnetic bead sorted cells compared to 
adherence sorted cells, p< 0.015. It was decided to continue to use the adherence 
method in all future experiments but take into consideration the fact that DCs 
prepared by different methods are not entirely the same, when comparing data 
from other groups.
5.3.2  Plaque assay determination of viral titre
After each new virus preparation an assessment was made of the titre by using a 
plaque assay on 293 cells as outlined in section 2.7.1.3. Figure 5.4 shows a 
representative plaque assay after infection of 293 cells with Rad35, where 5.4a) 
shows the regions of cell death due to viral replication where the red dye has not 
been taken up. Each one of these regions represents a single viral particle and 
from this and the dilution factor the viral titre could be calculated. 5.4b) shows cells 
that were infected at such a high concentration that they all died and c) shows 
uninfected cells. Figure 5.5 shows the same as figure 5.4 using light microscopy.
a)  b)  c)
Figure 5.4:  Photographs of plaque assays for virus stock PFU determination, a) 
108 dilution  where plaques are clearly visible, b) 1(f dilution where all cells have 
been killed by the virus so have not taken up the dye and c) uninfected cells where 
all the cells are alive and therefore stained red by the neutral red dye.
174a)  b)  c)
Figure 5.5: Light microscope photograph of plaque assays a) one plaque of virus 
killed 293 cells, b) 293 cells that have not taken up neutral red die as they have 
been killed by virus  and c) uninfected 293 cells that have taken up the dye. (X10 
x40 magnification).
5.3.3  Detection of pgal protein
The control construct Rad35 (containing cDNA coding for the P-galactosidase 
protein), was analysed for its capacity to infect certain cell types. This was done by 
detection of the p-galactosidase (p-gal) protein with the FDG assay (section 
2.7.2.1). This was performed to verify that the construct could infect both human 
myeloid cell lines and various populations of human PBMC and DC.
5.3.3.1  Detection in monocytic cell lines Thp1 and U937
Monocytic cell lines, Thp1  and U937 were used for optimization of methods. The 
pgal protein was efficiently expressed and detected in both of the monocyte like 
cell lines tested, Thp1  and U937 as shown in figure 5.6. Cells were infected at an 
MOI of 50 for 24 hours before being harvested, pulsed with FDG and analysed on 
the flow cytometer.
175U937
Uninfected cells 
Rad68 infected cells 
Rad35 infected cells
Figure 5.6: Expression of p-galactosidase protein in human myeloid cell lines.  Thp1 
and U937 cell lines were infected with Rad35 adenoviral construct (containing f$- 
galactosidase cDNA) at an MO  I of 50 for 24hours.  They were then subjected to the 
FDG assay to detect p-gal protein by flow cytometry. Where the FDG substrate is 
forced into the cells by osmotic pressure and cleaved to a fluorescent product.
5.3.3.2  Time course of protein expression
A time course experiment, measuring pgal protein expression after 24 48 and 72 
hours, was performed on the monocytic cell lines to find the time point with optimal 
protein expression. As shown in figure 5.7, after 24 hours expression in U937 cells, 
did not increase significantly. Therefore all assays were thereafter performed at 
this time.
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24 hr  Rad35infected 
48 hrRad35 infected 
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B-gal
Figure 5.7 Time course of pgal protein expression. U937 cells were infected with 
Rad35 adenoviral construct (containing p-galactosidase cDNA) at an MOI of 50 for 
24, 48 and 72 hours.  They were then subjected to the FDG assay to detect p-gal 
protein by flow cytometry. Where the FDG substrate is forced into the cells by 
osmotic pressure and cleaved to a fluorescent product.
5.3.3.3  Protein expression in DC
As shown in figure 5.8 pgal was efficiently expressed in DCs after infection with the 
Rad35 adenoviral construct. This experiment was repeated in 5 different donors, 
using monocyte derived immature DCs infected at an MOI of 50 on day 6 of 
generation in GMCSF and IL-4. Propidium Iodide (PI), which enters dead cells, but 
not live cells, if they have not been fixed, was also added to all DCs including 
immature and LPS stimulated cells to ensure the constructs were not having a 
cytopathic effect on the DCs. As can be seen in figure 5.8 there was no more death 
in Rad35 infected cells than non-infected. However it was observed that death was 
higher in cells that had undergone the FDG assay compared to standard flow 
cytometry methods at levels of 25% compared to 15% (data not shown).
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Figure 5.8: pgal protein expression in monocyte derived DCs and PI staining of 
dead cells, after infection with Rad35 (pink)adenoviral construct (containing /3- 
galactosidase cDNA) or Rad68(blue) (containing MV NP cDNA) at an MOI of 50 for 
24hours, immature (red) or LPS matured DCs (green).  They were then subjected 
to the FDG assay to detect (3-gal protein by flow cytometry.  Where the FDG 
substrate is forced into the cells by osmotic pressure and cleaved to a fluorescent 
product.
5.3.3.4  PFU titration in DC
A titration was done of Plaque forming units (PFU) of virus per DC (multiplicity of 
infection -MOI) using the Rad35 adenoviral construct. The result in figure 5.9 
shows that infection does titrate out, with pgal protein no longer detectable at a 
ratio of 1  PFU per DC.
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Figure 5.9: PFU titration in DCs. Monocyte derived DCs were infected with Rad35 
adenoviral construct (containing p-galactosidase cDNA) at an MOI of 100 (blue),
10 (pink),  1 (green) and 0.1(red) for 24 hours.  They were then subjected to the 
FDG assay to detect P-gal protein by flow cytometry.  Where the FDG substrate is 
forced into the cells by osmotic pressure and cleaved to a fluorescent product.
5.3.3.5  Visual verification of FDG staining using X-gal
To verify the results of (3-gal protein staining seen with the FDG substrate, Rad35 
infected DCs were also stained with 5-Bromo-4-Chloro-3-indolyl p-D- 
Galactopyronoside (X-gal) as outlined in section 2.7.2.3. Figure 5.10 shows DCs 
that have either been infected with Rad35 and contain p-galactosidase (5.10a) or 
DCs that have been infected with Rad68 and do not contain the p-galactosidase 
enzyme (5.10b) and then stained with X-gal. The DCs have then been pictured 
under a light microscope and as can be seen, there is blue staining in the cells that 
contained the enzyme, verifying the FDG staining data. Interestingly there appears 
to be some cells that stain heavily and are very blue but the majority of the other 
DCs also stain blue but to a lesser extent, compared with no staining at all in the
0.1 PFU Rad35 per cell 
1  PFU Rad35 per cell 
10 PFU Rad35 per cell 
100 PFU Rad 35 per cell
179DCs that were infected with Rad68. This result suggested a variable level of p-gal 
protein expression between individual cells. This verified the finding that at an MOI 
of 50, over 90% of the DC were infected with the constructs and efficiently express 
the transgene.
Figure 5.10: X-gal staining of p-gal protein in Rad35 infected DCs. Monocyte 
derived DCs were infected with Rad35 adenoviral construct (containing p- 
galactosidase cDNA) at an MOI of 50 for 24 hours, before being harvested and 
stained with X-gal for a further 24 hours before visualisation on a light microscope 
(x10x40) a) Population of Rad35 infected DCs stained with X-gal, b) Population of 
Rad68 infected cells stained with X-gal DC.
5.3.3.6  Tropism of virus to sub sets of PBMC
It has been suggested that due to varying levels of the coxsackie and adenovirus
receptor (CAR) on the surface of different cellular subsets that the virus may have
a tropism to one subset of PBMC over others. Since this study used PBMC which
had been infected with virus, as feeder cells to re-stimulate cell lines that had been
grown to adenovirus infected DCs, it was important to investigate the tropism of
these adenoviral constructs in this system. Figure 5.11 shows PBMC that were
infected at an MOI of 50 for 24hours with Rad35 then harvested and treated with
FDG to detect P-gal protein. The infected PBMC were stained for lineage markers
CD3, CD8 and CD4 (T cells), CD19 (B cells) and CD14 (monocytes). As shown in
180figure 5.11, all of the cell subsets stained equally well. This was also true at lower 
MOI where a smaller percent of each subset was infected but there was no tropism 
for one sub set over another (data not shown).
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Figure 5.11: Flow cytometry showing with FDG staining that the adenoviral vector 
has no tropism for a specific cell subset. Human PBMC were infected with Rad35 
adenoviral construct (containing p-galactosidase cDNA) at an MOI of 50 for 24 
hours.  The cells were then analysed using flow cytometry all cells were gated using 
a live cell gate and then for CD 14 (blue) analysis, a monocyte gate was used.  The 
other markers were analysed on cells from within the lymphocyte gate.  These 
gates are based of side and forward scatter properties of the PBMC.
5.3.4  Detection of measles NP protein after infection with adenoviral 
constructs
5.3.4.1  Polymerase chain reaction -PCR of the NP cDNA in Rad68 constructs
In order to ensure that the construct contained the correct cDNA, PCR (as outlined
in section 2.7.2.5) was performed using primers specific for the 5’ and 3’ ends of
181the NP cDNA and the adenovirus preparation was used as a template. The results 
of this PCR showed that the construct does contain the correct cDNA, the NP 
cDNA is a size of 1.5Kb and this is where the band is detected (figure 5.12). No 
band was detected in control reaction using Rad35 as the template.
KBp
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Lane 3 PCR 4pl Rad68 
Lane 4 PCR 4pl Rad35 
Lane 5 Rad68 - primers 
Lane 6 Reaction mix 
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Figure 5.12: Agarose gel electrophoresis of PCR products using primers for MVNP 
cDNA with adenoviral constructs Rad68 (containing NP cDNA) and Rad35 
(containing p-gal cDNA) as templates, run on a 1.5% agarose gel and stained with 
ethidium bromide.
5.3.4.2  Detection of MV NP protein in monocytic cell lines, Thp1 and U937
Once the construct was verified, several different antibodies (see table 2.3) were 
used to stain cells by flow cytometric analysis with intracellular staining, to detect 
the NP protein in cells infected with Rad68. Although successful in the monocytic 
cell lines (figure 5.13), this was not successful in the human DCs (figure 5.14) due 
to non-specific binding of the anti measles polyclonal serum used. Therefore other 
methods of MV NP protein detection were used, as outlined in section 5.3 4.3 
onwards.
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Figure 5.13 Staining of cell lines with anti measles rabbit serum.  U937(a)) and 
Thp1(b)) monocytic cell lines were infected with Rad35 (green), Rad68 (pink) 
containing MV NP cDNA or left uninfected (purple) for 24 hours.  The cells were 
then stained with anti MV rabbit serum or control rabbit serum (blue) at a dilution of 
1/100 and then a second layer antibody anti rabbit PE before being analysed by 
flow cytometry.
Cell lines Thp1 and U937 were infected with the Rad68 construct (containing MV 
NP full length cDNA) and then stained with anti measles rabbit serum (kindly 
provided by Dr Kenth Gustaffson, ICH, UCL) at a dilution of 1/100, 24 hours post 
infection. Figure 5.13 appears to show the detection of NP in cell lines infected with 
Rad68. However some non-specific binding was also demonstrated with the 
increased staining of Rad35 infected cells (green line). This experiment used 
polyclonal rabbit serum however this result could not be reproduced with the anti 
measles mouse and human sera, again due to non-specific binding despite efforts 
to block Fc binding sites (data not shown).
1835.3.4.3 Detection of MV NP protein in Rad68 infected DC
On dendritic cells non-specific binding of all anti measles sera tested was seen (for 
example anti measles rabbit serum shown figure 5.14). This made it technically
difficult to detect the NP protein by flow cytometric analysis.
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Figure 5.14: Staining of Rad68 infected DCs with anti MV serum.  Rad68 -MV NP 
construct (pink) and Rad35 -  P-gal construct (green) infected DCs were infected 
for 24 hours then stained with anti measles rabbit serum compared to control 
serum (filled histogram)and analysed using flow cytometry.
5.3.4.4  Western blotting to detect MV proteins
Using the more sensitive technique of western blotting, infected DC cell lysates 
were probed using all the sera available, each raised to either whole MV or NP 
protein. The 60KDa NP protein could be detected in Rad68 infected 293 cells 
compared to Rad35 infected 293 cells (figure 5.15a) However, as shown in figure 
5.15b), for human anti measles serum, despite low background, only the positive 
control could be detected on this gel. This positive control was a commercially 
obtained cell lysate from measles infected Vero cells.
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Figure 5.15 Western blots to detect MV NP using human polyclonal serum in a)293 
cells and b) human DCs.  The NP protein is 60KDa. Adenoviral construct infected 
cells were harvested 24 hours post infection, cell pellets were re-suspended in lysis 
buffer and used for western blot analysis. Positive control well contained MV 
infected Vero cell lysate treated in the same way. Blots were probed with anti MV 
human serum from an SSPE patient kindly provided by Prof John Stephenson.
185It appears that the proteins extracted from the DCs do not run through the gel 
efficiently as can be seen by the accumulation of staining remaining in the wells. 
This was a reproducible problem when trying to detect proteins in the DC lysates 
and was confirmed by coomassie blue staining of gels run in parallel from DC cell 
lysates (data not shown). As the NP protein was then detected by different 
confocal microscopy in DC (see section 5.3.4.5) this method of detection was no 
longer used so was not further optimized.
5.3.4.5  Confocal imaging of MV NP protein in adenoviral infected DC
Figure 5.16 shows DCs that were infected with Rad68 and after 24 hours, stained 
with anti measles serum a), and human serum isotype control b). Also DCs 
infected with Rad35 and stained with anti measles serum are shown in figure 
5.16c). The measles protein is stained green, the actin cytoskeleton in red and the 
nucleus in blue. Figure 5.16d) shows the morphology of a single DC. There 
appears to be more staining in figure 5.16a) than in the two control figures (5.16b) 
and c), although the number of cells showing strong staining is a small proportion 
of the cells and fewer that were seen with the pgal in the FDG assay. When 
manually counting each field 71% of the Rad68 infected cells were found to show 
green staining (indicating NP protein expression) where as only 13% of the cells 
infected with Rad35 are stained green. This is shown more clearly in figure 5.16e) 
and f) which are the pictures from 5.16 a) and c) without the other staining colours, 
therefore only showing staining for NP.
186Figure 5.15: Confocal images showing DC morphology and staining for measles 
NP (green) actin cytoskeleton (red) and nucleus (blue) in a) Rad68 and c) Rad35 
infected DC stained with anti measles human serum, b) Rad68 infected cells 
stained with control serum and d) high power image of one DC.  Confocal staining 
of e) Rad68 infected DCs and f) Rad35 infected DCs stained with anti measles 
human serum showing only the expression of the MV N protein in human DC 
without actin cytoskeleton and nucleus.
1875.3.5 T cell lines grown to autologous Rad infected DC
Once verification of the methodology had occurred and the gene products of 
cDNAs within the adenoviral constructs were detected in DCs, it was then possible 
to use these DCs to stimulate autologous T cells in order to culture T cell lines 
specific for the part of the MV protein which had been most dominantly processed 
and presented by the DCs.  Firstly, to establish whether T cells proliferated to DCs 
infected with adenoviral vectors containing measles proteins, DCs were prepared 
from 3 healthy MV immune volunteers and were infected on day 6 with Rad35, 
Rad68, Rad88 or Rad95 adenovirus vector, half of the cells were then matured 
with the cocktail of cytokines TNFa, IL-1p, IL-6 and prostaglandin E2  (Leen et al., 
2004a). The other half of the DCs were kept immature. Autologous PBMC were 
then stained with CFSE and co-cultured in a 10:1 ratio with the DCs for 6 days and 
analysed by flow cytometry. Figure 5.17 shows 1  representitive of 3 experiments.
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Figure 5.17: Percentage proliferation of non adherent AW88 autologous PBMC to 
adenovirus infected immature (blue bars) or mature (red bars) DCs either 
uninfected, containing p-gal protein (Rad35) or containing MV proteins NP 
(Rad68), H (Rad88) and F (Rad95). As measured by percentage of CD3+cells 
dividing as determined by CFSE staining as analysed using flow cytometry.
188T cells did not appear to proliferate well to the NP protein. However T cells did 
proliferate to F and H proteins when presented by mature DCs. Therefore 
autologous, matured DCs were used to stimulate MMR02 T cells from different 
time points post vaccination in order to grow out short term T cell lines. Prior to 
this, proliferation of MMR02 PBMC from pre (A) and 10 days post (C) MMR 
vaccination was tested to the different Rad infected DCs in the same way. All the 
DCs were matured for the experiment shown in figure 5.18. Figure 5.18 shows that 
proliferation increases post vaccination especially to MV F (Rad95) and H (Rad88) 
proteins. Interestingly, where the proliferative response does not increase either on 
maturation of the DCs (figure 5.17) or post vaccination (figure 5.18), for instance to 
Rad35 and Rad68 constructs, the proliferation to infected DCs is in fact less than 
the proliferation to uninfected DCs. This will be further discussed in chapter 6.
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Figure 5.18:  Proliferation of MMR02 PBMC from pre and post MMR vaccination to 
DCs infected with Rad containing MV proteins. Percentage proliferation of MMR02 
PBMC from pre (A) (red bars) or 10 days post (C)(blue bars)MMR vaccination, to 
mature DCs either uninfected, containing p-gal (Rad35) or containing MV proteins 
NP (Rad68), H (Rad88) and F (Rad95). As measured by percentage of CD3+cells 
divided after 6 days of culture by CFSE staining, analysed using flow cytometry.
1895.3.5.1  Re-stimulation of T cell lines grown to autologous Rad infected DCs 
with fresh autologous Rad infected DCs.
T cell lines from the vaccinated individual MMR02 were grown according to the 
protocol outlined in section 5.2.5.2. It was observed in preliminary experiments that 
prior to re-stimulation with fresh Rad infected autologous DCs for analysis of 
responses, T cell lines must be allowed to recover in IL-2 for 10 days to achieve 
maximum proliferation and cytokine production (data not shown). T cell lines were 
grown to Rad infected DCs from MMR02. The T cell lines grown were labelled 
according to the Rad construct they had been stimulated with and the time point 
that the responder PBMC were taken from post vaccination (see figure 4.1), e.g. 
Rad68B was a line grown to autologous DCs infected with Rad68 with PBMC 
taken from time point B. Figure 5.19 shows the number of cells producing IFNy as 
assayed by ELISpot in response to autologous PBMC, that were either infected 
with the same Rad that was used to grow the line- in this case Rad68, infected with 
the control construct, Rad35 or uninfected and used as antigen presenting cells. 
This showed specific IFNy production over background in the cell line MMR02, 
Rad68E, but little specific IFNy release in line Rad68B from the same individual. 
These experiments were only done on one of the vaccinated volunteers as MMR01 
was not available to give blood regularly enough to produce the DCs required to 
stimulate the PBMC to culture the T cell lines.
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Figure 5.19: Response of 2 T cell lines grown from MMR02 PBMC from time points 
B and E,  grown to DCs expressing the MV NP protein re-stimulated with 
autologous PBMC infected with Rad68 (red), Rad35 (blue) or uninfected (green). 
Number of cells in the cell line producing IFNy per 10,000 was assayed by a 
standard ELISpot stimulated by PBMC in a 1:1 ratio.  Values represent the mean 
and error bars, one standard deviation of triplicate wells.
Figures 5.20 and 5.21 show the results of re-stimulating the T cell lines from 
MMR02, grown to autologous DCs infected with Rad95 (figure 5.20) and Rad88 
(figure 5.21). As in figure 5.19 the lines were again re-stimulated with autologous 
PBMC that had themselves been infected with the relevant or irrelevant Rad or left 
uninfected. None of these lines shown appeared to have a specific response to the 
measles virus proteins since all responded to Rad35 infected control PBMC as 
much as to the PBMC infected with the specific adenoviral construct. This could be 
due to T cells being stimulated by adenoviral proteins also present in Rad35 and 
so T cells being specific for the adenoviral vector proteins rather than the specific 
MV protein. However where there were enough of the cell lines left after the initial 
analysis, they were re-stimulated with peptide pools relevant for the protein the line
was grown to as outlined in the next section.
191□ Rad95 
SI Rad35
□ Uninfected
Rad95B  Rad95C  Rad95E
Cell line
Figure 5.20: Response of 3 T cell lines grown from MMR02 PBMC from time points 
B, C  and E,  grown to DCs expressing the MV F protein re-stimulated with 
autologous PBMC infected with Rad95 (red), Rad35 (blue) or uninfected (green) in 
a 1:1 ratio. Number of cells in the cell line producing IFNy per 10,000 was assayed 
by a standard ELISpot and results expressed as mean and 1  SD of triplicate wells.
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Figure 5.21: Response of 3 T cell lines grown from MMR02 PBMC from time points 
B, C  and E,  grown to DCs expressing the MV H protein re-stimulated with 
autologous PBMC infected with Rad95 (red), Rad35 (blue) or uninfected (green) in 
a 1:1 ratio. Number of cells in the cell line producing IFNy per 10,000 was assayed 
by a standard ELISpot and results expressed as mean and 1  SD of triplicate wells.
1925.3.5.2 Re-stimulation of MMR02 T cell lines with MV peptide pools
In order to determine which peptides in the MV proteins were recognised by the T 
cell lines, ELISpot assays were carried out with the T cell lines from MMR02 
stimulated by the relevant peptide pools. Cells were plated at 40,000 cells per well 
and stimulated with peptides as described in chapter 3. Figure 5.22 shows the 
response of Rad35E (p-gal stimulated) and Rad95E (MV F stimulated) cell lines to 
MV F peptides. Although the background for the Rad95 line is high the pattern 
appearing is the same as for the normal volunteers, in that pools 8, 9, 10, 11 and 
12 are the more predominant pools. However these are not statistically significant.
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Figure 5.22: Response of 2 T cell lines grown from MMR02 PBMC from time point 
E, grown to DCs expressing the MV F protein (Rad95) (red) and the p-gal protein 
(Rad35) (blue) re-stimulated with the pools of peptides derived from the MV F 
protein. Number of cells in the cell line producing IFNy per 40,000 was assayed by 
a standard ELISpot and results expressed as mean and 1 SD of triplicate wells.
Figure 5.23 shows the responses of T cell lines grown to Rad68 infected DCs (MV
NP) or Rad35 infected DCs, grown from PBMC of MMR02 taken at time point C to
193MV NP peptide pools, as measured by ELISpot. However no single pool of 
peptides seems to induce a response which would indicate a dominant epitope in 
any one of the pools that is statistically significant, although the response to NP 
peptide pools 3 and 6 may warrant further investigation if this experiment was to be 
repeated. There were not enough of the cell lines grown to Rad88 infected DCs 
(MV H protein) to re-stimulate these with the MV H peptide pools, nor were there 
enough of the cell lines left to re-stimulate the cells with MV peptides that had been 
separated from the highlighted MV peptide pools.
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Figure 5.23: Response of 2 T cell lines grown from MMR02 PBMC from time point 
C, grown to DCs expressing the MV NP protein (Rad68) (red) and the p-gal protein 
(Rad35) (blue) re-stimulated with the pools of peptides derived from the MV NP 
protein. Number of cells in the cell line producing IFNy per 40,000 was assayed by 
a standard ELISpot and results expressed as mean and 1  SD of triplicate wells.
1945.4 Discussion
5.4.1 Alternative strategies for detecting epitopes
With the modified aim of identifying epitopes in adults and not quantifying the 
response in the first instance, alternative strategies to identify potential T cell 
epitopes were explored. The strategy identified, involved using dendritic cells as 
APC. However instead of pulsing these cells with MV peptides, they would be 
infected with antigen to more closely mirror the natural route of infection, and 
subsequent processing and presentation of antigen. These DCs could then be 
used as the stimulus to grow out short-term T cell lines to MV antigens presented 
on their surface. It was hypothesized that this might result in an amplification of the 
precursor antigen specific memory T cells. These specific T cell lines would then 
be put back into the ELISpot assay, and stimulated with pools of overlapping MV 
peptides as demonstrated by Goulder et al (Goulder et al., 2001). This strategy 
might allow detection of individual peptide sequences of importance. This was the 
strategy on which this part of the work was based.
5.4.1.1  Infection of DCs with MV
One strategy that had been previously discussed was that of using MV to infect 
monocyte derived DC cultures and use these to present antigen to T cells.
However as discussed in section 1.3.5 and 1.3.8, there have been several reports 
of cytopathic and negative regulatory effects of MV infection on DCs. These effects 
include; Fas mediated apoptosis of DCs (Servet-Delprat et al., 2000a), Syncytium 
formation post activation of DCs via CD40 ligation and decreased capacity to 
produce IL-12 (Fugier-Vivier et al., 1997) and modulation of signalling via CD40
(Servet-Delprat et al., 2000b). There has also been evidence that the expression of
195MV proteins F and H on the DC cell surface inhibit mitogen induced T cell 
proliferation by overcoming the positive co stimulation signals from the DC to the T 
cell (Klagge et al., 2000). Although it has also been reported that MV infection 
induced maturation and IL-12 production by immature DCs it was also observed 
that these DCs could not sustain proliferation of T cells to mitogen (Schnorr et al., 
1997). Thus although several mechanisms may be implicated, it is well 
documented that MV infection of DCs can substantially decrease the proliferative 
capacity of activated T cells, therefore it was necessary to investigate another 
route of MV protein delivery to antigen presenting cells.
5.4.1.2  Replication deficient adenoviruses (Rad)
Despite the reported lack of the most categorised of adenovirus receptors, the 
CAR on the human DC surface, at an MOI of 50, up to 90% of cells were efficiently 
infected with the adenoviral constructs as shown by staining with coloured 
substrates for the reporter gene p-galactosidase. The measles proteins themselves 
were harder to detect, as levels of protein in the cells were probably low and 
required the amplification of the signal such as that which occurred with the 
reporter gene substrates. This theory was further strengthened by the failure to 
detect the reporter gene with an anti P-galactosidase antibody in human DCs (data 
not shown). However after using several different techniques it was possible to 
demonstrate expression of the NP protein in human DCs via confocal microscopy. 
Once verification of infection was achieved, work shown in this chapter went on to 
optimise the culture of T cell lines from PBMC obtained before and after MMR 
vaccination, stimulated by DCs infected with adenovirus containing MV proteins.
Although some specific proliferation and production of IFNy by the cell lines that
196were grown to adenoviral infected DCs was observed, it remained difficult to 
observe a measles -specific response over the response to the control construct, in 
the individuals tested when cell lines were stimulated with peptide pools. The 
interesting observation was made that when compared to the control wells of 
PBMC stimulated with uninfected DCs, the PBMC stimulated with adenovirus 
infected DCs reproducibly proliferated less (see figures 5.17 and 5.18 and data not 
shown of observations made while optimizing the growth of T cell lines to 
adenovirus infected DCs), although the DCs containing MV proteins stimulated 
more proliferation than the DCs containing P-galactosidase. This was interesting 
and it was decided to investigate this phenomenon further. This is the basis of 
chapter 6.
197Chapter 6 Investigating the effect of adenovirus infection on DC 
function
6.1  Introduction
Following the observation made in chapter 5 that PBMC co-cultured with DCs 
which had been infected with adenovirus proliferated less than those co-cultured 
with uninfected DCs, it was decided that this phenomenon should be investigated 
further. Despite the wide use of adenoviral vectors in gene therapy and cancer 
immunotherapy protocols, as outlined in section 5.1.3, little is known of the 
functional consequences of adenoviral infection of human DCs.
6.1.1 The effect of adenoviral infection on cells
Previous studies have shown up-regulation of co stimulatory molecules such as 
CD80, CD86 and CD40 in response to adenoviral infection (Miller et al., 2002;Rea 
et al., 1999). These studies have also shown an increased capacity of infected 
DCs to produce IL-12 post CD40 ligation and therefore enhanced allo-stimulatory 
activity in a mixed lymphocyte reaction (Rea et al., 1999). Confirmation of these 
findings and further investigation of these phenomena in the mouse, was carried 
out by Morelli et al who showed that activation of DCs by adenoviral infection was 
via an NFkB dependent pathway (Morelli et al., 2000). In contrast other groups 
have reported no such up-regulation of co-stimulatory molecules on DCs infection 
with adenovirus (Tillman et al., 1999) and one group has reported a down 
regulation of MHC Class I on the infected DC surface post TNFa stimulation (Wold 
et al., 1999). These effects on DCs were therefore investigated in this adenovirus 
infection system. As no down regulation of co-stimulation or decrease in
198costimulatory cyokine prouction was reported by these groups, it was anticipated 
that  there would not be a problem as far as growing out T cell lines. In fact, if 
adenovirus infection did increase co-stimulation on the surface of the DCs in this 
system, it was predicted that adenovirus would improve the proliferation of T cells. 
However as described in chapter 5, T cell proliferation was reduced: this was 
therefore investigated, to characterize the effect of these adenoviral constructs on 
the phenotype and function of human DCs.
6.1.2  Adenovirus immune modulation
Previous work has shown that wild type adenovirus code for many genes that 
affect both acquired and innate immune responses (Horwitz, 2001). Most of these 
are within the E3 region of the viral genome which is deleted in the adenoviral 
constructs used for gene therapy (Horwitz, 2004), while others have been shown to 
be due to genes found in the E1 region (Wold et al., 1999). Both E1 and E3 regions 
are deleted in the constructs used in this study (Fooks et al., 1995). However 
recent findings have shown that despite the deletions in the E1 and E3 regions of 
the genome, adenoviral vectors can have a suppressive effect on the immune 
response in vitro when used to infect DCs (Tuettenberg et al., 2004).
Figure 6.1a) shows a schematic diagram of the adenoviral genome showing the 
different groups of genes. The E1  region is required for transcription of early genes 
which is deleted in the vectors used in this study. The deletions render the virus 
replication deficient, and it then requires the 293 packaging cell line for propagation 
since 293 cells are permanently transfected with the missing adenoviral genes
required for replication. The gene of interest is placed under the CMV promoter in
199place of deleted sections of genome (figure 6.1b)). There are however new 
generation vectors that are known as gutless vectors which have everything 
deleted except the inverted terminal repeats (ITR) and packaging sequences 
and these appear not to have the suppressive effect on DCs (Tuettenberg et al., 
2004).
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Figure 6.1:  a) Schematic diagram of the adenovirus genome.  The packaging 
sequence is a 400bp sequence upstream of the E1A region of the genome, b) 
Construction of the adenovirus recombinant genome containing the MV NP genetic 
sequence.  The NP sequence under the CMV promoter was inserted into the ad 
transfer vector pXCX2 to generate pMV68.  This provided the homologous Ad 
sequences to allow homologous recombination with the pJM17 plasmid to 
generate the recombinant viral genome of Rad68, the same principle applied for 
the generation of Rad35, 88 and 95.
2 0 06.1.3 DC maturation status and effect on resulting T cells
A large body of work has been generated recently relating to the role that the 
activation status and phenotype of DCs play in influencing the phenotype of T cells 
that have been co-cultured with those DCs. An interesting area of this research 
involves the induction of tolerance and generation of regulatory T cell subsets, 
when T cells are exposed to DCs in certain experimental situations.  Traditionally it 
has been believed that mature DCs induce a specific and appropriate immune 
response for the danger signals received and in contrast, immature DCs induce 
tolerance to self antigens. However emerging data is identifying DCs of many 
different subsets that can induce a population of T regulatory cells (Treg). 
Verhasselt and colleagues have shown that in the absence of foreign antigen it is 
LPS matured DCs rather than immature, monocyte derived DCs that induce FoxP3 
expressing CD4+ Treg cells in the responder population, which are specific for the 
donor antigens, since they do not suppress the proliferation of third party T cells 
(Verhasselt et al., 2004). A similar phenomenon has been observed in 
plasmacytoid DCs which when activated with CpG via TLR9 generate a similar 
population of CD4+CD25+ T reg cells which again express Fox P3 (Moseman et 
al., 2004). These data have implicated a role for mature DCs in the maintenance of 
peripheral tolerance during inflammatory and infection states. There is also 
evidence for CD8+ Treg generation in the gut by plasmacytoid DCs from the 
mesenteric lymph nodes (Bilsborough et al., 2003). In vivo studies in mice have 
shown that targeting of antigen to immature ‘natural’ DCs results in suppression of 
responses to that antigen on re challenge indicating another mechanism by which 
DCs can induce Treg in responder cells (Mahnke et al., 2003).
201Whether the suppression of responses seen in systems where DCs have been 
infected with adenovirus is due to the generation of de novo Treg remains unclear. 
However the potential for mature DCs to induce the production of Treg is clear. 
Whether this is a viral escape mechanism that subverts the natural function of DCs 
for immune evasion or a natural consequence of infection under certain conditions 
is a question that requires investigation.
6.2  Specific materials and methods
6.2.1  Luminex
Supernatants from either mock or Rad35 infected DCs were harvested 24 hours 
post infection and frozen immediately at -80°C until use. Supernatants from 
proliferation assays with either mock or adenovirus infected DCs were harvested 
after 5 days and stored in the same manner. Cytokine measurements in these 
supernatants were made using the Luminex multiple cytokine detection kit (Upstate 
Biotechnology) according to the manufacturer’s instructions. This assay is a bead 
based array based upon an ELISA principle, which can measure multiple ligands in 
one sample simultaneously (Khan et al., 2004)
6.2.2 Proliferation assays with DC
DC were generated as described in section 2.6.1.1. DC maturation was carried out 
using 100ngml"1  of PGE2, IL-6, TNFa (all from Sigma UK) and IL-13 (Peprotech 
UK) as this was thought to induce maturation of DC in a less organism polarised 
manner to that achieved with LPS (Leen et al., 2004a). Proliferation assays were 
cultured in RPM11640 supplemented with antibiotics (as described in section 2.3)
and 10% FCS (Invitrogen). DCs were either mock or adenoviral -infected and then
202matured before use in proliferation assays. Responder cells were either allogeneic 
non adherent PBMC, or autologous non adherent PBMC. In autologous 
proliferation assays, cells were stimulated with 5pgml'1  PHA. Responder cells were 
labelled (prior to addition of DCs) for 10mins at 37°C in serum free medium 
containing 1pM CFSE (Sigma) as described in section 2.5.5. Cells were cultured at 
a ratio of 10:1  PBMC: DC for 5 days at a final concentration of 106 cells per ml 
before harvesting (see section 6.2.6).
6.2.3 Transwell experiments
Transwell experiments were performed in 24 well trans-well plates pore size 0.4pm 
(Corning) with responder cells and stimulus (either PHA for autologous cells or 
mock infected DCs for allogeneic responses) in the lower well at a concentration of 
106 cells per ml and either infected or mock infected DCs in the upper insert at a 
concentration of 105  cells per ml.
6.2.4 Supernatant transfer
In supernatant transfer experiments, DCs were cultured for 24hours post infection 
with adenoviral constructs or mock virus preparation. Supernatants were harvested 
and added to autologous responder cells in place of culture medium at various 
dilutions as indicated.
6.2.5 Blocking antibodies and supplements
For blocking experiments either anti human TGF(3 (clone 1D11   R&D Systems) or 
anti human IL-10 (clone 23738 R&D Systems) antibodies were added to the culture
at a final concentration of lOpgml-1. Recombinant human IL-2 was added to the
203assay at dilutions from 10pg to lOOngml'1. Recombinant human IL-10 was added 
to the cultures at a concentration of 20ngml'1. The indoleamine 2, 3-dioxygenase 
(IDO) competitive inhibitor 1-methyl tryptophan was dissolved in DMSO and used 
at a final concentration of 250pM.
6.2.6 Cell analysis
After five days of culture cells were harvested and stained with anti-CD3-PE 
antibody (Becton Dickenson), washed three times, and fixed in 1  % formaldehyde in 
PBS (Sigma) as described in section 2.5.1.  Cells were run according to standard 
operating protocols on a Becton Dickenson FACScan (Becton Dickenson  UK) with 
CellQuest software. Live cells were gated on CD3 to analyse proliferation of T cells 
only and 150,000 events were collected per condition. Proliferation was measured 
as the percentage of cells that had undergone more that one division as compared 
to the negative control of un-stimulated CFSE labelled cells.
6.2.7 Analysis of cytokine production by DCs
DCs were mock or adenovirus infected at an MOI of 50 for 24 hours before LPS 
was added for 2 hours prior to adding Brefeldin A for a further 14 hours as 
previously described in section 2.5.3. These cells were then harvested and stained 
as described in section 2.5.3 before being analysed against the cell surface marker 
DC-SIGN , a protein expressed on the surface of myeloid DC (Engering et al., 
2002) for the cytokines TNFa, IL-6, IL-10 and IL-12.
2046.3 Results
6.3.1 Maturation of DCs in response to adenovirus construct
There are conflicting reports as to the effect adenovirus infection has on DCs, as 
outlined in section 6.1. To investigate the effect of the adenovirus used in this 
study, DCs from 5 different healthy donors were cultured in medium alone, 
stimulated with LPS or infected Rad35. After incubation for 16 hours at 37°C/5% 
CO2, phenotypic maturation was assessed using flow cytometric analysis of 
surface marker expression.
6.3.1.1 Surface expression on DC after infection with adenovirus constructs
Immature DC 
Rad35 Infected 
DC
LPS matured 
DC
CD40
CD83
Figure 6.2 Flow cytometric analysis of DCs infected by Rad35 adenoviral construct. 
Histograms to give examples of partial maturation induced by Rad35 construct 
infection in one representative donor, AW7 as shown by partial up regulation of 
CD40 and CD83. Each marker is shown for immature DCs (red) DCs matured in 
LPS (green) and those infected with Rad35 (blue).
There was no single cell surface protein that changed in a consistent manner in all
of the 6 donors. However there was a trend towards maturation with expression
205levels increasing moderately but less than the change in LPS matured DCs. This 
was the case for markers such as MHC Class II DR, CD83, CD86 and CD40. 
Figure 6.2 shows this effect in two different markers (CD83 and CD40) in one 
representative donor (AW7). In all experiments the maturational changes of DCs 
were very similar for both Rad35 (pgal) and Rad68 (NP) constructs.
In order to test whether DC maturational changes in phenotype seen on adenoviral 
infection could be due to traces of LPS in the viral preparation, an experiment was 
performed where the equivalent level of endotoxin as measured in the viral prep 
(25pgml~1 ) using the LAL assay (section 7.2.5) was incubated with DCs for 16 
hours. This small concentration of LPS did not have an effect on the phenotype of 
DCs therefore the partial up-regulation of markers on the surface of DCs infected 
with adenovirus constructs was not due to contaminating levels of LPS (data not 
shown).
Mock
infected DC
Adenovirus 
infected DC
Adenovirus 
infected DC
Mock
infected DC
MHC ll CD83 I
CD86f CD11c!
Figure 6.3 Histograms to compare the effect of adenoviral infection (Rad35) with 
mock infection on the phenotype of DCs from representative donor AW81. 
Histograms for markers CD83, CD11c,  MHC I and CD86 are shown for this donor.
206In order to establish if there were other contaminating agents within the virus 
preparation that may have an effect on the DC phenotype a mock preparation of 
virus was made. Figure 6.3 shows the results of this comparing DC surface 
expression of CD83, CD11c, MHC class I and CD86 on mock and adenovirus 
infected DCs in donor AW81. This donor has no change in CD83 and CD11c 
expression in response to adenovirus infection, however CD86 is up-regulated and 
in line with the findings of Wold et al MHC I is marginally down regulated (Wold et 
al., 1999).
6.3.1.2  Summary of different individuals
Table 6.1 shows a summary of the effect of adenovirus construct infection on 
maturation status defined by the expression of different markers in 5 different 
donors. The arrow represents the direction of the change in mean fluorescence 
intensity (MFI) of cells expressing the marker in the live DC gate.
Donor CD80 CD86 CD83 DC
SIGN
DR CD40 CD14
AW84 t t <-» I t <-» o
AW7 t t n o t t o
AW5 t t I o o I
AW27 o t t o t t <->
AW80 t t I <-> t o
Table 6.1 Summary of phenotypic changes in DCs post adenoviral infection in five 
donors as assessed by cell surface expression levels of markers assayed by flow 
cytometry; 24 hours post infection, f  represents increased expression in infected 
cells,  represents no change in expression and  4 represents decreased 
expression of marker in adenoviral infected cells.
2076.3.2  Cytokine production by DCs after infection with adenoviral constructs. 
Both cytokine production in response to adenoviral infection and cytokine 
production in response to LPS stimulation post adenoviral infection were compared 
in 5 donors. After stimulation with LPS alone, adenoviral construct infection or both, 
DCs were analysed for intracellular cytokine production by flow cytometry as 
described in section 6.2.7. The results of this are shown in figure 6.4.
Immature  LPS  Adenovirus  Adenovirus 
DC  stimulated DC  infected DC  infected DC +LPS
IL-6
IL-10
1.6
0.7
1.4
IL-12
TNFa
1.5
b 02
t  .  w   .
DC-SIGN
Figure 6.4:  Cytokine production by DCs in response to adenoviral infection. Flow 
cytometric analysis of cytokine production by (from left) immature DCs, LPS 
(100ngmr1) matured DCs, adenoviral infected (Rad35) DCs and both infected then 
matured DC (far right column)  compared to immature cells and cells matured with 
LPS.  The numbers in the upper right quadrants indicate the % of the live DC gate 
producing the cytokine indicated at the left of the figure.
208In all donors, there was no significant increase in IL-12, IL-10, TNFa or IL-6 
production in response to viral infection as shown in figure 6.4. In the donor 
represented in figure 6.4 the base line production is relatively high at 1.5% but this 
did not change on adenoviral infection with either Rad35 (figure 6.4) or Rad68 
(data not shown). In each plot events are shown after gating on live dendritic cells. 
Cells have been stained with an antibody to DC SIGN and the antibody to the 
relevant cytokine.
6.3.2.1  Effect of adenoviral infection on cytokine response to LPS
Although there was no effect on cytokine production by DCs after adenoviral 
infection when 100ngml'1  LPS was used, it was thought this may be too strong to 
allow demonstration of any small effects due to virus. Therefore an alternative 
concentration of LPS, lOngml1  was used and as shown in figure 6.5.
From these data on five donors there is a trend towards both IL-6 and TNFa 
production in response to LPS being reduced post adenoviral infection (see for 
example AW75 and AW84). Repeated experiments need to be carried out to test 
the statistical significance of this, as the study is too small to reach a significant p 
value with these data.
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Figure 6.5 Graphs showing a summary of data from cytometric analysis of cytokine 
production by adenovirus infected DCs showing the difference in TNFa (a) and IL-6 
(b) production on stimulation with LPS alone (10ng/ml), virus alone and response 
to LPS(10ng/ml) after adenoviral infection
2 1 06.3.2.2 IL-10 DC ELISpot
In order to verify the intracellular cytokine staining data for IL-10, an IL-10 ELISpot 
was carried out. This was because levels of IL-10 production were very low and 
hard to detect by intracellular cytokine staining. An ELISpot is a useful tool 
because it detects active cytokine secretion as opposed to intracellular staining 
which detects any cytokine inside the cell that may be being stored.  The levels of 
IL-10 from the ELISpot show that even un-stimulated DCs are producing IL-10, 
0.05% compared to 0.15% after stimulation with LPS. This is comparative to the 
numbers seen with intra cellular staining and using flow cytometric analysis. 
Intracellular staining shows 0.31% of DCs producing IL-10 before stimulation and 
0.55% after LPS stimulation in the same donor (AW81) as measured using the 
ELISpot (data not shown).
6.3.2.3 Measurement of cytokines by multiple cytokine assay (Luminex)
In order to measure a much larger range of cytokines without having to increase 
the number of DCs generated, the Luminex multiplex bead assay was used. DCs 
were generated as previously described and on day 6 were harvested and re­
plated into 24 well plates in 2ml medium. DCs were then infected with Rad35 or 
mock virus preparation. After 24 hours of incubation supernatants were harvested 
and stored at -80°C until use.
Table 6.2 shows the mean levels (+/- one standard deviation) for seven of the 
cytokines tested in 5 individuals from both adenovirus (Rad35) and mock infected 
DCs. IFNa, IL-5 , IL-12 and IL-13 were all below the level of detection this assay.
211Mean mock DC pg/ml +/- SD Mean adeno DC pg/ml +/- SD
IFNy 3.83 +/- 3.43 4.79 +/- 2.62
TNFa 1.37 +/-0.62 2.45 +/- 0.62
IL-1 p 0.39 +/- 0.29 0.79 +/- 0.71
IL-2 1.09 +/-0.84 6.86 +/-11.52
IL-4 426.19+/-350.35 512.18+/-515.46
IL-6 86.91 +/-101.64 76.44 +/- 110.43
IL-10 0.15+/-0.11 0.43 +/- 0.20
Table 6.2 Measurement of cytokine production by DC as measured in supernatants 
after either mock or adenovirus (Rad35) infection, measured by the multiple 
cytokine assay (Luminex). Mean of 5 individuals +/- 1SD
6.3.3  Functional consequences of adenoviral infection of DC 
As there did not appear to be a significant phenotypic difference between 
uninfected and adenoviral infected DCs, to address whether there were functional 
consequences to infecting DCs with adenovirus, the ability of adenovirus infected 
DCs to stimulate an allogeneic response was assessed. DCs prepared from one 
donor were infected with Rad35 or mock infected on day 6.  On day 7 the DCs 
were matured using a cocktail of cytokines containing TNFa, IL-1 p, IL-6 and PGE2. 
It had been previously shown that the phenotypic maturation of the DCs achieved 
with this cocktail of cytokines was equivalent to that with LPS (data not shown); 
however it was felt that maturation using cytokines would lead to an activation of 
the DCs less skewed towards one type of organism. On day 8 the DCs were 
harvested and added in a ratio of 1:10 with PBMC from a different donor, which 
had been labelled with CFSE. Cells were then incubated for 5 days and then 
harvested and stained with anti CD3, for proliferation of the T cells to be assessed. 
The effect of adenovirus infection on allogeneic responses is shown in figure 6.6. 
Figure 6.6 a) shows a representative experiment AW81 responder cells with AW89 
DCs and b) shows pooled data from 12 individual experiments with different donor
212pairs. A paired t test was carried out on these data showing statistical significance 
of p<0.0005 between proliferation induced by mock compared to adenoviral 
infected DCs.
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Figure 6.6: The effect of adenoviral infection on an allogeneic response. Flow 
cytometric analysis of CFSE labelled cells in an allogeneic proliferation assay, a) 
Representative CFSE plot (AW81 responder cells with AW89 DC 1 of 12 
independent experiments b) The differences between proliferation to mock and 
adenoviral infected DC are highly significant (p<0.0005).
2136.3.4 Active suppression of response to PHA
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Figure 6.7: The effect of adenoviral infection on the T cell response to the mitogen 
PHA. Flow cytometric analysis of CFSE labelled cells in a proliferation assay to 
PHA. a) Representative CFSE plot (AWQ1) of 12 independent experiments (b) The 
differences between proliferation to mock and adenoviral infected DCs are highly 
significant (p<0.0005).
As it had previously been shown that there was no increased death of DCs (see 
section 5.3.3.3), no significant down regulation of any co-stimulatory molecules (in 
fact the opposite) and no significant inhibition of ability to make cytokine on 
stimulation post adenoviral infection of DCs, it was decided to test the possibility
that the observed phenomenon was not in fact due to a DC defect but was due to
214an active suppression of proliferative responses by the adenoviral infected DCs.  In 
order to do this, DCs were generated as for the allogeneic experiment. However 
autologous responder cells were added instead of allogeneic cells. PHA was also 
added to the culture, this mitogenic lectin stimulates the T cells to proliferate but 
the effect would not be dependent on the additional DCs to allow the proliferation. 
Figure 6.7 shows that the adenovirus infected DCs actively suppress non specific 
proliferative T cell responses to PHA. Figure 6.7a) shows one representative donor 
(AW81). While in figure 6.7b), 12 independent experiments are summarised. Using 
a paired t test the data was analysed again reaching a significance value of 
p<0.0005, comparing proliferation to PHA in the presence of mock or adenoviral 
infected autologous DCs.
6.3.5  Adenoviral infection of monocytes can also suppress T cell responses. 
To investigate whether this phenomenon was restricted to DCs, or whether other 
cell types could mediate suppression, PBMC were allowed to adhere to plastic for 
two hours, non adherent cells were removed, then cells were infected with the 
adenovirus constructs. After 24 hours cells were harvested and co-cultured with T 
cells at a ratio of 10:1, as previously described for co-culture with DCs (section 
6.2.2). This fraction of cells (predominantly monocytes) was able to suppress the 
proliferation of autologous T cells to PHA as shown in figure 6.8. In addition by 
infecting one T cell population with adenovirus, and culturing this population with T 
allogeneic T cells in a traditional MLR, T cell proliferation was also suppressed in 
the responder T cell population (data not shown). Both these phenomena show 
that the ability to suppress proliferation of T cells upon adenoviral infection with 
these constructs is not confined to DCs.
215Mock infected monocytes  Adenovirus infected monocytes
Figure 6.8: Flow cytometric analysis of CFSE labelled T cells showing that 
adenovirus infected monocytes suppress T cell proliferation to PHA in one 
representative donor (AW81) out of 2 donors.
6.3.6  Suppression by adenovirus infected DCs is not reversed by addition of 
IL-2
Although no consistent change in IL-2 production was seen in the supernatants 
from infected DCs, (table 6.2), in certain individuals IL-2 was reduced in 
supernatants collected from adenovirally infected DCs compared to mock infected 
DCs (table 6.2). Using cells from such a donor (AW5), and given that some 
‘regulatory1  functions seen in in vitro assays may be overcome by addition of 
exogenous IL-2 (Takahashi et al., 1998), recombinant IL-2 was added to the 
culture of T cells and DC in the PHA assay, at a range of concentrations from 10pg 
to 100ng/ml, to investigate whether exogenous IL-2 would prevent the inhibitory 
effect of adenovirus- infected DCs. However the addition of h rlL-2 did not 
overcome the suppression (figure 6.9), even up to a concentration of 100ng/ml of 
exogenous IL-2.
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Figure 6.9: IL-2 has no effect at overcoming suppression. Flow cytometric analysis 
of proliferation of CFSE labelled cells incubated with either mock (left panel) or 
adenoviral (right panel) infected DCs with IL-2 titrated into the culture system 
between 10pg and 100ngmr1 , this has no effect on the suppression by adenovirus 
infected DCs (1 of 2 experiments shown from donor AW5).
It was then tested whether T cells would proliferate when infected with adenovirus 
themselves. The results of this for one representative donor (AW5) of three are 
shown in figure 6.10. This showed that small numbers of T cells do proliferate to 
adenovirus. However proliferation of infected T cells to PHA was considerably 
reduced when compared to mock infected T cells. These data in figure 6.10 show 
that the suppression of T cell proliferation that has been observed, may not be 
restricted to an infected population inhibiting proliferation of an uninfected 
population but that the suppression can also occur within a population of cells that
217have been infected. It is not likely that the uninfected cells in the population are 
being affected as infection of PBMC was typically 95% (see section 5.3.3). 
Therefore, not only can infected cells inhibit proliferation in other cells but they 
themselves are prevented from proliferating.
In order to ensure that the protein p-galactosidase which is expressed in Rad35, 
the construct used for these experiments was not responsible for the observed 
suppression, the same experiment as in section 6.3.4 was carried out using a 
lentiviral vector containing p-galactosidase kindly provided by Barry Flutter. DCs 
infected with this construct had no effect on the proliferation of T cells to PHA 
leading to the belief it is an adenovirus specific phenomenon (data not shown).
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Figure 6.10: Proliferative response of T cells to adenovirus infection. Flow 
cytometric analysis of CFSE labeled cells that have been infected with adenovirus 
and incubated for 5 days with or without PHA.  1% of T cells proliferate in response 
to being infected with adenovirus (bottom panels) yet proliferation of infected cells 
to PHA is impaired (top panels) (1 of 3 experiments shown).
2186.3.7  A soluble factor (or factors) is responsible for the suppression seen 
with adenoviral infected DCs.
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Figure 6.11: Summary of data from CFSE labeled cells in a proliferation assay after 
transwell culture. A soluble factor is responsible for the suppression of T cell 
proliferation.  Percentage proliferation with DC/T cell contact (red bars) and without 
contact (blue bars) when T cells were stimulated a) with PHA and b) in an 
allogeneic response. Data represent mean values from 5 donors, with error bars 
showing one standard deviation.
219To test whether this phenomenon was cell contact dependent or could be mediated 
by soluble factors, a transwell system was used, where the DCs (either infected or 
uninfected), were placed at the top of the transwell, with responder cells in the 
bottom chamber, either cultured with PHA (figure 6.11a) or with a population of 
uninfected DCs (figure 6.11b). This system was used to test whether contact was 
required to suppress the allogeneic response, as well as the response to PHA. The 
adenovirus infected- DCs were able to suppress both responses over a transwell. 
This was reproducible in 5 donors and reached a significance value of p<0.01 
(figure 6.11a) and p<0.025 (figure 6.11b), when comparing co-cultures of 
stimulated T cells and DCs that have been mock or adenoviral infected separated 
over a transwell.
6.3.8  Suppressive activity can be transferred by adenovirus infected DC 
supernatants.
Figure 6.12 confirms the results seen in section 6.3.7 by again showing that a 
soluble factor is responsible for the suppression by adenovirus infected DCs. In 
these experiments, DC supernatants were harvested 24 hour post infection or 
mock infection, and frozen at -80°C until use. Supernatants were then added to 
cultures of T cells with PHA at 50% this was repeated in 3 donors (figure 6.12) and 
suppression was observed in all cases when comparing proliferation of T cells in 
the presence of mock infected DC supernatant to those proliferating in the 
presence of adenovirus infected DC supernatant. Supernatants were then titrated 
into T cell/PHA cultures showing that the suppressive effect was concentration 
dependent (figure 6.13).
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Figure 6.12: Effect of addition of supernatant from mock infected DCs (red bar) or 
adenoviral infected DCs (blue bar) on T cell proliferation to PHA. Assayed by 
CFSE labeled cell proliferation analysed by flow cytometry. Bars represent mean 
values from 3 donors and error bars are one standard deviation.
a)
Figure 6.13 a) Effect of titrating supernatant from mock (red) or adenovirus (blue) 
infected DCs into the culture of T cells and PHA a) Graphical representation of the 
effect of mock and adenovirus infected DC supernatants on the proliferation of 
CFSE stained T cells to PHA in a five day culture as analysed by flow cytometry.
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Figure 6.13 b) Flow cytometry plots showing CFSE labeled T cells proliferating to 
PHA in the presence of increasing dilutions of supernatant from adenovirus 
infected DCs. Data are from one representative (AW88) of two donors tested.
6.3.9  5 and 10 day supernatants also suppress T cell responses
Contrary to the suggestion of others that the factor involved in suppression was
only active early in the infection process(Tuettenberg et al., 2004), supernatants
harvested from adenovirus infected DCs, after both 5 and 10 days suppressed T
cell proliferation to PHA as shown in figure 6.14.
Mock DC supernatant  Adenovirus DC supernatant
Figure 6.14:5 and 10 day supernatants also suppress proliferation.
Flow cytometry plots showing CFSE labeled T cells proliferating to PHA in the 
presence of 50% supernatant from adenovirus infected DCs after 5 and 10 days. 
Data are from one representative (AW89) of three donors.
2226.3.10  Blocking inhibitory cytokines IL-10 and TGF-p 
To address the question of whether an inhibitory cytokine was responsible for the 
suppression, blocking antibodies to IL-10 and TGF-p were used in the PHA 
proliferation assay, to look at the role that these cytokines may play in the 
suppression. IL-10 appeared to be involved in the suppression in one out of 4 
donors tested, as blocking partially restored proliferation to PHA (figure 6.15). 
Blocking TGF-p had no effect in any of the donors (figure 6.15 and data not 
shown).
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Figure 6.15 Blocking IL-10 reverses the suppression in one donor. Histogram plots 
of T cells stained with CFSE and stimulated with PHA co-cultured with mock and 
adenoviral infected DCs and blocking antibodies, showing restoration of 
proliferation in one donor by addition of an anti IL-10 blocking antibody to the T 
celUPHA culture. One individual donor of four tested that had this effect.
As an increase in IL-10 production was not detected in DCs post adenoviral 
infection (table 6.2), cytokine production in the proliferation assay was measured in 
2 individuals. Supernatants from PHA proliferation assays were harvested after 5 
days and analysed using the multiplex bead assay (Luminex). An increase in IL-10
223production in the cultures with adenovirus infected DCs was seen when compared 
to mock infected DC cultures (table 6.3). IL-10 also increased and levels of IL-5 
and IL-13 were reduced (table 6.3). However further experiments of this type will 
need to be performed to increase the power of these observations, and determine 
their significance.
PHA Mean pg/ml +/- 
SD
PHA + ad DC Mean pg/ml +/- 
SD
PHA + Mock DC Mean pg/ml +/- 
SD
IFNy 479.61 +/- 550.62 11980.23+/-3087.67 12943.57 +/- 18304.94
TNFa 20.57 +/- 17.25 755.34 +/- 76.51 1019.62+/- 533.81
IL-1P 1.19+/-0.24 312.27+/-15.32 51.69+/-15.1
IL-4 3.70 +/- 5.23 130.47 +/- 180.42 42.34 +/-12.79
IL-5 47.53 +/- 65.07 228.53 +/- 87.72 790.22 +/- 240.9
IL-6 196.83 +/- 169.27 1577.27 +/-2230.59 912.17 +/- 1290
IL-10 20.59 +/- 27.9 305.11 +/-50.02 193.55+/- 14.86
IL-12 0.00 +/- 0 41.20+/-8.05 55.18+/-67.25
IL-13 136.46 +/- 184.58 675.46 +/- 368.57 2032.11 +/-249.13
Table 6.3: Luminex measurements of mean cytokine levels (+/- one standard 
deviation) from 2 donors in supernatants from T cells cultured with PHA,  PHA and 
mock infected DCs and PHA and adenovirus infected DCs
6.3.11  Addition of IL-10 and inhibition of IDO
Recently the work of Tan and colleagues has implicated a role for indoleamine 2,3- 
dioxygenase (IDO) in the reduced response of T cells in  MLR with adenovirus 
infected DCs. Therefore the role of IDO in this system was investigated, by adding 
the IDO competitive inhibitor 1-methyl tryptophan as described in section 6.2.5. 
However in the 3 individuals tested, one of which is shown in figure 6.16 IDO did 
not appear to play a role in this system. Figure 6.16 also shows that adding back 
IL-10 at a concentration of 20ngml'1  has no effect on the proliferation of cells and 
does not cause a suppression of proliferation when added alone, indicating there 
must be another mediator or pathway involved in mediating the suppression.
These experiments are preliminary and must be extended to larger numbers of
224samples in order to gain a true representation of what mechanism the T cells are 
suppressed by including investigating the phenotype and function of the T cells 
generated through co-culture with infected DCs.
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Figure 6.16: Effect of IDO inhibition on suppressive effect of adenoviral infected 
DCs.  The IDO competitive inhibitor 1-methyl tryptophan or recombinant human IL- 
10 was added to T cells labelled with CFSE and cultured with PHA and either mock 
or adenovirus infected autologous DCs. Analysed by flow cytometry (1 (AW89) of 3 
individuals tested).
6.4 Discussion
The data presented here show that adenoviral infection of DCs using the 
constructs containing either MV-NP (Rad68) or p-galactosidase (Rad35) induced a 
small degree of maturation in DCs as measured by up regulation of surface co 
stimulatory markers, such as CD83 and CD40. This study also found no significant 
change in cytokine production by adenoviral infected DCs either with MV NP 
protein construct or (3gal protein construct, once stimulated with LPS. These 
findings are in agreement with studies that have also shown up regulation of co
225stimulatory molecules such as CD80, CD86 and CD40 in response to adenoviral 
infection (Miller et al., 2002;Morelli et al., 2000;Rea et al., 1999).
This study contributes novel information to our current knowledge of how viruses, 
and specifically adenoviral constructs, may affect dendritic cell function. These 
results show that in human monocyte-derived immature DC (iDC), infection with 
Ad5 E1 and E3-deleted adenovirus leads to a reduced capacity of the DCs to 
stimulate T cells, whether these are stimulated in an allogeneic manner (figure 6.6) 
or by the mitogen PHA (figure 6.7). In the PHA-driven response, additional DCs are 
not required for responder cells to proliferate: therefore reduction of proliferation 
seen on the addition of adenovirus-infected DCs cannot be due to a DC defect, but 
instead suggest an active inhibition, mediated by the infected DCs. These results 
are compatible with previous reports of reduced alio- stimulatory capacity of 
adenoviral infected DCs in humans (Jonuleit et al., 2000;Tan et al., 
2005;Tuettenberg et al., 2004). However both these studies, and the data 
presented here conflict with earlier evidence, which suggested an enhanced 
capacity to stimulate T cells by DCs infected with adenovirus, an effect attributed in 
part to increased expression of co stimulatory molecules CD80, 86 and 40 (Rea et 
al., 1999;Zhong et al., 1999). These results are the first to demonstrate formally 
that the suppressive effect of some adenoviral constructs is a dominant inhibition, 
since it is seen in both an allogeneic stimulation assay and also in the response to 
the mitogen PHA. In this system, the inhibitory effect was very powerful, as it was 
clearly demonstrable at ratios of T: DC as low as 50:1  (data not shown). Most 
previous studies of a parallel type have used cells at a T: DC ratio of 10:1. In
addition to this the results show that the suppression can be mediated by cell types
226other that DCs such as monocytes, although suppression using monocytes at an 
equivalent ratio was less powerful.
In line with previous reports of increased expression of CD80, 86 or other cell 
surface molecules after adenovirus infection of iDCs (Rea et al., 1999;Tan et al., 
2005;Zhong et al., 1999), the data presented here shows small changes in the 
phenotype of DCs upon infection by adenovirus, including small increases in 
expression of CD80 CD86, CD83, CD40 and HLA-DR in some individuals, 
indicating a trend towards maturation upon adenoviral infection. In addition to 
investigating the phenotype of DCs after infection by adenoviral constructs these 
cells were analysed for cytokine production. There was no production of IL-12, IL- 
6, IL-10, TNFa, or IFNy from infected DCs when cultured alone. In addition, 
infected DCs were able to mount a strong response to the TLR4- signal by addition 
of LPS, as analysed by intracellular cytokine staining (figure 6.4). Multiplex 
cytokine measurements on supernatants collected from a total of 5 individuals 
confirmed these results. Some earlier reports also suggested no change in 
cytokine production by DCs infected with adenovirus (Rea et al., 2004) but a more 
recent study has suggested up-regulation of many type-1 and pro-inflammatory 
cytokines in this system (Tan et al., 2005). Data from work in mice are also 
conflicting with some reports suggesting IL-12 production post adenoviral infection 
(Miller et al., 2002). However others show production of IL-6, IL-15, IFNy and TNFa 
in response to adenovirus infection but without IL-12 and IL-10 production (Morelli 
et al., 2000;Philpott et al., 2004).
227Small but critical differences in reagents or protocols may account for these 
discrepant results, such as the exact gene content of the adenoviral constructs, or 
the timing of infection and agents to induce DC maturation. Thus, for example, the 
fact that ‘gutless’ vectors confer less change on DC phenotype, and also that 
active adenoviral protein synthesis is required to see changes in DC expression 
following infection, implicating specific adenoviral products in these effects 
(Tuettenberg et al., 2004).
With respect to the mechanism of inhibition conferred by adenoviral infected DCs 
in this study, the results demonstrate that suppression of T cell proliferation with 
these constructs is largely mediated by soluble factors. Thus supernatant from the 
infected DCs transferred inhibition, and when DCs and T cells were separated by a 
transwell which prevented cell contact, inhibition was still seen in both assays 
(figure 6.11). In contrast, previous studies have suggested that the inhibition 
mediated by adenoviral infected DCs requires cell-cell contact (Jonuleit et al.,
2000). The production of IL-10 by DCs after viral infection has been described for 
several other viruses, in particular measles, (Servet-Delprat et al., 2000b) 
influenza, (Oh and Eichelberger, 2000) and RSV (Bartz et al., 2002). Therefore it 
was considered that adenovirus infection with these constructs may also alter 
cytokine production by DCs and thereby have an inhibitory effect on T cell 
stimulation.
Although no clear candidate cytokine was identified in the supernatants from 
infected DCs, two possible soluble factors which may be mediating the inhibition
seen in this study were investigated. This showed that at least in one individual,
228blocking of IL-10 (but not TGF|3) partially reversed the inhibitory effect of 
adenovirus infected DCs, on the T cell response to PHA.  However intracellular 
cytokine staining of DCs and cytokine assays of supernatants from adenovirus- 
infected DCs failed to detect the production of IL-10 by infected DCs. The finding 
that blocking IL-10 reversed the suppression in some donors, yet it could not be 
detected in adenovirus-infected DCs indicates that IL-10 may not be the 
predominant or sole DC- derived soluble factor responsible for the suppression. It 
does however implicate IL-10 as a possible effecter molecule in one of several 
possible pathways that may be induced by these constructs. This also raises the 
possibility that as the IL-10 is produced not by the DCs in this system, but by T 
cells within the responding population. One mechanism for this effect may be the 
induction of IL-10 production in a population of the T cells, perhaps of a Tr-1  like 
phenotype (Levings et al., 2005;Roncarolo et al., 2001;Wakkach et al., 2003).
Recent work by Tan and colleagues has implicated a role for indoleamine 2,3- 
dioxygenase (IDO) in the reduced response of T cells in  MLR with adenovirus 
infected DCs. Therefore the role of IDO in this system was investigated. IDO is an 
enzyme that degrades the essential amino acid tryptophan. Tan et al found that 
adenovirus infected DC inhibited T cell proliferation in an MLR and that blocking 
the activity of IDO restored proliferation (Tan et al., 2005). One mechanism of IDO 
action is to inhibit T cell proliferation by depriving them of tryptophan. Cells have 
been shown to undergo cell cycle arrest when deprived of tryptophan (Lee et al., 
2002;Munn et al., 1999) which would relate well to the work of Tuettenberg et al 
who show T cells arrest in G1 phase after being exposed to Adenovirus infected
DC (Tuettenberg et al., 2004). Although IDO production by DCs could explain the
229suppression observed in this study, IDO is an intracellular protein and no secreted 
form has been described. Thus the effects seen here may have identified a down 
stream effecter of IDO that is soluble and can be released into the micro 
environment. This could be due to pathways activated by IDO or it could be the 
direct action of tryptophan metabolites such as kynureine which has been shown to 
have effects on T cell viability (Grohmann et al., 2003). Tan et al have speculated 
that the production of IDO causing suppression of T cell proliferation could be the 
immune systems way of balancing and restricting the response to adenovirus (Tan 
et al., 2005). However Tuettenberg et al have shown that it is not merely the 
infection process that causes the suppression. With the use of “gutless” vectors 
and inhibitors of protein synthesis it has been shown that a viral product could be 
responsible and could be another mechanism by which adenovirus can subvert the 
immune system (Tuettenberg et al., 2004). This may be a more general 
phenomenon since evidence is emerging that show Herpes Simplex virus infection 
of DCs having a similar inhibitory effect on T cells in an MLR (Pollara et al., 2003). 
Despite extensive work in the area and the knowledge that IDO is produced by 
stimulated DCs and can inhibit T cell proliferation (Hwu et al., 2000) it is not yet 
clear whether IDO produced by DCs can stimulate the production of Treg in the 
responding T cell population. It is known that although IDO is constitutively 
expressed in DCs, T reg expressing the CD80/86 ligand CTLA4 are required to 
stimulate the DCs to express functionally active IDO (Munn et al., 2004). This may 
be a mechanism by which Treg function. However it is unclear whether this is part 
of a positive feed back loop that reinforces the inhibition of the T cell response by 
producing T reg. Interestingly IL-10 has been shown to enhance the production of
IDO overcoming the down regulatory effect pro inflammatory cytokines such as
230IFNy have on IDO production by DCs (Munn et al., 2002). While IDO production by 
DCs may be involved in the suppression in this system, it is an intracellular protein 
and no secreted form has been described to date. Further work is in progress to 
investigate the role of this pathway in our system.
In conclusion, the results presented in this chapter show that in this system the 
infection of iDC with these adenovirus constructs leads to a population of DCs that 
are powerfully inhibitory to T cells, and that this is a dominant effect, mediated by 
soluble factors. The effect is independent of the cDNA inserted (either MV-NP or p- 
galactosidase genes). The results show that one of the molecules in mediating this 
effect may be IL-10, at least in some individuals, although they also suggest that 
the source of this IL-10 is not the virally infected DCs themselves, but perhaps a 
population of regulatory T cells which have been generated de novo in vitro. Work 
is now in progress to identify both this ‘secondary regulator1  population as well as 
the soluble factors which mediate this powerful inhibition. In conclusion caution 
should perhaps be used in consideration of vectors for the delivery of gene therapy 
since it is increasingly clear that small differences in constructs may lead to large 
differences in effects on the immune system.
231Chapter 7 Meningitis B vaccine study
7.1 Introduction
7.1.1 N. Meningitidis Background
Neisseria Meningitidis is an intra cellular gram negative diplococcus capsulated 
bacterium (figure 7.1).
Figure 7.1 N. Meningitidis B coloured electron micrograph picture 
It is usually a commensal organism of the nasopharynx (Tzeng and Stephens, 
2000). However N. Meningitidis is also a major cause of bacterial meningitis and 
sepsis posing a serious threat to global health and as such contributes to a global 
annual death rate of 171,000 (WHO, 2002). Despite advanced treatment in 
industrialised countries case fatality rates are still 5-10% being even higher in the 
developing world, also leaving 10-12% of survivors with permanent symptoms such 
as epilepsy and mental retardation (Jodar et al., 2002). There are still epidemics
232that are caused by specific serogroups that circulate in regions of the developed 
world. There is a current epidemic that is affecting New Zealand. Rates of case 
numbers have risen from 1.5 per 100,000 of population in 1990 to 17.4 in 2001. 
This epidemic is driven by one strain suggesting that it may be controlled by a 
strain specific OMV vaccine, a strategy which is currently being implemented by 
the public health association in New Zealand (Dyet et al., 2005).
7.1.2 Serogroups of meningitis
N. Meningitidis isolates can be divided into 12 groups based on antigenically 
distinct polysaccharide capsules. Five of these are the pathogenic serogroups A,
B, C, Y and W135 (Branham, 1953). In Europe 50-90% of cases are caused by 
group B and the remainder by group C, where as A predominates in the so-called 
“meningitis belt” in sub Saharan Africa. The incidence of group B disease is highest 
in children under one year of age. In contrast C often causes outbreaks in 
teenagers, army recruits and young adults (Jodar et al., 2002).
7.1.3 Vaccines against N meningitides
In recent times significant efforts have been made to produce effective vaccines 
against N. Meningitidis. Polysaccharide capsules of most serogroups are important 
determinants of virulence and their purified capsules form the basis of successful 
vaccines against serogroups A, C, W and Y therefore are important vaccine 
candidates. They form the basis of polysaccharide vaccines against N. Meningitidis 
strains and other potentially invasive bacteria.
233The first successful capsular polysaccharide vaccine against strains A and C was 
developed over 30 years ago in the USA in response to epidemics among new 
military recruits. Although a temporary solution to the spread of the disease, these 
vaccines did not lead to immunological memory and were not effective in young 
children (Jodar et al., 2002).
Much more recently following the success of the Haemophilus influenzae type b 
(Hib) and pneumococcal conjugate vaccines, immunogenicity of the meningitis 
capsular vaccines was improved via conjugation of the polysaccharides to a 
protein carrier, thus inducing a T cell dependent antibody response. This vaccine is 
also immunogenic in infants and induces long term protection, with the added 
advantage of reducing carriage and therefore transmission (Goldblatt, 1998) thus 
increasing herd immunity. The meningitis C conjugate vaccine has been introduced 
into the UK vaccination schedule and was used in a catch up campaign for 
everyone in the UK under the age of 18, starting in 1999.
Multivalent conjugate vaccines are now in licensed for A, C, Y and W135 
serogroups. However, an effective vaccine against group B is proving to be more 
of a challenge because the serogroup B capsule has homology with the human 
neural cell adhesion molecule (NCAM) and therefore is not immunogenic in 
humans.
7.1.4  Correlates of protection
Traditionally protective immunity against bacterial pathogens has been measured
by serum bactericidal activity (SBA) titres, which is considered to be the best
234correlate of protection. Serum bactericidal activity is measured either using human 
or baby rabbit complement. To perform the SBA assay, serial dilutions of human 
sera are incubated with complement and the target strains of the bacterium. The 
specific antibodies bind to the meningococcus and the complement component 
C1q binds to the Fc portion of the Ig. This then activates the classical pathway of 
complement (as described in chapter 1) which results in the death of the target cell. 
The number of bacterium present before incubation with serum and complement is 
compared with the number present after and SBA titres expressed as the serum 
dilution at which 50% killing of the bacterium occurred (Borrow et al., 2005).
The original gold standard of protection was established by Goldschneider et al in 
1969 (Goldschneider et al., 1969b). They bled army recruits at the beginning of 
their training and determined the SBA titre for serogroup C with human 
complement. The recruits were followed and monitored for the development of 
meningococcal disease. Out of the 54 prospective meningococcal cases only 3 
had SBA titres of >4 compared with 444 of 540 individuals who did not develop 
disease (5.5% compared with 82.2%). It was also found that as the percentage of 
children with an SBA titre of £4 declined from birth due to the waning of maternal 
antibodies the incidence of MenC disease increased peaking at 1-2years 
(Goldschneider et al., 1969a). Thus an SBA titre using human complement of >4 
was considered to be protective. Later it was recommended by the World Health 
Organisation (WHO) that in order to further standardise this assay between 
laboratories baby rabbit complement should be used in a SBA assay for evaluation 
of meningococcal polysaccharide vaccines. As baby rabbit complement rendered
meningococcus more susceptible to lysis than human complement, the assay had
235to be re-evaluated this resulted in a SBA titre of >8 being considered as protective 
when using baby rabbit complement (Borrow et al., 2005).
These standards applied well to assessing protection against Meningococcus C 
infection, however it appeared meningococcus B was harder to evaluate. It 
appeared that there was a wider variation of SBA titres between laboratories and it 
may be more appropriate to use a four fold (2 dilutions) rise in SBA titre as an 
indication that an individual has responded to a meningococcus B vaccine (Borrow 
et al., 2005;Vermont and van den, 2002). This was validated by Martin et al (Martin 
et al., 2005) who investigated the antibody response associated with a 
meningococcus B vaccine trial. They used human complement for this assay that 
was batch tested to meet certain parameters such as less than 15% kill at 25% 
concentration. The findings of this investigation were that there was wide variability 
in the assays at the lowest dilution factors and therefore the lower limit of SBA titre 
measurable was >2. This meant that protection was defined as >8 (a 4 fold 
increase in titre) for individuals with a pre vaccination titre of £2 or >16 if the pre 
vaccination level was >4 etc. However other correlates of protection should be 
investigated in the absence of SBA increase as otherwise response to a vaccine 
could be under estimated in the population (Vermont and van den, 2002).
7.1.5  Interaction with the immune system
N.  Meningitidis is constantly circulating within the population, carried in the 
nasopharynx of colonised individuals, however disease, caused by the organism 
crossing the mucosa and entering the bloodstream, is relatively rare this suggests
that there is a substantial amount of natural mucosal immunity to the organism.
236The factors involved in the pathogenesis of this bacterium in certain individuals are 
at this time still unclear.
Protection is strongly correlated with antibody production, however in order for 
class switching and affinity maturation to occur, T helper cells must be involved in 
the immune response. Recent work by the Heyderman group (Davenport et al., 
2003) has investigated meningococcus specific T cells in tonsils of human patients. 
They have found that there are specific T cells in the mucosa which were more 
abundant, giving stronger proliferative responses to serogroup B derived OMV, the 
older the individual. They also found that these T cell responses correlated well 
with anti meningococcus IgG levels but not with bactericidal activity (section 7.1.4). 
Interestingly more recent unpublished data from this group would suggest that 
although specific T cells are present in the mucosa, they are hard to detect in the 
peripheral blood. In contrast, a different group has shown a there is a correlation 
between SBA titres and T cell proliferation however this was to the PorA protein 
but not whole OMV after vaccination with an OMV based vaccine (Oftung et al., 
1999)
There is also an emerging body of work on the effect of meningococcus outer 
membrane proteins on the phenotype and function of human dendritic cells. Much 
work has been done on the effect of LPS on DCs (Dixon et al., 2001;Sprong et al.,
2001)  which has a wide range of immunomodulatory effects, and can contribute to 
adverse reactions to vaccines (Geier and Geier, 2002) however it has been shown 
that outer membrane proteins can also have an effect. Al-Bader et al (Al Bader et
al., 2003;AI Bader et al., 2004) firstly showed that exposure to OMV with or without
237LPS differentially up-regulated expression of TLR4 and TLR2 on DCs and went on 
to show that the PorA protein was responsible for this. Singleton et al showed that 
PorA acted via a TLR-2, MyD88 dependent mechanism (Singleton et al., 2005). 
The fact that single proteins from the outer membrane of N. Meningitidis can 
activate the immune system is an important observation. As current vaccine 
development and immunogenicity studies use OMVs derived from the organism 
which contain all the outer membrane proteins from the surface of the bacterium. 
This could be a positive effect of vaccinating with OMV, whereby the immune 
system is activated in an appropriate way by activation through ligation of TLR 
molecules.
7.1.6  Vaccine strategies for serogroup B
The polysaccharide capsule of N. Meningitidis serogroup B is a homopolymer of 
sialic acid a2-8 N-acetylneuraminic acid. This molecule is structurally and 
antigenically identical to polysialosyl glycopeptides of the human neural cell 
adhesion molecule (NCAM), which is expressed in human neural and extra neural 
tissues (Finne et al., 1983).
This fact makes vaccine development using the group B capsule difficult for two 
reasons; firstly, the capsule is poorly immunogenic as reactive T and B cells to this 
molecule would have been deleted during development and the molecule tolerated. 
Secondly while trying to increase the response to this molecule, there is a risk of 
raising an immune response against a self-protein which could result in some form 
of autoimmunity. Thus, alternative vaccine targets for meningitis B are being 
investigated.
238Animal models have been used to investigate the effect of potential vaccine targets 
on the immune response to N. meningitides. As the only natural host for the 
organism is humans, it is difficult to develop a good animal model. The two main 
models that are currently used are intraperitoneal infection of adult mice or infant 
rats. However in order for the animals to develop lethal bacteraemic infection the 
injection must also include an exogenous iron source such as human transferrin. 
These models can be used to investigate either direct immunization of the animal 
using different vaccine candidates and protocols or passive protection provided by 
human serum from vaccinated or naturally immune individuals. More recent 
models have used humanized mice that are transgenic for human CD46. These 
mice do not require an exogenous iron source to be infected and the bacterium can 
cross the blood brain barrier in these mice but not in wild type mice. This new 
model would appear to be better that the previous two however as there is only 
15% mortality post infection it may be hard to evaluate any vaccine candidates and 
so perhaps other innate immune mechanisms could be knocked out in these mice 
to make  them more susceptible to meningococcus challenge (Gorringe et al., 
2005).
Models such as these have been used to investigate such parameters as 
verification of OMV vaccination in mice (Quakyi et al., 1999) and to show that 3 
doses were required for an increase in IgG avidity while 4 doses induced a larger 
range of ab specificities. Although the group of mice given the 4th  dose when 
boosted 7 months after the primary dose series, had a reduction in SBA titre but
not IgG recall responses, compared to mice given only 2 or 3 does in the primary
239series. It was thought that this could be due to the generation of blocking IgG that 
could block bactericidal killing, although this has not been observed in human 
studies (Gioia et al., 2005). Studies in mice have shown that intra nasal 
immunization can induce the same levels of spleen cell proliferation and antibody 
levels as subcutaneous injection with no evidence of tolerance to these antigens at 
the mucosal surface, this being very encouraging for future vaccine strategies 
(Bakke et al., 2001). Animal models have also been used to identify new antigenic 
targets by vaccinating with individual proteins two of which, a lactate permease 
(LctP) and an iron acquisition protein (ExbB) elicited protective immunity in mice 
(Sun et al., 2005). Two separate groups have also shown that the NadA protein 
which is present in the outer membrane of N. meningitidis B, both elicits 
bactericidal antibodies and is protective in an infant rat model (Comanducci et al.,
2002). It also induced SBA and specific T cells in mice following intra nasal 
vaccination however protective immunity from re-challenge was not proven (Bowe 
et al., 2004).
Immune responses to specific proteins of meningococcus have also been 
investigated in humans. Jose et al (Jose et al., 2000) identified predicted peptides 
from the IgA protease from pathogenic meningococci. 16 out of 20 donors reacted 
to one of the peptides and T cell lines were grown out that were CD3+CD4+ and 
were Th1 biased. T cells responses have also been analysed to the class 5 outer 
membrane proteins OpaB, Opa5d and Opc. This was done using overlapping 
peptides to the individual proteins to stimulate PBMC and observe proliferation. It 
was found that the Opa proteins stimulated more proliferation in a larger number of
donors and that many of the responses were to the non hypervariable region of the
240protein, although no specific dominant epitopes were identified (Wiertz et al.,
1996). In a further attempt to identify meningococcal T cell epitopes, a different 
strategy was used by Meiring et al (Meiring et al., 2005) where an isotope tagged 
porin A antigen was added to human DCs then purified and analysed as to the 
sequence of the potential MHC class II epitopes. This method identified several 
immunodominant regions of the porin A protein that may be important in future sub 
unit vaccine production.
One of the other alternative strategies for vaccine development utilises the natural 
blebbing action of the bacterium. Blebbing results in outer membrane vesicles 
(OMV), which are particles of bacterial membrane and therefore contain all the 
potential targets that would be on the surface of the bacterium itself. Importantly 
these are in their natural conformation. The OMV also contain LPS and are treated 
with detergents to remove as much of this as possible due to the extreme pro 
inflammatory effects that LPS can have on the immune system (Martin et al.,
2005,-Sprang et al., 2001). As carriage of the commensal bacterium N. Lactamica 
has been implicated in cross protection to N.  Meningitidis, OMV from N. Lactamica 
are being used in vaccination strategies that have proved protective in animals and 
are moving towards clinical trials in humans (Gorringe et al., 2005).
The major protein targets are the porin proteins PorA and PorB which constitute 
almost 70% of the proteins in the OMV (Naess et al., 1998). Trials of OMV based 
meningitis B vaccines have showed both production of bactericidal antibodies and 
stimulation of T cell memory showed by specific T cell proliferation in response to
241both OMV and individual porin proteins post vaccination, both in adults (Naess et 
al., 1998) and to some extent in children (Tappero et al., 1999).
7.1.7  Study plan
Pollard et al (Pollard et al., 1999) studied children recovering from meningococcal 
disease and postulated that the inability of vaccines to work in the youngest 
children was due to the immaturity of cellular immunity. They went on to find a 
trend towards higher proliferative responses in older children, which correlated with 
an increase in Th2 cytokine production (higher IL-10/ IFNy ratio).  This resulted in 
the suggestion that any new meningococcal B vaccine may be able to protect 
young children if it was formulated to stimulate Th2 pathways as well as Th1. Up 
until recently this is the extent of the work that has been done to characterise the T 
cell response to meningitis B infection in children in the context of the nature of the 
response.  The aim of this study was to analyse the nature of the immune 
response to a meningococcal B vaccine. The work presented here is the result of 
an immunogenicity study of an OMV based meningococcal B vaccine. Alongside 
SBA titres and T cell proliferation data, using the ELISpot we hoped to further 
analyse the Th1/Th2 cytokine balance by measuring IL-10, IL-5 and IFNy. It was 
also hoped that a more exact phenotype of the cells that were proliferating and 
producing cytokine in response to the vaccine could be studied using flow 
cytometry.
2427.2 Specific Materials and methods
7.2.1 Meningitis B vaccine
The vaccine preparation that was used for this study was a N. meningitidis 
serogroup B outer membrane vesicle preparation from a specific strain -H44/76. 
The outer membrane of N. meningitidis constantly releases blebs of outer 
membrane proteins (OMPs) and LPS in their natural conformation.  The vaccine is 
based on these blebs of bacterial membrane or OMV. Chiron provided the vaccine, 
the exact composition of which is unknown. 10 volunteers received 3 doses of this 
vaccine at intervals shown in figure 7.2.
7.2.2 Bleeding schedule
The bleeding and vaccination schedule for the meningitis B study is shown below 
in figure 7.2. 50ml of blood was taken and PBMC and serum were stored as for the 
MMR study outlined in chapter 4.
1 “ Boost 2-6 Boost 1« Vaccination
-1 5
Days 1  Year
Pre- 2*®  
Boost 
Bleed D
Post- 2“®   Post- 2*“ ®   Post- 2°® 
Boost 
Bleed Ei
Post- 2«* 
Boost 
Bleed  F
Final Bleed Post 1* 
Boost 
Bleed C
Pre- 1E 
Boost 
Bleed B
Boost  Boost 
Bleed E  Bleed Eti
Final bleed •will not have taken 
place before the end of this study
Only 3 volunteers 
participated in the extra 
post 2“®  boost bleeds
Figure 7.2 Meningitis B bleeding and vaccination schedule (not to scale)
2437.2.3 Antigens
The antigen used to detect memory responses in the meningitis B vaccine 
recipients was the major component of the vaccine (OMV). A related control was 
also used.  The vaccine made use of the natural blebbing process of N. 
meningitidis and consisted of purified outer membrane vesicles (OMV) from one 
specific strain of N. Meningitidis -H44/76. The OMV contain outer membrane 
proteins and LPS in their natural conformation. The OMV were treated with 
detergent to remove some but not all of the LPS as when used as a vaccine 
antigen as outlined in section 7.1, high levels of LPS are not desirable. The two 
OMV used in the in vitro studies were the relevant OMV derived from the vaccine 
strain H44/76 and the irrelevant OMV derived from a different N. meningitidis strain 
M0I-240013 The company Chiron and Dr Ray Borrow in Manchester kindly 
provided the vaccine antigens. They were stored at a concentration of 1mgml'1  at - 
70°C. ELISpots were carried out using 1pgml"1  OMV to stimulate PBMC from 
vaccinated individuals as described in chapter 2.
7.2.4 Proliferation assays
7.2.4.1  [3H]-T-cell proliferation assay
200jnl of RPMI was put in all the outer edge wells of a flat-bottomed tissue culture 
plate (Falcon, Becton Dickinson, France); this was done to prevent artefacts due to 
edge effect, which can occur in these assays. PMBC at a concentration of 106ml'1  
were added to the other wells 100pl per well. Following this, the antigenic stimulus 
was added to the designated test wells in quadruplicate. Outer membrane vesicles
244(OMV) were used at the same concentration as in the ELISpot. The plate was 
placed in a humidity box and incubated for 5 days at 37°C/5%C02.
7.2.4.2 Pulsing cells
After the 5-day incubation, cells were pulsed with [methyl-2H] thymidine 
(Amersham Pharmice Biotech, Amersham, UK). Each well was pulsed with 1  jnCi 
3H thymidine. The required number of Ci were removed from the stock vial (IpCifxl 
1 ) and diluted 1/10 in PBS and 1  O j l iI of this was transferred to each test well. The 
plate was then put back in the humidity box and incubated at 37°C/5%C02 for a 
further 16 hours. After this incubation the cells were either frozen at -70°C or 
harvested directly if frozen the plate was removed from the freezer one hour prior 
to harvesting.
7.2.4.3 Harvesting and data analysis
Cells were harvested using standard protocols on a Harvester 96® (TOMTEC, 
Wallac, Finland). Radioactivity was measured on a 1450 MicroBeta Trilux counter 
(Perkin Elmer™, Life Sciences), in counts per minute (cpm) using standard 
protocols. Proliferation values were expressed in cpm and were calculated as a 
mean of the quadruplicate unless one obvious outlier was observed.
7.2.5  Limulus Amebocyte Lysate (LAL) assay
The LAL assay was used to semi quantify the endotoxin (lipopolysaccharide,
LPS) content within the OMV. This was to rule out any differences in response 
between the test and control OMV as being due to differences in LPS content
245and also to make sure it was not the LPS in the preparations that was causing an 
in vitro response. The assay was carried out using the ETOXATE® kit (Sigma 
Chemicals Company) following the manufacturers instructions. The assay was 
carried out in endotoxin free glass culture tubes(Pyrex®, VWR International Ltd, 
UK). This was prepared using E-TOXA-CLEAN®(Sigma) following the 
manufacturers instructions. Instead of the standards provided in the kit which 
would give endotoxin levels in EU, commercially obtained LPS (Sigma) at known 
concentrations were used. A range of LPS dilutions and OMV concentrations 
were used, OMV from 1mgml'1  to 10ngml'1 and LPS from 1  jug to 1pg. All dilutions 
were made in the endotoxin free water provided with the kit and all controls were 
prepared as directed by the instructions. A positive test was the formation of a 
hard gel and from the dilution series prepared, a semi quantitative endotoxin 
level could be calculated.
7.3  Results
This study was done in collaboration with the Health Protection Agency (HPA) and 
some of the laboratory work was done jointly with Miss Ihjaaz Quireshi, a visiting 
Masters student from the London School of Hygiene and Tropical Medicine. Ihjaaz 
was taught to do proliferation assays and then generated the bulk of the H- 
thymidine proliferation assay data. The ELISpot had to be optimised before the 
study began for the OMV antigen, as it had been originally optimised for peptide 
antigens.
2467.3.1  OMV and irrelevant OMV titrations
It was known that some individuals in the pre vaccination bleed would already 
respond to some antigens in the OMV, including LPS. Thus titrations of both the 
relevant and irrelevant OMV were carried out in unvaccinated healthy donors to 
ensure the correct concentration was being used for optimal response. The results 
of the titration to the relevant OMV in 3 healthy donors are shown in figure 7.3. 
Throughout the subsequent study OMV was used at a protein concentration of 
1pgml'1 .
140
o
I  120
o  100 
o
m
— A W 4 4  
— a—AW80
— A W 5
£  - j f r T .   -
0  1   2  3  4  5  6
Concentration of OMV in micro g per ml
Figure 7.3: Titration of relevant OMV in 3 healthy donors in the ELI  Spot with 
250,000 PBMC per well, showing an optimal response at 1pgmf1 . Data points 
represent mean and standard deviation from triplicate wells.7.3.2 IL-5 ELISpot optimization
As it was T cell help that was being investigated in this trial and not only Th1 but 
also Th2 responses would be expected, an IL-5 ELISpot was developed. As the 
responses were so low from unvaccinated donors, a titration of responses by 
atopic donors to dust mite antigen was carried out to ensure the IL-5 ELISpot was 
working. One donor made a clear positive dose response to the antigen (AW81) 
shown in figure 7.4.
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Figure 7.4:  Results of an IL-5 ELISpot with 250,000 PBMC per well from 3 atopic 
donors stimulated with dust mite antigen at increasing concentrations. Mean and 
standard deviation are shown from triplicate wells.  This was used as a positive 
control on all IL-5 plates in future experiments.  Values are mean of 3 wells and 
error bars represent 1SD.
2487.3.3 Responses to OMV in fresh and frozen PBMC
As the samples were to be stored for use at a later time, to enable the responses 
at different time points post vaccination to be compared simultaneously, the 
response of fresh and frozen cells to OMV was compared in figure 7.5 to ensure 
there was no difference. A student’s paired T test was done and no significant 
difference was found between the fresh and frozen samples p»0.1.
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Figure 7.5: Comparison of IFNy responses to OMV by fresh and frozen PBMC as 
measured in the standard ELISpot in 6 adult volunteers with 250,000 cells per well. 
Mean and standard deviation are shown from triplicate wells.
7.3.4  Study results
All of the samples from the different time points from each volunteer were 
compared in the same assay after freeze thawing, to avoid any inter-assay 
variation in both the ELISpot and proliferation assays.
2497.3.4.1 ELISpot
The results from both IL-5 and IFNy ELISpot assays showed no significant 
alteration in response between pre and post vaccination although there seemed to 
be a transient boost in T cell production of IFNy at time point C-10 days post 
vaccination, in some individuals as shown in figure 7.6 (IFNy ELISpot) and 7.7 (IL- 
5 ELISpot).
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Figure 7.6 Summary of responses of vaccinated individuals to the relevant OMV 
preparation by production of IFNy over the course of the vaccination schedule. 
Data points show the mean and standard deviation from quadruplicate wells after 
the response to medium alone was subtracted.
In these experiments OMV from the vaccine strain and an irrelevant strain of 
meningococcus were tested. Figure 7.6 shows the IFNy response to the vaccine 
strain OMV however the response to the irrelevant strain of OMV appeared to be
higher than the response to the vaccine strain in most vaccinated individuals (data
250not shown). Therefore OMV preparations were tested for endotoxin levels and 
were found to be smaller in the irrelevant OMV than in the relevant OMV, so the 
higher response of vaccinees to the irrelevant OMV could not be attributed to 
endotoxin levels. This result may reflect a higher number of cross reactive epitopes 
between commensal species such as N. lactamica or more common non 
pathogenic circulating strains of N. meningitides and the M0I-240013 strain of 
bacterium used, however a more detailed study than this, looking at protein 
homology between the species would need to be carried out to confirm this.
40
MB022
MB023
MB024
MB025
CM
MB026
CO
MB027 CO
MB028
  MB029
—  MB030
  MB031
Bleed
Figure 7.7 Summary of responses of vaccinated individuals to the relevant OMV 
preparation by production of IL-5 over the course of the vaccination schedule. Data 
points show the mean and standard deviation from quadruplicate wells after the 
response to medium alone was subtracted.
2517.3.4.2 Proliferation assay
No significant change in proliferation to the OMV could be detected over the course 
of the vaccination schedule in any of the donors as shown in figure 7.8.
Proliferation assays were carried out as outlined in section 7.2 with samples 
assayed in triplicate. Very low levels of proliferation were seen with often higher 
proliferation in control wells than in antigen stimulated wells, this is why there are 
negative values for cpm in figure 7.8. Prior to study samples being assessed, 
healthy volunteers were used to optimise the proliferation assay methodology. 
Comparable responses were seen to PHA and Tetanus toxoid antigens as other 
groups showing that the proliferation assay was working (data not shown).  Due to 
restriction in sample sizes- approximately 60million cells per time point per 
volunteer for all cell based analysis, all these experiments were performed once.
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Figure 7.8 Summary of proliferation assay data to OMV in all donors over the
vaccination schedule.  The values of cpm were calculated by subtracting 
background proliferation from proliferation to the antigen. All values are mean of 3 
wells SD are not shown for ease of viewing. None of the changes were statistically 
significant when a student’s t test was used to compare pre and post vaccination 
proliferation.
2527.3.4.3 SBA titres from study participants
Serum samples were also taken throughout this study and analysed for specific 
SBA activity by collaborator Dr Ray Borrow in Manchester. The result of this 
analysis was disappointing and shows that few of the vaccinated individuals 
responded to the vaccination programme. As outlined in section 7.1.4, response to 
vaccination against serogroup B of meningococcus may involve more than only 
SBA activity, however this study failed to show a cellular response to vaccination. 
A significant response to vaccination when measuring SBA titres is considered to 
be a four fold (2 dilution factor) rise in activity pre and post vaccination.
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Figure 7.9: Line graph to show SBA titre to the vaccine strain of N. meningitidis, 
throughout the course of the vaccine schedule. Serum from vaccinated individuals 
was incubated with complement and the bacterium at increasing dilutions. SBA 
titre represents the serum dilution at which 50% of the bacteria are killed. A 
positive response to the vaccine is considered to be a 4 fold rise in SBA equivalent 
to an increase in SBA of 2 dilutions. Only MB024 and MB029 are considered as 
responder to this vaccine by SBA titre.
253Figure 7.9 shows the SBA titres for the vaccinees over the course of the 
vaccination schedule. These data were provided by Ray Borrow and colleagues in 
Manchester. According to the parameters -  an increase in SBA of 2 dilutions 
considered significant, only 2 individuals responded to this vaccine, MB024 and 
MB029. When looking at the proliferation assay data both these individuals have 
positive proliferation of T cells in response to OMV at the later points in the 
vaccination schedule which is encouraging, however an increase post vaccination 
in cytokine production was not detected in these individuals. SBA titres to several 
other strains of meningococci were measured and showed similar results to figure 
7.9. There were very few individuals whose SBA titre increased 4 fold between pre 
and post vaccination. This shows there was also minimal boosting of shared 
antigen responses with this vaccine (data not shown).
7.4 Discussion
These data suggest that there has been little or no response in the vaccinated 
individuals studied to the OMV vaccine against N. meningitidis B. As discussed in 
chapter 4 the sensitivity of the assay is potentially 1/250,000 cells (the number of 
cells per well) depending on the background (non specific spot formation). Thus in 
this system as few as 24 specific cells per million would be detectable. Proliferation 
to OMV antigen has been detected in vaccinated individuals, although the 
precursor frequency of responding cells is hard to extrapolate from a thymidine 
incorporation proliferation assay.  In addition to this, not all of the cells that 
proliferate to OMV will produce cytokine but a response of some level with the 
production of Th1  or Th2 associated cytokines would be expected. Proliferation
was also measured in this study in the same way as in other studies that had
254showed positive results, however a boost in proliferation to OMV was not observed 
in these donors and SBA titres were not boosted in most individuals. It is therefore 
likely that there was not a response to be detected in the individuals vaccinated in 
this study.
Significant responses to OMV vaccination have been recorded by measuring SBA 
titres in vaccine trials both large and small. Tappero et al reported the results of a 
vaccine trial in Chile. However the percentage of vaccinees that responded to the 
vaccine strain of N. meningitidis was very small -only 35% and children under 4 
years of age did not respond at all (Tappero et al., 1999). A similar disappointing 
result was recorded by Katial et al where less that 50% of vaccinees responded by 
an increase in SBA levels (Katial et al., 2002). However two more recent studies 
have shown more encouraging results one group showing that SBA titres, 
opsonophagocytic activity, class switching and affinity maturation of antibodies are 
increased post vaccination however only after intra muscular vaccination but not 
intra nasal vaccination (Aase et al., 2003).  Results of the OMV vaccine trial in New 
Zealand show that the vaccine is well tolerated and 96% of adults and 74% of 
children responded with a four fold increase in SBA (Oster et al., 2005). There are 
only three studies by 2 groups that have so far investigated the T cell response to 
OMV vaccines against N. meningitidis B. One of these studies has shown 
proliferative responses in three vaccinees to an OMV vaccine containing 6 different 
PorA proteins from 6 different target strains along with boosting of specific antibody 
responses (van der Voort et al., 1997). Studies conducted in Norway have shown 
significant rises in levels of PBMC proliferation post vaccination that can be
boosted with further doses of vaccine, and that these responses are predominantly
255to the PorA protein of N. Meningitidis B. They show this for both intra muscular and 
intra nasal routes of vaccine delivery (Naess et al., 1998;Oftung et al., 1999). 
However still not all of the vaccinees respond and responses to whole OMV in 
some cases are very low compared to PorA responses with this especially true 
after intra nasal vaccination. The latter two studies used the same vaccine that was 
used in the study outlined above.
The reason for the lack of detectable response in this study is at present unclear. It 
could be that the sample size of vaccinees was not large enough to account for so 
many non responders, or as this vaccine has been used successfully in the past, it 
could be that there was a problem with the vaccine batch or inappropriate storage 
which could not have been foreseen at the start of this study, and caused the 
failure of the vaccine. The data generated in this study can only suggest that this 
vaccine produced no induction of T cell immunity in the 10 individuals studied and 
did not promote a protective boost in SBA levels in 8 out of 10 vaccinees.
Further work on the remaining samples from this study could be undertaken, such 
as pre incubation of autologous DCs with OMV prior to performing proliferation 
assays and ELISpot assays to allow processing and more efficient presentation of 
the OMV antigen to the T cells which may boost observed responses. CFSE 
assays could also be carried out in place of the proliferation assays using H 
thymidine incorporation this would allow phenotypic identification of proliferating 
cells, as currently PBMC have been used in all the studies mentioned so it is not 
actually proven that it is T cells and not B cells or monocytes proliferating to the
OMV antigen. However as the vaccine does not appear to have boosted even SBA
256titres in most individuals studied there may not be any T cell responses to observe, 
even with renewed effort and modified methods aimed at boosting observed 
responses. Yet the original questions still stand- there must be N. meningitidis B 
specific T cells present in immune individuals as they are required for class 
switching and affinity maturation of specific antibodies therefore, what is there 
phenotype? Which cytokines do they produce? and are they boosted by 
vaccination? In order to answer these questions further vaccine immunogenicity 
studies are under way with different OMV based vaccines which it is hoped will 
show boosts in SBA titres and therefore allow a full investigation in to the nature of 
the T cell response against N. meningitidis B.
251Chapter 8 Conclusions and future work
8.1  Measles epitopes
The aim of the work described in chapters 3, 4 and 5 was to discover peptides 
derived from the measles virus (MV) that are recognised by human T cells from 
immune donors, in the context of HLA-A2*0201. Firstly, peptides that had been 
identified by other groups were investigated, to test their ability to stimulate T cells 
to produce IFNy, as assessed by ELISpot. Before this could be done, the ELISpot 
assay was set up and optimised for the identification of low frequency cells in this 
system. Although several strategies were investigated to try to increase the 
detection of antigen specific responses to the predicted peptides, no amplification 
of responses was seen over background in MV-immune individuals.  This may 
have been due to very low precursor frequencies of responder cells and in light of 
the negative results a better approach may have been to measure T cell 
proliferation to whole MV, individual proteins and peptides to be investigated. This 
would have had two benefits, firstly it may have amplified the signal to ensure that 
there was a response to be measured in the donors used in the study, and 
secondly may have identified the individuals who had the highest responses, prior 
to quantification of this response using the ELISPOT. Due to the negative nature of 
the first, more specific approach to epitope identification, a broader approach was 
developed, where pools of overlapping 15mer peptides derived from MV proteins F 
(fusion), NP (nucleoprotein), and H (haemagglutinin) were used to stimulate PBMC 
from immune donors. This section of the work was presented in chapter 3.
258The first strategy did not identify any definite epitopes. It is known from previous 
studies of viral immunity that precursor frequency of memory CD8 T cells may be 
in the range of 40 per million in the case of influenza epitopes (Rehermann et al., 
1996) to 2,500 responders to one peptide detected per million PBMC in EBV 
infected patients (Tan et al., 1999).  The limit of detection of the ELISpot over 
background is typically over 1   in 40,000. Therefore, in theory if memory T cells to 
MV exist at this frequency or above, they would be detectable in this assay.lt is 
possible that memory cells which are specific for the chosen peptides are present 
but at a frequency below the detection limit of the assay. Alternatively these may 
not be immunodominant epitopes for the HLA-A2 donors.
Due to the inability to identify MV epitopes, a new strategy was developed which is 
discussed in chapter 4. This involved the vaccination of two adult volunteers with 
the MMR with the aim of transiently boosting responses in vivo, which could have 
enabled the identification of epitopes due to increased precursor frequency of 
responding cells. PBMC from different time points post vaccination were stimulated 
with MV peptide pools in the ELISpot. This strategy enabled identification of some 
pontentially interesting sequences. However the number of responder cells was so 
low that a confident identification of HLA-A2 specific epitopes could not be made. 
The results are difficult to interpret given that vaccination was in only two 
individuals. This was the weakness of this section of the work, for confident 
identification of HLA-A2 epitopes it would have been necessary to recruit more 
individuals for vaccination with the MMR. This was not done in the first instance, as 
once interesting sequences had been identified in adults the intention was to study
them in a larger number of recently vaccinated children. The epitopes of interest
259would need to be identified first however as the size of the blood samples from 
children would be too small to scan for new epitopes. Thus if this work was to be 
repeated more adult volunteers should be vaccinated in the initial part of the study 
and T cell proliferation to whole MV measured in each prior to stimulation with 
peptide pools.
In a study of frequency of memory T cells proliferating to MV in immune adults, the 
mean frequencies of memory T cells were 0.35% for CD4+ and 0.24% for CD8+ 
cells (Nanan et al., 2000). The donors used in this study had had natural measles 
infection and although the donors used in the study described in this thesis were 
believed to have had measles in childhood, the specific cells may not have been 
boosted by vaccination. Furthermore in proliferation assays carried out using 
PBMC from both pre and post vaccination after stimulation with MV (see section 
4.3.2), no clear T cell proliferation was demonstrated. Thus it is possible that these 
donors had a poor response to the MMR boost given. In a study of responses just 
after natural MV infection (Jaye et al., 2003), responses were very strong to one 
epitope from the MV core protein in the weeks after infection however were short 
lived and failed to persist to memory. This may be a reason for the inability of this 
study to detect such memory responses in the boosted individuals who had had 
natural MV infection during childhood. Therefore a method was developed by 
which DCs from the vaccinated individuals could be made to express individual MV 
proteins at high levels, by infection with adenoviral vectors containing the cDNA 
coding for these proteins. This would enable the in vitro boosting of T cell 
responses by the culture of T cells with DCs that had processed and presented
individual MV proteins in order to grow short term T cell lines.
260Others have used vaccinia viral vectors containing measles proteins for similar 
studies to infect target cells with MV antigens to observe MV protein specific killing 
by CTL (Whittle 1998). In retrospect these constructs could have been used for the 
purpose of infecting DC and expanding autologous T cell lines. The adenoviral 
constructs however had been used to vaccinate mice and had shown protective 
responses (Fooks, 1995). Also there was no indication in the literature that 
adenoviral infected DC would not stimulate T cell proliferation. Therefore the 
adenoviral vectors were used as protocols were set up in the laboratory for working 
with adenovirus and not vaccinia at this time.  In order for this method to be 
utilised, the protocols had to be optimised and methods for verification of infection 
and protein expression were developed. These were successful and protein 
expression was demonstrated in both monocytic cell lines and human DCs. The 
effect of infection on DC phenotype was also investigated and in line with the 
findings of others (Miller et al., 2002;Rea et al., 1999) a trend towards a more 
mature phenotype was observed. However, no one molecule was consistently up 
or down-regulated in response to adenovirus infection. Phenotypically the DCs 
were not changed enough by adenoviral infection to suggest that infection would 
prevent their ability to stimulate T cells to proliferate, or to act as efficient antigen 
presenting cells to enable culture of short term T cell lines. The viability of the DCs 
was also investigated and there was no increased death in adenovirus infected 
DCs than in uninfected DCs. However the proliferation of T cells to infected DCs 
was much lower than might have been predicted, and it therefore remained difficult 
to identify a measles specific response in the T cell lines re-stimulated with peptide 
pools derived from MV. This was the basis of the data presented in chapter 5.Despite the difficulty in identification of T cell epitopes derived from the MV virus, 
this is still a very interesting and important area of work as discussed in section 
1.3. As for the future direction of this work, the approach used by the van Els group 
(van Els et al., 2000) which shows identification of naturally processed epitopes by 
purification of epitopes for MV infected cell lines via microcapillary high 
performance liquid chromatography-electrospray ionization-tandem mass 
spectrometry may be an important method. If this could be adapted for use with 
primary cells such as DCs either infected with MV or using the same methodology 
as the adenovirus work presented here, using viral vectors to express individual 
MV proteins within DCs to allow the identification of naturally processed epitopes. 
Once epitopes have been identified by this method they can go on to be tested in 
ex vivo assays to stimulate PBMC taken from both recently vaccinated and MV- 
infected children. This would also allow for a comparison in responses to these 
epitopes in the two groups and to gain further information on the difference 
between vaccine induced and natural immunity.
8.2  Dendritic cells and adenovirus
During the investigation which involved using DCs infected with adenoviral vectors 
containing MV proteins, outlined in chapter 5, the observation was made that T 
cells stimulated with DCs that had been infected with adenovirus consistently 
proliferated less than cells proliferating to uninfected DCs. This phenomenon was 
therefore further investigated, and this work is the basis of the data presented in 
chapter 6. Firstly the question of adenovirus making the DCs less efficient APCs
was addressed by using PHA to stimulate the proliferation of T cells. This
262stimulation does not typically require additional DCs to stimulate proliferation of 
PBMC, since PHA is a T cell mitogen. This showed that the reduction in the 
proliferation of the T cells was due to an active suppression by the adenoviral 
infected DCs, rather than it being the DCs that were defective (see section 6.3.4).
The suppression observed was shown to be due to a soluble factor or factors with 
the use of transwell and supernatant transfer experiments (section 6.3.7). Blocking 
experiments showed that in one donor, IL-10 was partly responsible for the 
suppression observed. However investigation into the production of cytokines by 
DCs after adenoviral infection, using the supernatants from adenoviral infected 
DCs compared to uninfected DCs failed to show a significant increase in IL-10 
production by DC post adenoviral infection. Analysis of supernatants from 
adenoviral infected DC/T cell co-cultures did however show an increase in IL-10 
with adenoviral infected DCs compared to uninfected DCs. This may imply that 
adenoviral infected DCs are able to promote the production of Treg -Tr1 cells. Tr1 
cells are typically defined by their ability to suppress other T cell responses and 
their production of IL-10 (Jonuleit and Schmitt, 2003). Several methods are 
described to generate such Tr1 cells in vitro (Barrat et al., 2002;Kemper et al., 
2003;Levings et al., 2005). Whether this system using adenovirus infected DCs 
may be generating such Tr1 cells, remains to be investigated.
It was also shown that other cell types could mediate the suppression when 
infected with adenoviral constructs although to a lesser extent which may reflect 
the cell type’s ability to make one or more secreted suppressive factors. The
addition of IL-2 did not overcome the suppression, nor did blocking TGF0. This is
263interesting given that both IL-2 consumption and TGFp have been implicated in the 
mechanisms of action of Treg (von Boehmer, 2005).
Recent reports have implicated I DO as having a role in adenovirus induced 
suppression of T cell proliferation (Tan et al., 2005;Terness et al., 2005). 
Preliminary investigations in this study have not shown that I DO has an effect 
(section 6.3.11) and as IDO is not known to have a soluble form, the data 
presented here may have identified a down stream effector molecule of IDO. 
However this remains to be further investigated in the system described here. In 
addition to the investigation of the role of IDO, future work on this project would 
involve the characterisation of the T cells resulting from a proliferation assay with 
adenovirus infected DCs. Both phenotype and intracellular cytokine production 
could be analysed using flow cytometry. In order to evaluate the hypothesis that 
suppression may be due to the generation of Treg, secondary proliferation assays 
could be carried out using T cells from the primary proliferation assay to co-culture 
in a secondary proliferation assay. This would allow the investigation of any 
secondary suppressive effect that the T cells generated by co-culture with 
adenovirus infected DCs may possess. Another interesting area of work would be 
the generation of deletion mutants of the adenoviral vector. It has been shown that 
“gutless” vectors do not have a suppressive capacity (Tuettenberg et al., 2004). 
Thus the use of deletion mutants would enable the identification of the specific 
area of the viral genome responsible for the suppression. In the future, this may 
also enable the identification of the molecule responsible for the suppression and 
therefore investigation into this molecule as a potential therapeutic agent.
264The work presented here is only in a relatively small number of donors. Therefore 
in order to verify these results and investigate a mechanism of suppression, further 
donors need to be tested in this system. There are many ways as outlined above in 
which this work should be expanded on and further verified, which due to time 
constraints were not addressed in this thesis.
8.3  Meningitis B vaccine development
The work presented in chapter 7 shows the results of an immunogenicity trial of an 
OMV based meningococcal B vaccine. IFNy and IL-5 production in response to 
OMV stimulation was measured by ELISpot and proliferation to OMV was also 
measured by thymidine incorporation. The results of the trial did not show a boost 
in T cell responses to vaccine antigen. However SBA titres which have shown to 
be boosted in other studies were not boosted in majority of individuals vaccinated 
in this study. Other studies however have observed a T cell response. One of 
these studies recorded T cell proliferative responses in three vaccinees to an OMV 
vaccine containing 6 different PorA proteins from 6 different target strains along 
with boosting of specific antibody responses (van der Voort et al., 1997). Also 
studies conducted in Norway utilising the same vaccine as used for this study, 
have shown significant rises in levels of PBMC proliferation post vaccination that 
can be boosted with further doses of vaccine, and that these responses are 
predominantly to the PorA protein of N. Meningitidis B (Naess et al., 1998;Oftung 
et al., 1999). However, not all of the vaccinees respond to vaccination. The reason 
for the lack of detectable response in this study is at present unclear. It could be 
that the sample size of vaccinees was not large enough to account for so many
non responders, therefore if this was to be repeated a larger study population
265should be used. Alternatively, as this vaccine has been used successfully in the 
past it could be that this specific batch of vaccine may not have been effective in 
the individuals that were vaccinated in this study.
As the question surrounding the phenotype and quantity of meningococcal B 
specific T cells, remains unanswered, larger future studies could be carried out 
which may account for the fact that a large proportion of people in the study may 
not respond to the vaccine. It may also be interesting to use individual MenB 
proteins to stimulate PBMC in both the ELISpot and proliferation assays, as studies 
have shown a greater boost to T cell proliferation when re-stimulated with the PorA 
protein rather than to whole OMV (Naess et al., 1998;Oftung et al., 1999). This 
may reflect an inability of PBMC to efficiently process and present whole OMV and 
work is in progress to investigate whether autologous DC pulsed with vaccine 
derived OMV will allow observation of cytokine production in the individuals that 
appeared to respond to the vaccine by SBA titres. In addition to this different OMV 
meningococcal B vaccines are also currently being investigated. PBMC taken from 
donors in trials using these vaccines may allow identification of the phenotype of 
responder T cells in both cytokine release and proliferation assays using CFSE so 
cell surface markers on responder cells can be identified.
In conclusion, these studies have used several different approaches to investigate 
the human T cell response to a virus (measles) to which protective memory 
immunity is present, and to a new vaccine product, of a bacterial pathogen. 
Although the studies failed to identify clear MV epitopes, or the phenotype of cells
responding to N. Meningitidis B derived OMV, the work did generate a novel and
266exciting set of data, and a system in which suppressive effects of DCs may be 
further investigated in the future.
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302Appendix
Table of all “adult well” volunteers used in this study, their date of birth, HLA-type 
and anti MV antibody titre. Where n/d is used it represents not done.
AW# DOB (mlU/ml) HLA typing
4 07/10/1968 1211 A26,11/B8,57
5 26/06/1960 3414 A2,24/B7,50
7 12/06/1967 9221 A1,2/B57,51
27 16/06/1977 5498 A11,24/B35,51
37 28/06/1971 12634 A2/B07,44/DR0103,15
39 12/03/1969 1176 A2,24/B15,51/DR8,11
49 06/01/1978 5217 A2,26/B8,1501/4,C0302/4,0701/6,
69 17.9.1958 31705 A2/B07,51/00702,14
73 30.7.1974 1468 A2
75 28/04/1969 11035 A2,68/B1501/4,56/00102-4,0302/4
76 29/08/1969 7683 A2,32/ B8,1516/17 00302/4,14
80 27/12/1972 n/d A11,33/B38,44/01302,1303/4
81 18/03/1980 17062 A2.29/B27,44/00202,0501
84 17/06/1971 391 A2,1/B7,35/00702,04/18
85 09/02/1974 3057 A2,25/B7,18/00702,1203/6
87 21/11/1979 n/d n/d
88 04/05/1970 n/d n/d
89 26/02/1977 5483 A2
90 12/10/1974 n/d n/d
303